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ABSTRACT

The goal of this study is to determine the role of Toll-like receptor (TLR) signaling in
acute myeloid leukemia (AML). AML is a hematopoietic malignancy that predominately affects
the elderly. The median age of AML diagnosis is 67 years old. The standard of care of AML is
treatment with cytotoxic chemotherapy, which elderly patients are often unable to tolerate. To
identify novel pathways as potential targets for treatment, a microarray on AML primary patient
samples was performed to determine the expression of key inflammatory genes. This microarray,
and other published datasets, showed that TLR are overexpressed in myelomonocytic (M4) and
monocytic (M5) AML subtypes. TLRs are components of the innate immune system that sense
and respond to inflammatory stimuli from infections or tissue injury. TLR signaling is mediated
by one of two adaptor proteins, myeloid differentiation factor 88 (MYD88) or Toll/IL1 receptor
(TIR) containing adaptor molecule 1 (TICAM-1). Inhibition of kinases downstream from these
receptors inhibits MLL-AF9 leukemia cell growth. To investigate TLR signaling in the setting of
AML, two models were employed. First, inducible genetic deletion of the Myd88 gene in MLLAF9 leukemia cells was applied. Myd88 was determined to be required for leukemia cell
stemness, colony forming potential, proliferation, resistance to chemotherapy, and
leukemogenesis in vivo. Next TICAM-1 expression was suppressed by shRNA in human and
murine models and found to have similar effects, protecting leukemia cell stemness,
proliferation, colony forming potential, and leukemogenesis in vivo. Knockdown of downstream

xviii

kinases, IL-1 receptor-associated kinase 1 for Myd88, and Tank-binding kinase for Ticam-1,
failed to recapitulate these phenotypes. While the exact mechanism of Myd88 pro-leukemic
function remains undetermined, TICAM-1 was shown to protect protein levels of receptorinteracting protein kinase 1 (RIPK1) and RIPK3, and TICAM-1 knockdown in human ML-2 or
murine MLL-AF9 cells resulted in corresponding loss of RIPK1 and RIPK3. Together, these
data indicate that TLR-associated adaptor proteins participate in pro-leukemia signaling
pathways independently from TLR-associated kinases. These findings have implications for the
treatment of AML and suggest that targeted disruption or inhibitions of MYD88 or TICAM-1dependent signaling pathways might have clinical benefit.

xix

CHAPTER ONE
INTRODUCTION AND BACKGROUND
Overview
Acute myeloid leukemia (AML) is a malignancy of the blood derived from hematopoietic
progenitor cells. AML is known clinically for its heightened incidence in the elderly, diverse
array of mutation events and fusion proteins, poor outcomes, and few targeted therapies. Often,
AML patients of advanced age cannot tolerate doses of cytotoxic chemotherapy required to
eradicate AML cells and induce remissions. As a result, overall five-year survival is 26% and
falls even lower with advanced age. Compared to many other malignancies, the survival of AML
has improved relatively little since modern cytotoxic chemotherapy was implemented clinically
three decades ago. AML is divided into a range of subtypes either by morphological presentation
or recurring genetic mutations. Depending on the subtype, it will confer a range sensitivity to
different treatments, leading to positive or negative prognoses. Because of the wide range of
recurring and co-occurring mutations in AML, few targeted therapies have been shown to be
clinically effective. Toll-like receptors (TLRs) and interleukin 1 (IL-1) receptors (IL-1R) are
transmembrane receptors for conserved molecular patterns associated with inflammation and
innate immunity. Leukemia cells of acute myelomonocytic (M4) and monocytic (M5) subtypes
have been shown to be protected from cell death by IL-1 in both preclinical models and primary
patient samples.1

1
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Additionally, AML cells of all subtypes are known to express Toll-like receptors and their
associated signaling components, but monocytic and myelomonocytic subtypes demonstrate the
highest expression of these pathways. I hypothesized that key TLR signaling pathways are
required for leukemia development and progression. In this dissertation, the contribution of TLR
signaling to AML pathogenesis from two key TLR adaptor proteins, myeloid differentiation
primary response 88 (MYD88) and TLR adaptor molecule 1 (TICAM-1) will be examined.
Innate Immunity
During infection, the presence of bacteria, viruses, or tissue damage in multicellular organisms
is first detected by the innate immune system. The innate immune system serves as a first line of
defense against pathogens and endogenously derived tissue-damage factors and is required to
initiate a signaling and transcriptional response to them. Innate immunity is mediated by pattern
recognition receptors (PRRs).2 These PRRs are expressed in most tissues throughout an
organism, and primarily act in epithelial and endothelial cells to detect tissue damage or infection
and initiate an inflammatory response. This generalized inflammatory response to PRR stimuli is
then mediated by tissue-resident immune cells, such as macrophages, natural killer cells, and
histiocytes, and circulating immune cells, such as monocytes and neutrophils, among others.
Both local tissue cells and these immune cells are also known to express distinct PRR
repertoires. PRRs include several groups of receptors that are known to recognize pathogenassociated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs).
Subgroups of PRRs include Toll-like receptors (TLRs), C-type lectin receptors, NOD-like
receptors, and retinoic acid inducible gene (RIG)-1-like receptors.2 Innate immune receptors
induce an inflammatory response to these molecular patterns that stimulate inflammatory
responses mediated by nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)

3
and other pro-inflammatory pathways. This response leads to the production of pro-inflammatory
cytokines, IL-1, interleukin 6 (IL-6), tumor necrosis factor a (TNFa), and other genes. In the
case of viral stimuli, type I a and b interferons are produced through NF-kB-independent
signaling.3
These cytokine signals activate the immune response, leading to generalized, local
inflammation and causing immune cells to home to the site of infection and/or tissue damage.
This inflammatory response, when appropriately regulated, is vital for the recruitment of immune
cells to the site of tissue infection or injury, clearing of pathogens and tissue damage, initiation of
healing processes, mobilization and expansion of myeloid precursors from the bone marrow
niche, and initiation of the adaptive immune response. When this response is dysregulated or
chronically stimulated, it is known to contribute to the pathogenesis of various disease processes,
including autoimmunity, immunodeficiency, hematopoietic dysfunction, and malignancy.4-7 The
TLRs are the best studied family of PRRs. Their mechanisms of activation, cognate ligands,
regulation, and roles in disease are relatively well understood. All TLRs are required for
competent innate immune function, and specific loss, mutation, or even single nucleotide
polymorphism of individual TLRs or downstream mediators results in corresponding specific
immune deficiencies.8-10
Toll-like Receptor Signaling
Toll-like receptors (TLRs) comprise a widely studied subset of pattern recognition receptors
(PRRs). TLRs act by recognizing conserved molecular patterns at the cell surface or within
endosomes. These molecular patterns are not specific to individual species of pathogens, but
conserved across a variety of bacterial and viral infections. TLRs sense PAMPs in the setting of
an infection as well as DAMPs arising from injury or chronic inflammatory states. All TLRs
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have a single transmembrane domain, an N-terminal extracellular domain, and a C-terminal
intracellular domain. The TLR extracellular domain interacts with PAMPs and DAMPs to
initiate TLR activation, downstream signaling, and subsequent cytokine secretion in response to
the infectious or damage-associated event. Toll-like receptors were the first subset of PRRs to be
associated with this function.
The Toll gene was first identified in the Drosophila melanogaster model organism and shown
to be required for dorso-ventral polarity in the developing fly embryo.11 Several Toll homologs
were later identified in the genomes of humans, mice, and other metazoan organisms because of
their similar intracellular domains and were termed Toll-like receptors (TLRs).12 Several TLR
subfamilies are conserved across all metazoan organism genomes surveyed to date. Genomes of
higher order organisms often encode homologous TLRs, but rarely have identical TLR
repertoires.13 For example, mice are known to express twelve individual TLRs, while humans
have ten known TLRs. TLR1-TLR9 are expressed in both mice and humans and retain
homologous functions. Despite this, mice lack the equivalent for human TLR10, and humans lack
the equivalent genes for murine Tlr11, Tlr12, and Tlr13. Recent phylogenetic and structural
studies have shown that significant variation of TLRs exists across vertebrate species.13
Structural analysis of the extracellular domain has determined that TLRs fall into one of several
ancestral families. The highly conserved presence and structure of extracellular domains of these
TLRs across nearly all species indicates their essential function.
Though the precise ligands of TLRs were not known when TLR genes were being first
identified, they were hypothesized to function as receptors, with distinct cognate ligands. The
TLR extracellular domain possesses 19-25 leucine rich repeats (LRRs), which form horseshoelike concave structures that determine ligand specificity.14, 15 Despite lacking specific ligands for
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the extracellular LRR domains, the TLR intracellular domain was shown to be homologous to
that of interleukin-1 (IL-1) receptor (IL-1R).14 The shared TLR and IL-1R intracellular domain
was termed the Toll/IL-1R (TIR) homology domain.16 This TIR domain is shared on adaptor
proteins and required for the recruitment of myeloid differentiation primary response 88
(MYD88) to both IL-1R and TLRs, except for TLR3.17-19 Because of this shared TIR domain and
MYD88 recruitment, TLR and IL-1R signaling overlap to a great degree. MYD88 is an adaptor
protein comprised of a C-terminal TIR domain, which allows interaction with TIR domains on
TLRs and IL-1R intracellular domains via a homotypic interaction. In this manner, the
downstream signaling mediators of IL-1R and TLRs were built and studied in parallel.
Toll-like Receptor Ligands.
Pathogen-associated molecular patterns. As the field of TLR study expanded in the 1990s,
these receptors remained without identified ligands. Even before the discovery of TLRs, many
immunologists hypothesized that an unidentified mechanism of ‘innate immunity’ mediated the
initial inflammatory phase of infections and injuries. For some, TLRs were poised to be key
mediators of the early inflammatory response, if their ligands were indeed associated with
inflammation.
The first identified TLR ligand identified was lipopolysaccharide (LPS), the PAMP ligand for
TLR4.12, 20-22 Also known as endotoxin, LPS is found on the outer membrane of Gram-negative
bacteria. LPS is characterized by an O-antigen, an outer and inner core domain, and a lipid
component, resulting in a structure that is highly specific for Gram-negative bacterial infections.
In infections with Gram-negative bacteria, TLR4 is required for LPS detection and activation of
the immune system in response to it. After many decades of hypothesizing about the nature of
‘innate immunity’, the determination that LPS is one of the cognate ligands of TLR4 was the

6
first empirical finding to validate this hypothesis. This finding bound the field of TLR study to
that of innate immunity and spurred the rapid identification of other TLR ligands.
Currently, TLRs are well-characterized, and each TLR has multiple PAMP and DAMP
ligands (Figure 1). TLR2 forms heterodimers with either TLR1 or TLR6, resulting in ligand
specificity to triacylated and diacylated lipopeptides, respectively.23, 24 These PAMPs are
associated with mycobacterial infections, such as M. tuberculosis and M. leprae, and functional
TLR2 is required for an adequate immune response.21,25 The ligand of TLR5 is bacterial
flagellin.26, 27 The TLR3 PAMP ligand is double-stranded RNA (dsRNA).28, 29 The TLR7/8
heterodimer ligand is single-stranded RNA (ssRNA).30 Lastly, the PAMP ligand of TLR9 is
unmethylated DNA CpG fragments present in bacteria and viruses, but methylated in
eukaryotes.31 Each of these PAMPs are associated with bacterial or viral infections, and their
localization and downstream signaling reflects these functions. While other TLRs sense bacterial
components at the cell surface, TLR3, TLR7, TLR8, and TLR9, localize to endosomal
compartments to sense viral PAMPs.32, 33 In contrast to other TLRs, TLR10 exerts antiinflammatory effects and has no known ligand.34
Under unstimulated conditions, TLRs exist either as dimers in a 'relaxed' conformation or as
monomers. With the introduction of known stimuli, TLRs that exist as monomers assemble into
dimers, and, once dimerized, undergo a conformational change.27, 28, 35, 36 This conformational
change extends to the intracellular domains and allows the TLRs to recruit MYD88 and TICAM1 directly or by intermediate adaptor proteins. These events are required to transduce the
extracellular signal of TLRs to the intracellular signaling compartment to activate the
proinflammatory and/or interferon response.
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Figure 1. Toll-like Receptor Signaling. Toll-like receptor (TLR) signaling is composed of several
cell surface and endosomal transmembrane receptors that function to detect inflammatory and
infectious molecular patterns and induce a downstream transcriptional response through
overlapping downstream signaling pathways. Endosomal TLRs and TICAM-1 mediated TLRs
may induce interferon regulatory factors (IRFs) to transcribe interferon. MYD88-dependent and
TICAM-1-dependent signaling result in the activation of p38, NF-κB, and JNK to generate a stress
response and proinflammatory cytokines.
Damage-associated molecular pattern ligands. TLRs have been shown to recognize
endogenous DAMP ligands as well as the aforementioned PAMPs. DAMPs are markers of tissue
damage or inflammatory cell death. These DAMPS act on TLRs to induce an inflammatory
response, which may aggravate the initial injury. For example, TLRs are well characterized as
mediators of inflammation in ischemia/reperfusion injuries following DAMP release in
myocardial infarctions and other ischemic events.37 Also, TLR-DAMP stimulation occurs in a
range of chronic inflammatory conditions and malignancies. In addition to PAMPs, most TLRs
also recognize DAMPs. Unlike PAMP ligands, multiple DAMP ligands may stimulate individual
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TLRs. For example, TLR4 is robustly stimulated by LPS, but it is also stimulated by several
S100 proteins and HMGB1, both of which can indicate localized tissue damage, inflammatory
cell death, or malignancy.38, 39 Additionally, TLR4 may be stimulated by several distinct heat
shock proteins (HSPs), several components of the extracellular matrix, and many others.40, 41
TLR1-TLR2 may also be stimulated by extracellular matrix proteins, HMGB1, and HSPs.38, 42
Lastly, nucleic acid-specific TLR9 may also detect HMGB1 and human cardiac myosin, so they
are not necessarily limited to the surveillance of nucleic acids or similarly structured
molecules.43, 44 Thus, the innate immunity of TLRs may be stimulated by a range of factors, often
in the absence of infection and with pathogenic consequences.
Interleukin 1 inflammasome-mediated activation and receptor stimulation. Interleukin 1
is a well-established inflammatory cytokine that acts as one of two subunits, either IL-1α or IL1β. The generation of IL-1α and IL-1β is mediated by the inflammasome, which holds proIL1α/β and pro-IL18 in a primed state so that it may be rapidly cleaved and activated by caspase
1 in the presence of TLR stimulation and a second, concurrent inflammatory signal. In
unstimulated conditions, caspase 1 exists in a primed pro-caspase 1 form, which is then cleaved
to generate active caspase 1, which cleaves and activates IL-1α and IL-1β.45 This second signal
may consist of potassium ion efflux or reactive oxygen species, as well as other stimuli of
infectious or sterile origin. Once sufficient signaling stimuli have been met, the inflammasome is
activated, resulting in the cleavage of IL-1α or IL-1β into their active forms and their subsequent
secretion. Once secreted, IL-1α or IL-1β are detected by nearby cells bearing the IL-1R, which
requires the co-receptor IL-1R accessory protein (IL-1RAP), which forms a dimer with IL-1R
and mediates the recruitment of intracellular receptor associated complex factors. Inflammasome
activation and consequent IL-1α/β production is carefully regulated. A key mediator of TLR
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signaling, TGF-β activated kinase-1 (TAK1), exerts a suppressive effect on the inflammasome.
Genetic deletion of TAK1 results in overactivation of the inflammasome and persistence of a
chronic inflammatory state.46
MYD88-Dependent Signaling.
Myddosome formation and IRAK activation. Downstream TLR signaling is mediated by
adaptor proteins such as MYD88, which is required for signaling downstream of all TLRs except
for TLR3. MYD88 may interact with TLRs directly, or indirectly via interaction with Myd88adaptor-like protein (MAL), a membrane-associated adaptor.47 Upon TLR stimulation, the
intracellular TIR domain undergoes a conformational change required for MAL/MYD88
homotypic TIR interaction. MYD88 also possess an N-terminal death domain (DD, Figure 2),
which recruits IL-1R-associated kinase 4 (IRAK4). IRAK4 is a serine/threonine kinase that is
activated by phosphorylation of two of three required phosphorylation sites within its activation
loop: Thr342, Thr345, and Ser346. Discovered as a homolog to the Drosophila Pelle gene,
IRAK4 is required for downstream signaling for both IL-1R and MYD88-dependent TLR
signaling.48, 49 Upon recruitment to MYD88, IRAK4 undergoes an oligomerization-induced
dimerization and trans-autophosphorylation.50 IRAK4 then recruits IRAK1 as a substrate and
phosphorylates it. This results in a cytosolic, membrane-associated receptor complex called the
Myddosome. Crystallization studies indicate that each Myddosome is composed of six MYD88
proteins, four IRAK4 proteins, and four IRAK1 proteins.51 Phosphorylation of IRAK1 leads to
partial IRAK1 activation and enables IRAK1 to phosphorylate and activate Pellino-1, an E3
ubiquitin ligase. Signaling downstream of IRAK1 requires K63-linked ubiquitin chain formation
mediated by E3 ubiquitin ligases factor α (TNFα) receptor associated factor 6 (TRAF6), Pellino1, or Pellino-2.52 These K63-linked ubiquitin chains form on IRAK1 or TRAF6. K63-linked
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ubiquitin chains recruit downstream mediators and are required to induce activation of
downstream TAK1-mediated signaling.

Figure 2. MYD88 Adaptor Protein Domains. MYD88 is known to have an N-terminal death
domain (DD) and a C-terminal Toll/IL-1 receptor (TIR) domain. The intermediate domain is not
known to have a conserved structure or function. The TIR domain is recurrently mutated in B cell
lymphoma subtypes and Waldenstrӧm’s macroglobinemia, a low grade malignancy of B cell
origin. However, it is not known to be mutated in AML.
TRAF6 activation and-downstream TAK1-mediated signaling. The polyubiquitination of
IRAK1 and TRAF6 mediates the recruitment of TAK1. TAK1 is known to interact closely with
TAB1, TAB2, and TAB3. TAB1 interacts with TAK1 through its N-terminal domains, whereas
TAB2 and TAB3 interact with TAK1 through its C-terminal domains and facilitate TAK1
activation by binding to K63-linked ubiquitin chains.53 Activation of TRAF6 results in the
phosphorylation and activation of the TAK1 complex upon binding to ubiquitin chains. TAK1
then phosphorylates Jun N-terminal kinases (JNK), p38, and the IKK complex, which also
interacts with K63-linked ubiquitin chains via NEMO, leading to NF-kB activation.54 The
activation of these downstream signaling pathways and NF-kB transcription factor results in the
transcription of key cytokines for the immune response. These cytokines include IL-1β, G-CSF,
IL-6, and TNFa, among others, and are required to generate an immune response.
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TICAM-1-Dependent Signaling.
Aside from MYD88-dependent signaling, a phenomenon of MYD88-independent NF-κB
induction and interferon transcription occurs following LPS-TLR4 stimulation in Myd88
knockout (Myd88-/-) macrophages and dendritic cells. This LPS-TLR4-NF-κB induction
demonstrates that MYD88-independent TLR signaling occurs through independent pathways.55,
56

Two research groups discovered an additional adaptor protein, TLR adaptor molecule 1

(TICAM-1, also known as TIR Domain Containing Adaptor Inducing Interferon-β, or TRIF).57-59
TICAM-1 mediates MYD88-independent signaling through endosomal TLR4 and TLR3.
Therefore, TLR4 stimulation induces activation of both MYD88-dependent and TICAM-1dependent signaling.60 In contrast, TICAM-1 is the sole adaptor protein known to transduce
endosomal TLR3-mediated signaling.59, 61 Additionally, TICAM-1 has an accessory TIRcontaining adaptor protein, TICAM-2 (also known as TRAM), which bridges the stimulated
TLR4 receptor to TICAM-1, resulting in subcellular localization to the stimulated TLR4
receptor.62 The TIR domains on each protein mediate interaction of TICAM-2 and TICAM-1.
Homotypic interactions between TICAM-2 molecules are required for recruitment of TICAM-1
and downstream signaling.63 TICAM-2 functions as adaptor in MYD88-dependent signaling.64
To regulate TLR4-mediated signaling and TICAM-1 activity, TICAM-2 transcript is
downregulated by mir-27a following TLR4 stimulation in injury models.65
Like MYD88, the TLR adaptor protein TICAM-1 has no catalytic activity of its own, and its
functions are dependent upon the recruitment of other proteins. Formation of the TICAM-1
signalosome is dependent on conserved domains within the TICAM-1 protein and
polymerization of TICAM-1 at the site of TLR3/4 stimulation. Unlike MYD88, TICAM-1 is
known to interact with a diverse set of signaling partners via conserved domains. TICAM-1 has a

12
TIR domain, a RIP homotypic interacting motif (RHIM), and several TRAF-interacting domains
(Figure 3). Depending on which proteins are recruited to the TICAM-1 multimer, downstream
signaling can range from induction of innate immune cytokine effectors to induction of
necroptotic signaling.
The TICAM1 TIR domain is required for interaction with the intracellular TIR domain of
TLR3 and that of TICAM-2 in TLR4 signaling. Upon stimulation, TICAM-1 aggregates at the
receptor and recruits a large set of proteins. Proteomic approaches have studied the TICAM-1TLR complex and identified 14-3-3-zeta as a required protein for multimerization of TICAM-1
and propagation of downstream inflammatory signaling.66 However the exact relationship
between TICAM-1 and many of its other complex partners and their respective significance
remains to be determined.66
The best studied function of TICAM-1 is its ability to induce the interferon response. TICAM1 multimerization is required for the activation of TANK-binding kinase 1 (TBK1) and IKKe.
Upon

TICAM-1

stimulation,

TBK1

is

recruited

to

TICAM-1

and

undergoes

a

transautophosphorylation-mediated activation in which recruitment to the TICAM-1 multimer is
required.67 Activation of TBK1 permits TBK1-mediated phosphorylation of IKKe. Activation of
IKKe results in phosphorylation of interferon regulatory factors (IRFs). IRFs are a family of
transcription factors that are required for transcription of downstream interferons following TLR3
or TLR4 stimulation. In unstimulated conditions, IRFs exist as monomers in the cytosol, but form
dimers and translocate to the nucleus following IKKe-mediated phosphorylation.
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Figure 3. TICAM-1 Adaptor Protein Domains. TICAM-1 is known to have several conserved
domains required for downstream signaling. TANK-binding kinase 1 (TBK1), TRAF2, and
TRAF6 interact with TICAM-1 through conserved domains and are required for downstream
signaling. Unlike most TLR adaptors, the TIR domain is centrally located in the protein. Lastly,
TICAM-1 has a C-terminal receptor interacting protein (RIP) homotypic interaction motif (RHIM)
domain, which allows it to interact with RIPK1/3 proteins.
Though precise mechanisms remain unclear, the recruitment of not only TRAF3, but also
TRAF2 and TRAF6, is required to induce downstream interferon and NF-κB induction. By
extension, the recruitment of these TRAFs is also required to initiate TBK1-mediated IRF
induction. TICAM-1 is known to interact directly with several TRAF family members through
distinct conserved TRAF-binding domains. TRAFs are known to act as E3 ubiquitin ligases to
initiate construction of K63-linked ubiquitin chains and ubiquitin-dependent signaling. TICAM-1
interacts directly with TRAF3. TICAM-1 may also interact directly with both TRAF2 and TRAF6
through conserved TRAF-binding domains distinct from those required for interaction with
TRAF3.68 TRAF2 and TRAF6 polymerize with TICAM-1 upon stimulation. TRAF2/6 interaction
with TICAM-1 mediates K63-linked ubiquitination and is required for the induction of
downstream activation of both IRF3 and NF-kB.
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As previously mentioned, MYD88-dependent and TICAM-1-dependent signaling are known
to have overlapping downstream signaling mediators. Pellino-1 is a known substrate of IRAK1mediated phosphorylation. TBK1 and IKKe directly interact with and phosphorylate Pellino-1 to
activate its E3 ubiquitin ligase activity.69 TBK1 and IKKe may also induce crosstalk with other
IKK family members and are required to induce TICAM-1-mediated NF-kB activation.
Importantly, TICAM-1 induces TRAF6 activity, so inhibition of MYD88-dependent signaling
using inhibitors against IRAK1/4 would fail to prevent downstream signaling in the presence of
TICAM-1-mediated stimuli.
TICAM-1 possesses a RIP homology interacting motif (RHIM), which permits interferonindependent signaling. RHIM domains are present in receptor interacting protein kinase 1 (RIPK1)
and RIPK3.70 Both RIPK1 and RIPK3 are serine/threonine kinases known to function in TNFα
receptor-induced cell death and NF-kB induction. Both RIPK1 and RIPK3 are required for cells
to undergo necroptosis, a form of cell death. In the setting of necroptosis, RIPK1 and RIPK3
interact closely via their RHIM domains. RIPK1 activates RIPK3 by phosphorylation, and RIPK3
in turn phosphorylates mixed lineage kinase like (MLKL) protein. Activation of MLKL is required
for successful necroptosis, in which it is required for pore formation in the plasma membrane.71 In
the setting of TLR signaling, RIPK1 and RIPK3 are required for TICAM-1-mediated ERK and
NF-κB induction after LPS stimulation.72,

73

Necroptosis has also been reported to occur in

response to TLR3 stimulation, perhaps as a mode of limiting the spread of viral infection.
Regulation of Toll-like Receptor Signaling.
Because TLRs stimulate such a strong inflammatory transcriptional response, they are carefully
regulated. Shortly after the introduction of inflammatory stimuli several processes are initiated that
limit or deactivate cell membrane-mediated TLR signaling, most often by ubiquitination and
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degradation of key TLR signaling intermediates. For example, following TLR2 and TLR4
stimulation, MAL is phosphorylated in an IRAK1 or IRAK4 dependent manner, which permits its
ubiquitination and subsequent degradation.74 TICAM-2 is known to be downregulated by mir27a.65 Downstream, after IRAK1 is phosphorylated and ubiquitinated, it is rapidly degraded.75
Further, several deubiquitinases including A20 limit both the duration and degree of the
transcriptional response. A20 is known to negatively regulate multiple nodes within TLR signaling
pathways. For example, it is known to interact with the C-terminal domain of NEMO to limit NFkB activation.76 The failure of A20 recruitment leads to an accumulated of K63 ubiquitination and
prolonged NF-kB activation. When A20 function is limited by disruption of the A20-NEMO
interaction, expression of nonfunctional A20, or deletion of A20, the TLR-mediated immune
response is dysregulated, leading to hyperactive transcriptional responses, increased cytokine
secretion, and higher incidence of autoimmunity.76, 77
Conversely, TLRs are known to augment their own transcription, as well as that of their
adaptors. This response is thought to increase the sensitivity of the stimulated cell to other TLR
ligands and amplify the immune response. TLR2 is well-known to induce its own transcription.78
Recent Discoveries Challenge Conventional TLR Models.
While the framework of TLR signaling was set over the past twenty years, recent studies
suggest that the divisions between MYD88-dependent and MYD88-independent pathways may
not be as straightforward as initially thought. For example, while TLR1/2 heterodimers and
TLR4 homodimers were thought to be the only modes of dimerization, TLR2 and TLR4 are now
known to form functional heterodimers in an MYD88-dependent manner.79 Further, a small
subset of genes, including CCL4 and CCL5, downstream of TLR2 are induced in a TICAM-2
(TRAM)-TICAM-1-TBK1-IRF3-dependent manner.78 TICAM-1 is also known to be induced by
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MYD88-dependent signaling through TLR1/2 and TLR4, which contributes to the TICAM-1
mediated effects of both signaling pathways.80
These recent studies continue the illumination of the complex and overlapping network of
TLR signaling. Going forward, this dissertation will examine the known functions of TLR
signaling pathways in hematopoiesis, solid tumor malignancy, and hematopoietic pathology and
malignancy in support of a role for TLR signaling in acute myeloid leukemia.
Hematopoiesis and the Bone Marrow Niche
Hematopoiesis is the process by which all blood cells are generated. All blood cells arise from
hematopoietic stem cells (HSCs). HSCs are a multipotent cell population capable of
differentiating into myeloid and lymphoid cells and regenerating both compartments. In order to
generate hematopoietic progenitors and blood cells while also maintaining the HSC population,
HSCs undergo asymmetric cell divisions in which one daughter cell loses HSC potential and the
other daughter cell retains it. The daughter cell that loses HSC potential cannot become or
generate an HSC, but instead acts as a multipotent progenitor (MPP) to maintain terminally
differentiated populations of myeloid or lymphoid cells and their respective progenitors. By
maintaining the quiescent HSC population while also generating a proliferative MPP population
as needed for hematopoietic homeostasis, HSCs are said to have the ability to 'self-renew'.
However, HSCs are not able to autonomously maintain themselves in a multipotent state, and
must be maintained in an organized, specialized, and stable niche by a balance of several discrete
signaling pathways.81-83 This microenvironment protects the HSC and is comprised of both
secreted cytokines and direct cell-to-cell contact with niche cells.84, 85 In support of the goal of
expanding HSCs in vitro for the treatment of hematologic disease by autologous transplantation,
the HSC niche has been carefully studied and dissected. However, HSCs, MPPs, other
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hematopoietic progenitors, and stromal cells that comprise the HSC niche all express TLR
signaling, which influences the proliferation, differentiation, and repopulating potential of HSCs.
Hematopoiesis under Toll-like Receptor Stimulation.
Hematopoietic progenitors are known to respond to infectious stimuli, and this process serves
various functions from embryonic development to adulthood. In the developing embryo, TLR
signaling is required for the establishment of the HSC population. Sterile TLR4-MYD88-NF-kB
signaling has been shown, using genetic deletion models, to be required for the emergence of
embryonic HSCs from hemogenic endothelial cells of the aorto-gonad-mesenephros (AGM)
region in both mouse and zebrafish models.86 Therefore, TLR stimulation is required for the
establishment of the embryonic HSC population. Local production of several inflammatory
cytokines induced by TLR4 are associated with the emergence of embryonic HSCs. These
cytokines include interferon g, interferon a, TNFa, IL-3, and IL-1b.87-91 Each of these cytokines
is required for HSC emergence, and loss of any individual cytokine signal reduces the efficiency
of HSPC emergence. The precise mechanism of TLR4 stimulation in this setting remains to be
determined, but the controlled, localized production of endogenous TLR4-specific DAMPs is a
likely possibility. Interestingly, the requirement for Toll-mediated signaling in facilitating the
origin of hematopoietic cells extends into D. melanogaster, the organism in which it was initially
discovered. In D. melanogaster, hemocyte proliferation and differentiation within the developing
larva is regulated by the Toll/Cactus pathway.92 The repeated implication of TLR4 in the
embryonic emergence of HSPCs in distantly related model systems underlies an ancestral role
for this TLR4 signaling axis in hematopoiesis.
Formerly, in the absence of infection, no TLR signaling was thought to occur in adult
organisms. However, basal stimulation of hematopoietic progenitors by compounds derived from
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a healthy microbiota appears to have neutral effects on the robustness of the HSC population, but
results in the maintenance of bone marrow resident myeloid cell and neutrophil populations
through both MYD88 and TICAM-1 dependent stimulation.93 This stimulation by microbiotaderived PAMP stimuli is well below the threshold to elicit an inflammatory response. However,
this low level of stimulation was shown to maintain a population of myeloid cells with in the
bone marrow. Accordingly, the depletion of gut microbiota or deletion of MYD88/TICAM-1
results in a comparatively smaller myeloid pool within the bone marrow. These findings suggest
that the presence of the gut microbiota and other tissue-specific microbiota facilitate a basal
production of myeloid cells that may serve to later augment the innate immune response.
Consistent with this observation, infections of numerous etiologies have been known in
humans and animal models to stimulate hematopoiesis above baseline blood cell production in a
myeloid-skewed manner, resulting in production of granulocytes, monocytes, and other myeloidderived cells, at the expense of homeostatic production of lymphocytes.94 This phenomenon of
augmented myeloid cell production and accelerated differentiation during infection is known as
emergency myelopoiesis. Bone marrow hematopoietic stem and progenitor cells (HSPCs) are
able to detect infection-derived PAMPs via TLRs and generate a functional response to the
infectious stimuli. Induction of HSC cycling and differentiation leading to emergency
myelopoiesis response may be elicited by known synthetic TLR ligands such as PAM3CSK4 or
R848.95-98 HSPCs directly respond to TLR ligands in a cell-autonomous manner after
transplantation of wildtype Lin- Sca-1+ c-Kit+ IL7Ra- HSPCs into Tlr2-/-, Tlr4-/-, or Myd88-/mice. Following transplantation, treatment with respective TLR ligands induces HSPC
macrophage differentiation, showing that HSPCs directly respond to TLR stimulation.99 While
HSPCs may directly respond to TLR ligand stimulation, emergency myelopoiesis may also be
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induced indirectly by G-CSF cytokine secretion from endothelial cells presented with LPS or by
IL-6 cytokine release from stimulated HSPCs.100, 101 Following the resolution of the infection, the
stimuli are no longer present, and the bone marrow niche returns to a quiescent state to preserve
HSPC functional potential.
Persistence of TLR stimuli, however, results in perpetually stimulated HSPCs, eventually
reducing their hematopoietic potential. Chronic LPS stimulation of also results in the
differentiation of common myeloid progenitors, but also stimulates the differentiation of
common lymphoid progenitors into dendritic cells.96 A variety of in vivo TLR stimulation and
infection models have been shown to elicit similar myelopoiesis responses.102-106 However,
chronic in vivo TLR stimulation has been shown to result in defects in HSC proliferation and
differentiation due to HSC exhaustion.107 Conversely, Myd88-/-, Tlr2-/-, or Tlr4-/- HSPCs are
marked by enhanced repopulating capacity, demonstrating that TLR signaling regulates HSC
function in the absence of infection.108 Thus, overstimulation of TLRs on HSCs is detrimental to
the functional repopulating capacity of HSCs. However, TLR stimulation drives the expansion
and differentiation of myeloid progenitors. This effect may influence the myeloid skew in
hematopoiesis often observed in aging bone marrow microenvironments.109
Bone marrow microenvironments may also be disrupted by leukemia-derived cytokines to
result in a myelopoiesis phenotype. In emergency myelopoiesis granulocyte/macrophage
progenitor (GMP) populations are dispersed throughout the bone marrow and expand forming
localized GMP clusters that produce terminally differentiated granulocytes within the bone
marrow. This is due to the controlled activation of myelopoiesis by cytokine signals, including
IL-1b. These cytokine signals are eventually deactivated to restore the quiescent hematopoietic
niche, but, in leukemia, the pro-myelopoiesis cytokine signal is chronically activated by the
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invading leukemia cells, so GMP clusters are always present.110 Therefore, disease processes,
including malignancies, activate the bone marrow niche using the same cytokine signals
identified in TLR-mediated emergency myelopoiesis. These observations within a healthy
hematopoietic compartment have led to the study of TLR signaling in diseases and malignancy
arising from excessive TLR stimulation or dysregulation. This TLR dysregulation has been
shown to be a key element of several hematological diseases, including myelodysplastic
syndrome.
Toll-like Receptor Signaling in Malignancy and Disease
MYD88-Dependent Signaling in Solid Tumors.
Since the discovery and assembly of the TLR signaling pathways, they have been primarily
studied in the immune system. However recent work implicates TLR signaling mediators in the
development and progression of malignancy of both hematopoietic and solid tissue origin. TLR
signaling was first implicated in the development of malignancy when it was determined that
Myd88 deletion reduces the incidence and slows the progress of colorectal tumors in both
APCMin/+ and colon cancer induced by the carcinogen azoxymethane (AOM).111 Thus, Myd88 is
required for intestinal tumorigenesis for both genetic and carcinogen-induced tumorigenesis.
More recently, genomic analysis of a large set of colorectal cancer patients has demonstrated that
single nucleotide polymorphisms (SNPs) of TLR5 correlate with activation of downstream
signaling pathways and unfavorable patient survival.112 Further, even elevated expression of
TLR5, MYD88, IL-1a, and IL-6, downstream of TLR signaling, are correlated with poor
survival in colorectal cancer cohorts.113 These studies and others have established that TLR
signaling promotes tumor establishment and progression, and might serve as prognostic
indicators for colorectal tumors.
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Since the initial discovery of MYD88 as a promoter of colorectal cancer, MYD88 and TLR
signaling pathways have been studied in a range of malignancies. These include both cancers of
hematopoietic origin and solid tumors, including breast cancer, brain cancer, pancreatic cancer,
hepatocellular carcinoma, and many others. A relatively large number of cancers tend to express
TLR2 and TLR4 highly. Despite this, the exact function of TLR signaling in solid tumor
malignancy appears to be diverse and tissue-specific. TLR function has been shown to be
required for tumors, tumor progression, survival, and metastases. Because diverse tumor types
are derived from a wide range of tissues, often with unclear connections to the oncogenic drivers
for individual tumor types. TLR signaling promotes the initiation and progression of breast
cancer, and DAMP signaling has been associated with breast cancer stem cell maintenance.114, 115
Similar findings demonstrate IRAK1 promotes cancer cell stemness in hepatocellular
carcinoma.116 TLRs have been linked to lung cancer, and IRAK4 is active and targetable by
inhibitors in preclinical pancreatic adenocarcinoma models.117-119
However, activation of TLR signaling within certain tumors is actively suppressed because it
prevents tumor progression by inducing inflammation and apoptosis. Therefore, a range of TLR
modulatory agents that block or stimulate TLR signaling are being considered for potential
therapeutic use. Glioblastoma multiforme, the most common brain cancer in adults, differs from
other solid tumors in that it actively suppresses TLR signaling. In glioblastoma multiforme
cancer stem cells, TLR4 expression and activity is reduced to protect tumor stem cell function.120
Further, glioblastoma stem cells suppress IL-1b-induced TLR4 expression in a b-defensin-3dependent mechanism.121 Therefore, in these models for glioblastoma multiforme, TLR
signaling, especially TLR4 signaling, is evaded and suppressed to protect the malignant
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glioblastoma stem cells. However, in breast cancer subtypes, metastases have been shown to
occur in a TLR4-dependent manner.
Variants of MYD88 and Toll-like Receptor Mediators Associated with Hematopoietic
Disease.
MYD88 mutations in lymphomas and B cell malignancies. While overexpression of
wildtype MYD88 is associated with a range of solid tumors, mutant variants of MYD88 are
known to recur in several other malignancies. As previously described, MYD88 has two
functional domains, the N-terminal DD (Figure 2), which directly interacts with IRAK4 and
TRAF6, and the C-terminal TIR domain, with interacts with the intracellular domains of TLRs.
MYD88 is known to be recurrently mutated in several B cell lymphoma subtypes and
Waldenström’s macroglobinemia.122, 123 The recurring MYD88 mutation consists of a conversion
of leucine to proline (L265P) within the TIR domain. This mutation allows MYD88 to
spontaneously assemble, without upstream stimulation or interaction with TLR intracellular
domains. The spontaneous assembly of L265P-mutant MYD88 results in the chronic activation
of IRAK4 and IRAK1, leading to the chronic activation of NF-kB and transcription of NF-kBregulated genes.123 This MYD88 L265P mutation is known to occur in over 86-95% of
Waldenström’s macroglobinemia cases and 87% of cases of monoclonal gammopathy of
undetermined significance (MGUS).124-126 Among B cell lymphomas, 29% of activated B celllike diffuse large B cell lymphomas (ABC-DLBCL) possess this mutation.122 The site of the
lymphoma seems to have a significant role in DLBCL with L265P MYD88. Clinical metaanalyses indicate 60% and 77% of central nervous system and testicular ABC-DLBCLs present
with L265P MYD88, respectively.127 Another subtype of DLBCL, primary cutaneous DLBCL,
leg type (PC-DLBCL-LT), is known to have L265P MYD88 mutations in 59% of cases.128
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Across several studies, the mutation is associated with advanced age and adverse outcomes.127,
129

Because the MYD88 L265P mutation confers spontaneous and constitutive myddosome
assembly and activation of downstream IRAKs, IRAK inhibitors would be ideal agents for
treating lymphomas and other diseases with such activating mutations. Currently no IRAK1/4
inhibitors are part of DCBCL or Waldenström’s macroglobinemia treatment plans, though novel
inhibitors of IRAKs are being developed and undergoing preclinical testing.130 Currently one
clinical trial is testing the efficacy of IRAK inhibitors against MYD88 mutant and MYD88
wildtype refractory non-Hodgkin’s lymphomas.131 131 131 131 131 130 130 128 128 Since the MYD88
L265P mutation seen in Waldenström’s macroglobinemia and DCBCL is known to activate
Bruton’s tyrosine kinase (BTK), it is currently treated with ibrutinib, a BTK inhibitor.132-135
However, whether targeted inhibition of IRAK1/4, downstream of activated mutant MYD88
L265P, is clinically effective remains to be determined.
Toll-like receptor signaling dysregulation in myelodysplastic syndrome. Myelodysplastic
syndrome (MDS) is a hematological disorder in which hematopoiesis within the bone marrow
fails to produce a sufficient number of cells to replace lost erythrocytes, immune cells, and
megakaryocytes. Patients with MDS exhibit a variety of chronic cytopenias. MDS arises due to
the development of clonal hematopoiesis bearing recurring MDS-related mutations. The
incidence of this disease is 5.3-13.1 per 100,000 individuals and, like AML, this incidence
increases to with age, eclipsing AML with an incidence of 75-162 per 100,000 people over age
65.136 It also has a five-year survival of 35%, and median overall survival ranges from a median
is 46 months, although it varies depending on the subclassification.137, 138 A subset of MDS
patients will see their disease convert into a secondary AML and face the accompanying poor
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prognosis, but this is difficult to predict and transformation varies with both subtype and specific
mutation events. Dysregulation and activation of TLRs and downstream innate immune signaling
pathways is known to be a key element of MDS.
Several upregulated genes in MDS, identified using H3K4me3 chromatin
immunoprecipitation and sequencing, belong to TLR signaling pathways.139 Independently,
MYD88 is overexpressed in 40% of MDS and correlated with poor survival compared to MDS
patients without MYD88 overexpression.140 MYD88 overexpression induces activation of
downstream IRAK1/4 signaling that can be efficiently targeted by specific IRAK1/4
pharmacologic inhibitors.141 TLR4 is upregulated in HSPCs in MDS in a TNFa-dependent
manner, resulting in increased apoptosis and favoring the expansion of the dysfunctional MDS
clone.142 Upstream of TLR4, known TLR4 ligands, principally S100A8 and S100A9, are also
overexpressed in certain MDS models. Overexpression of S100A8 and S100A9 results in a
progressive anemia by stimulating TLR4 to cause a block in erythroid differentiation.143
Furthermore, the presence of the TLR4 signaling axis in mesenchymal stem cell niches induces
mitochondrial and genotoxic stress in HSPCs, inducing hematopoietic dysfunction and raising
the risk for MDS progression to leukemia.144
Activating variants of TLR2 (F217S) recur in MDS in 11% of the studied cohort and inhibit
the production of erythroid, megakaryocytic, and lymphoid lineages.5 This results in a skewing
hematopoietic production toward granulocytes and monocytic cells, as would be expected if
TLR2 were to be chronically stimulated. The chronic TLR2 stimulation also leads to an
exhaustion of the HSPC clone and worsening of the hematopoietic inefficiency in MDS.
Interestingly, the expression of TLR9 has been shown to be upregulated in MDS, but relatively
downregulated after conversion to AML. Like TLR9, TNFa is downregulated with MDS
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conversion to AML, but TLR2 and TLR4 transcripts remain elevated compared to healthy
controls.145
Recurring mutations in myelodysplastic syndrome lead to TLR dysregulation. MDS patients
with the recurring deletion of the 5q chromosome arm (del(5q)) also lose both miR-145 and
miR146a microRNAs, which are known to regulate TRAF6 expression.146 An MDS-like
phenotype may be elicited by knockdown of these microRNA or overexpression of TRAF6 in
HSPCs, validating the involvement of downstream TLR mediators in MDS. The association of
TRAF6 to MDS has been shown to occur through TRAF6-mediated alternative splicing of
negative regulators of the Rho GTPase Cdc42, causing its activation and hematopoietic
dysfunction.147 Dysregulation of TLR signaling plays a prominent role in the pathogenesis of
MDS, and future treatments may be targeted to downstream mediators of TLR signaling.
Acute Myeloid Leukemia
Development and Symptoms.
The goal of this dissertation is to determine the role of TLR signaling in acute myeloid
leukemia. Acute myeloid leukemia (AML) is a malignancy that arises from hematopoietic stem
and progenitor cells. In AML, hematopoietic stem/progenitor cells (HSPCs) gain mutations
and/or global epigenetic alterations that accumulate over time.148 These alterations do not
directly result in leukemia, but rather, competing clonal subpopulations of HSPCs. A subset of
these clonal HSPC populations then acquires sufficient genome and epigenome alterations to
become leukemia precursor cells, cells that can be transformed into leukemia cells by few further
alterations. This process culminates with the transformation of a leukemia precursor cell from
one of these clonal populations into a leukemia initiating cell. Once this transformation occurs,
the leukemia initiating cell proliferates rapidly, leading to the expansion of the leukemic clone
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within the bone marrow and disruption of the homeostasis of the bone marrow niche.
Accordingly, the population of leukemia blasts may be composed of several clonal populations,
defined by the presence of individual mutations and/or gene expression profiles. These leukemic
clonal populations demonstrate varying degrees of chemotherapy resistance and acquire new
mutations with treatment, amplifying the clinical challenge of disease reoccurrence.149
The expansion of the leukemic clone within the bone marrow disrupts ongoing
hematopoiesis, leaving critical systemic needs for erythrocytes, granulocytes, megakaryocytes
and other blood cells unmet. The unmet need for these hematopoietic cells results in the
development of symptoms classically associated with AML: frequent and prolonged bleeding,
bruising and contusions with very minor insult, susceptibility to infection, fatigue, and anemia. If
untreated, the expansion of the leukemia clone in the bone marrow will lead to death due to bone
marrow insufficiency or opportunistic infections. Additionally, leukemia cells may travel
throughout the body through the vasculature, seeding bone marrow niches throughout the body
and invading organs, such as the lungs, liver, and spleen.
AML may occur at any age, and overall AML incidence is 1.8 cases per 100,000 individuals.
However, the incidence rises to 12.2 cases per 100,000 individuals for patients over the age of
65. In the United States, 19,520 people are expected to be diagnosed with AML in 2018,
accounting for 1.1% of the overall cancer burden.150 Sadly, in 2018, approximately 10,670
people are expected to die of AML, accounting for 1.8% of cancer deaths. The increased
incidence of AML occurs in a progressive manner once the patient reaches the sixth decade.
Each decade thereafter increases the risk of AML development. Older patients tend to fare worse
than younger patients, with the five year survival of patients aged <65 years at 43%, 65-74 years
at 5.2%-13.5%, and 75-84 years at 2.0-3.0%.151 The frequent occurrence of AML in elderly
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patients poses obstacles for treatment, because, with advancing age, patients are at increased risk
for development of AML with adverse cytogenic profiles, other comorbidities, poor performance
status, and other predictors of adverse outcomes. Not only does the advanced patient age
predispose them to poor outcomes, but it also limits treatment options for older AML patients.
Causes of AML.
AML is primarily associated with four causes: 1) age; 2) prior exposure to carcinogens or
chemotherapy; 3) hereditary conditions; and 4) preexisting hematological disorders. As
previously described, AML incidence increases significantly with age, which is often described
as the primary risk factor for AML. Increased AML incidence with age co-occurs with other agerelated hematological diseases, such as MDS, clonal hematopoiesis, skewed myelopoiesis, and
increasing adiposity and inflammation within the bone marrow niche.
Prior exposure to a variety of genotoxic chemicals and stressors are associated with AML
development. Occupational exposure to benzene, a widely used solvent in rubber manufacturing,
oil and gasoline refineries, cleaning supplies, detergents, paints, dry-cleaning, and other
materials, is a well-established as a risk factor for AML. Cigarette smoking also results in
benzene exposure to the body and increased AML risk. Relative risk for AML development is
increased with both increased cigarette consumption and increased duration of smoking
activity.152 Interestingly, preclinical studies have shown upregulation of TLRs and inflammatory
cytokine expression in bone marrow mononuclear cells when they are exposed to cigarette
smoke extract.153 Lastly, preleukemic conditions, including MDS, have also been associated with
smoking.154, 155
The other chemical risk factor for AML is prior exposure to DNA damaging
chemotherapeutic agents, such as alkylating agents and topoisomerase II inhibitors.156 These
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treatments are applied to treat unrelated malignancies, but then result in the development of
treatment-related AML. Unfortunately, due to its poor response to chemotherapy and high
incidence of adverse cytogenetic factors, treatment-related AML has relatively unfavorable
prognoses compared to de novo AML.157 This same phenomenon is observed with therapeutic
doses of radiation. Thus, genotoxic stress, whether it is occupational, habitual, or therapy-related,
increases the risk of AML development.
AML is also associated with a number of hereditary conditions. Most notable among these is
trisomy 21 (Down Syndrome). Patients with trisomy 21 are at greater risk for AML characterized
by somatic mutations in the transcription factor GATA1, which coordinate with gene
dysregulation specific to trisomy 21.158, 159 Fortunately, Down syndrome patients with AML
respond very well to chemotherapy. Increased risk of AML is also associated with syndromes
characterized by mutation of tumor suppressor genes, including ataxia telangiectasia (ATM) and
Li-Fraumeni syndrome (TP53).160 AML is also associated with Fanconi anemia, WiskottAldrich syndrome, and Diamond-Blackfan anemia and germline GATA2 and RUNX1 genes.159,
161

Lastly, AML is known to development from preexisting hematological pathology, such as

MDS as previously described. This may also occur in aplastic anemia and paroxysmal nocturnal
hemoglobinuria (PNH).162, 163
Current AML Treatments.
For the past three decades, the standard of care for AML patients has been a 7+3 induction
chemotherapy regimen. This regimen is comprised of a dose of 60-90 mg/m2 daunorubicin or 1012 mg/m2 idarubicin delivered over 15 minutes on days 1-3 and a continuous, 24 hour 100
mg/m2 dose of cytarabine on days 1-7.164 These chemotherapy regimens yield a long-term
disease-free survival of approximately 30% for patients under the age of 60. However, for
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patients older than 60, only 5-10% will survive for five years or more, because the majority of
those that attain remission will see their disease relapse. Furthermore, the treatment-related
mortality for adults over 60 may be as high as 30%. As a result, an urgent unmet need for novel
treatments persists. More tolerable treatments for AML include azacitidine, which acts as a DNA
hypomethylating agent, reversing the silencing DNA hypermethylation observed in AML.
Azacitidine is used to treat AML in elderly patients to avoid treatment-related toxicities and was
recently shown to extend median survival by 3.8 months over conventional treatments in an
older patient population.165
Minimal Residual Disease.
Despite the achievement of complete remission rates of 64% by combination anthracycline
and cytarabine cytotoxic chemotherapy, median survival following an AML diagnosis stands at
8-9 months, with an overall five-year survival of 26%.166 Despite achieving complete remission,
certain subpopulations of leukemia cells, thought to persist in a quiescent stem-like state, survive
the cytotoxic chemotherapy regimen. These leukemia stem cells (LSCs) then proliferate and
regenerate the leukemia blast population, resulting in disease reoccurrence. This phenomenon is
known as minimal residual disease (MRD), wherein residual leukemia cells that survive the
initial chemotherapy treatment regenerate the initial disease. Because AML has such a high rate
of MRD, the goal of numerous preclinical studies and clinical trials is to develop a treatment that
successfully eradicates LSCs, preventing MRD.
Classification Methodologies and Subtypes of AML.
So far, AML has been described here as a singular disease. However, like many other
malignancies, AML is best described as a group of diseases which are phenotypically similar, but
genetically diverse. Accordingly, the two primary modes of categorizing AML subtypes rely on
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the morphological phenotype of the undifferentiated AML blast cells or the recurring genetic
mutations that have been observed in AML. The French, American, and British (FAB)
classification system divides AML into seven discrete subtypes based on the lineage and degree
of differentiation as determined by subtype morphologies as follows: M0: undifferentiated
myeloblastic leukemia; M1: acute myeloblastic leukemia with minimal maturation; M2: acute
myeloblastic leukemia with maturation; M3: acute promyelocytic leukemia (APL); M4: acute
myelomonocytic leukemia; M4eos: acute myelomonocytic leukemia with eosinophilia; M5:
acute monocytic leukemia; M6: acute erythroid leukemia; and M7: acute megakaryoblastic
leukemia.167 Of these AML subtypes, APL has the best prognosis. APL is characterized by a
t(15:17) translocation, resulting in a PML-retinoic acid receptor α (RARα).168 APL is effectively
treated with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide, both of which
act to degrade the PML-RARα fusion protein.168 These treatments yield remission rates greater
than 95% and cure rates greater than 80%.169 ATRA acts on the retinoic acid receptor to promote
myeloid differentiation in both APL and non-APL cells. However, ATRA-induced
differentiation is blocked in non-APL cells, and much research has been aimed at sensitizing
other AML subtypes to ATRA-induced differentiation. The FAB classification was used since
the 1970s, but it has since been widely replaced by the World Health Organization (WHO)
classification.
The WHO classification divides AML into groups based on a subset recurring genetic
mutations, with priority given to subtype-defining translocations. These include AML with
t(9:11) (MLL-MLLT3/AF9), t(8:21) (RUNX1-RUNX1T1/ETO), inv(16) (CBFβ-MYH11), APL
with t(15:17) (PML-RARα), and several other recurring translocations. Other categories include
AML related to previous DNA-damaging chemotherapy or radiation, AML with myelodysplasia-
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related changes, AML not otherwise specified, and other less commonly occurring AML
groups.170 Certain subtypes of AML respond more favorably to cytotoxic chemotherapy and thus
confer favorable prognoses.
AML with MLL Rearrangement.
As previously mentioned, several well-characterized translocations occur in AML. One gene
that is a frequent fusion partner in AML is the histone-lysine N-methyltransferase 2A (KMT2A)
gene, also known as mixed lineage leukemia 1 (MLL1 onward). The MLL1 gene is located at the
11q23 locus and encodes a 500kDa protein that acts as a histone methyltransferase through its
numerous functional domains and binding partners. As a histone methyltransferase, MLL1 is
required for epigenetic regulation of histones by removing activating methyl marks on the
histone 3 tail. MLL1 acts to exert silencing of gene expression through epigenetic modification
of enhancer regions. Approximately 11% of all AML patients exhibit MLL1 translocations or
rearrangements with a variety of recurring fusion protein partners.171 MLL-rearrangement occurs
in 38% of M5 monocytic AML subtype, accounting for 32.7% of adult M5 AML and 52.6% of
pediatric M5 AML.171 The resulting fusion proteins are characterized by the loss of the Cterminal MLL1 exons, corresponding functional domains, and methyltransferase activity. The
retention of the N-terminal KMT2A domains permits localization to normal genomic regions
through intermediary proteins. Despite this, the MLL1 translocation partners, which comprise the
C-terminal domains of the resulting fusion protein, yield novel activity, which allows the fusion
protein to promote leukemogenesis.
The translocation of MLL1 is known to occur recurrently in leukemia with more than 80 other
genes, yielding a diverse group of fusion proteins. Fusion partners of MLL1 frequently are
members of a super-enhancer complex (SEC).172, 173 The fusion of silencing MLL1 with SEC
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components amplifies the epigenetic dysfunction inherent to MLL1 mutation. Rather than acting
to downregulate epigenetic loci across the genome by removing gene expression promoting
methylation, MLL1 fusions or rearrangements exert an activating effect on the genome by
allowing SEC components to activate RNA polymerase II mediated gene transcription. MLL1
rearrangements are characterized by reactivation of the embryonic HOXA gene cluster, MEIS1,
and other genetic programs to drive leukemia pathogenesis. In particular, HOXA9, PBX3, and
MEIS1 have been shown to be required for MLL-fusion leukemic transformation and leukemia
stem cell maintenance and surface, and knockdown of these genes.174, 175 Lastly, MLLMLLT3/AF9 (termed MLL-AF9 onward) has been widely studied in preclinical murine models.
This is because retroviral expression of human MLL-AF9 cDNA efficiently transformed murine
progenitor cells into a potent cell line, capable of serial in vivo transplantation and
leukemogenesis.176 This model system has been widely used to study the pathogenesis of MLLAF9 leukemia in vivo in a preclinical setting, and will be using in this study of TLR signaling in
AML.
Toll-like Receptor Signaling in AML.
Because AML cells are partially differentiated blasts, arising from stem and progenitor cells,
they bear many of the cell surface markers and immune signaling pathways also found in
granulocytes, monocytes, macrophages and their progenitors. These shared markers and
signalings pathways are known to include TLRs and IL-1R. However, despite the knowledge
that TLRs are present on AML cells, the literature is divided on their exact role, if any. Some
believe that TLRs and IL-1R are required to maintain leukemia cells, and that blocking these
pathways would be a viable treatment for leukemia. However, others contend that the presence
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of TLRs allows leukemic blasts to be differentiated by way of a specific TLR-stimulation. Here,
the current status of published literature will be reviewed as it relates to TLR signaling in AML.
Toll-like receptor signaling to induce AML blast differentiation. Several studies show that
the stimulation of certain TLRs induces partial differentiation in human cell lines and primary
tissues. The goal of these stimulations is to either partially mimic the terminal differentiation
induced by ATRA and arsenic trioxide treatment in APL or to partially differentiate leukemic
blast cells so that they become autoreactive and elicit cytotoxicity against blast cells. Both TLR7
and TLR8 synthenic agonists, imiquimod and R848 respectively, have been shown to induce
differentiation of human cell lines.177, 178 TLR7/8 stimulation by R848 suppresses colony
formation and enhances nitrotetrazolium blue (NTB) signal in treated human HL60 and THP-1
cell lines through a MYD88 and p38 dependent mechanism.177 Stimulation of human cell lines in
vitro in a TLR7-MYD88-dependent manner by imiquimod induces cell cycle suppression and
apoptosis in a subset of cell lines.178 Stimulation of TLR7/8 by R848 also enhanced T cell
activation and killing of leukemia cells when co-cultured in vitro. Lastly, primary AML cells
may be induced to differentiate into AML-derived dendritic cells (AML-DCs) by IL4 and GMCSF.179 Following this differentiation, enhanced cytotoxic activity and leukemia cell killing was
elicited by combined treatment with TNF-a, R848, and LPS. Thus, several possible mechanisms
exist that favor TLR stimulation as a therapeutic adjunct to AML treatment.
Of note, the subcutaneous administration of TLR7 synthetic agonist 852A has been clinically
tested on a small cohort of patients with AML, ALL, non-Hodgkin’s lymphoma, Hodgkin’s
lymphoma, and multiple myeloma.180 The 852A TLR7 agonist was intended to stimulate
plasmacytoid dendritic cells to have an anti-tumor response, and, of the thirteen patients studied,
resulting in 1 complete response, 1 partial response, 2 stable diseases, and 9 patients with
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progressive disease. The precise effect of the TLR7 agonist on the tumor cells themselves was
not studied, but observed tolerability of the prolonged drug administration and clinical
effectiveness in a subset of patient merits further study to clarify the precise mechanism of TLR7
agonism.
Toll-like receptor and IL-1 receptor inhibition to treat AML cells. In contrast, several
studies have indicated that TLR and IL-1R signaling protects leukemia cells and are required for
their survival and pathogenesis. The most significant and thorough of these studies links
MYD88-IRAK4 signaling and the epigenetic modifier MLL1, specifically in MLL1-rearranged
leukemia.181 Stimulation of MYD88 signaling activates IRAK4 and results in IRAK4-mediated
activation of the ubiquitin ligase UBE20. UBE20 then ubiquitinates MLL1 on its C-terminal
domain, marking it for degradation. However, this domain is lost in MLL1-rearranged leukemia,
and chronic stimulation of MYD88-dependent signaling results in the selective degradation of
wildtype MLL1, with no effect on mutated MLL1 fusions, which allows the MLL1-rearranged
fusion protein to exert its pro-leukemia epigenetic effect without having to compete with the
epigenetic silencer MLL1.
The protective effect of MYD88-dependent signaling in leukemia cells was shown by the
sensitization of leukemia cells to NF-kB inhibitors after dual IL-1R and TNFR inhibition using
murine in vitro and in vivo systems and primary patient samples.182, 183 Primary AML samples
may induce their own proliferation by production of IL-1 and IL-1-mediated induction of GMCSF.184 This protective effect was thought to occur by IL-1b-mediated induction of NF-kB
transcription of pro-survival genes and complementary pro-survival pathways.
Interestingly, TLR4 is stimulation is known to result in ligand-specific responses. Known
TLR4 ligands S100A8 and S100A9 are produced by a subset of AML cells in myelomonocytic
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and monocytic primary patient samples as well as murine and human in vitro model systems.185
When TLR4 is stimulated with S100A9, differentiation is induced by downstream ERK1/2, p38,
and JNK signaling. However, stimulation with S100A8, which may be produced by leukemia
cells as well, blocks this effect. The field of TLR stimulation in AML cells appears split with
respect to what the precise effect of TLR signaling is on AML cells, but this study raises the
possibility that the differentiation phenotypes observed in AML cells might be receptor-specific,
or even ligand-specific. The presence of certain ligands might even blunt or block the prodifferentiating effect of other ligands, as with S100A8 blocking the effects of S100A9. Lastly,
these findings suggest that AML blast cells are capable of modulating their own differentiation
by producing these TLR4 ligands to potentially block differentiation induced by TLR4. Though
TLR4 is known to have many more DAMP ligands than other TLRs, nearly every other TLR has
known DAMP ligands, and their effects on AML pathogenesis remains uncharacterized.
Lastly, downstream TLR signaling pathways are known to have potent pro-leukemia effects.
TAK1 is known to be overexpressed in AML primary patient samples and genetic knockdown or
pharmacologic inhibition of TAK1 impairs AML survival in vitro.186 TAK1 inhibition exerts
negative effects on NF-kB activation, which is well-known to be required for AML
pathogenesis. Several combinatorial approaches have been proposed and validated in preclinical
models that would integrate targeted inhibition of NF-kB with standard chemotherapy or with
other targeted inhibitors of IL-1R, JNK and other pathways activated in AML.
Summation, Hypothesis and Aims
In summary, TLR signaling is an essential signaling network for functional innate immune
responses. TLR signaling maintains hematopoiesis and is required for myelopoiesis during
infections. Recently, TLR signaling has been shown to promote carcinogenesis in numerous
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solid tumors, including breast cancer, colorectal cancers, pancreatic cancer, hepatocellular
carcinoma, and others. In hematopoietic diseases, particularly MDS, TLR signaling is known to
be dysregulated due to loss of suppressors of TRAF6 and other TLR mediators. MYD88 is also
known to be mutated in Waldenstrom’s macroglobinemia and several B cell lymphoma subtypes,
leading to aberrant and constitutive NF-kB activation. TLR signaling pathways are expressed in
AML cells, though their exact function remains unclear. Previous research efforts have sought to
induce partial differentiation of AML cells by TLR stimulation, either alone or in combination
with other agents. TLR and IL-1R signaling in AML cells is known to protect AML cells from
cell death.
Recent microarray data on a large cohort of AML patients, generated by Jianjun Chen, Ph.D.
in collaboration with Jiwang Zhang, M.D./Ph.D. and previously published in Leukemia, indicates
that expression of TLR signaling factors is enhanced, specifically in M4/M5 AML subtypes
(Figure 5, modified from Figure 1 in Xin et al.).187 Several cell surface TLRs, including TLR1,
TLR2, TLR4, and TLR5, both TLR adaptors MYD88 and TICAM-1, and several TLRassociated signaling components were found to be overexpressed, specifically in M4 and M5
AML when compared against their expression in other FAB subtypes. This microarray was used
to support the presence of inflammatory signaling in the M4/M5 FAB subtype propagated by
RIPK1 and RIPK3. However, this microarray also indicates a specific upregulation of TLRs and
their signaling intermediaries.
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Figure 5. Primary Patient Microarray Demonstrates Upregulation of TLR-Associated
Transcripts. Microarray and clustering analysis performed by Jianjun Chen, Ph.D., and
published in Leukemia.187 It has been reproduced here with permission. Specific genetic
alterations and clusters of upregulated TLR transcripts are highlighted, and TLR-associated
genes in clusters A and B are highlighted in red.
Informed by this data and literature, I hypothesized that TLR signaling, through both MYD88
and TICAM-1, protects the leukemia cell by activating downstream NF-kB in certain leukemia
subtypes. To determine a possible differential role of TLR signaling pathways in AML subtypes,
this study examined multiple leukemia subtypes, but primarily focused on MLL-AF9 murine
leukemia models and MLL-rearranged human cell lines. I divided this study into two broad aims.
First, the precise contribution of MYD88 and MYD88-dependent signaling to TLR signaling was
to be determined both in vitro and in vivo. Second, the contribution of TICAM-1 and TICAM-1dependent signaling was to be determined both in vitro and in vivo. These studies utilized both
pharmacological inhibition of kinases dependent on these adaptors and direct genetic deletion or
knockdown of MYD88 and TICAM-1.
AIM 1: Determine the contribution of MYD88 and MYD88-dependent signaling to TLR
signaling both in vitro and in vivo.
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AIM 2: Determine the contribution of TICAM-1 and TICAM-1-dependent signaling to TLR
signaling both in vitro and in vivo.

CHAPTER TWO
MATERIALS AND METHODS
Cell Culture
All cells are cultured at 95% humidity, 37° Celsius, and 5% carbon dioxide. 1640 Roswell Park
Memorial Institute (RPMI) medium with 2.05mM glutamine with 10% heat-inactivated fetal
bovine serum (FBS), 100IU penicillin, and 100µg/mL streptomycin (CorningTM CellGroTM,
MT30002CI) was used for in vitro cell culture. Human leukemia cell culture was applied as
indicated by the American Type Culture Collection. For murine leukemia and hematopoietic cell
culture, it was supplemented with 100 ng/mL recombinant murine stem cell factor (rmSCF), 20
ng/mL recombinant murine IL-3 (rmIL-3), 50 ng/mL recombinant murine IL-6 (rmIL-6), and 20
ng/mL recombinant murine granulocyte/macrophage colony stimulating factor (rmGM-CSF).
Human 293T cells were cultured in HyCloneTM Dulbecco’s modified eagles medium (DMEM,
catalog number: SH3002201, Fisher Scientific) supplemented with 10% FBS, 100IU penicillin,
and 100µg/mL streptomycin.
Retrovirus and Lentivirus Generation and Infection
Both retrovirus and lentivirus were generated using calcium phosphate transfection using the
CalPhosTM Mammalian Transfection Kit as indicated (Clontech®, catalog number 631312). For
retrovirus to be used to infect cells of murine origin, Phoenix-Eco cells were transfected and
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used to generate retrovirus. For generation of lentivirus or retrovirus for infection of human cell
lines 293T cells were transfected. 15µg DNA of vectors bearing the desired shRNA or gene to be
expressed were mixed with packaging and backbone vectors. For retroviral infections, 15µg
pCL-Ampho was used as the packaging vector and 3.5µg pCMV-VSVG was used as the
backbone vector. For lentiviral infections, 6.5µg pCMV-dR8.2 was used as the packaging vector,
and 3.5µg pCMV-VSVG was used as the backbone vector. The DNA mixture was transfected
into 3x106 virus-producing 293T or Phoenix-Eco cells overnight at 37° Celsius. After sixteen
hours, the original medium to which the transfection was added was removed, and 5mL DMEM
with 10% FBS was added. The transfected cells were then kept at 32° Celsius for 48 hours.
Media was collected at 24 hours and 48 hours after the initial media change and kept as virusenriched media to be used for infections. Before infection, virus-enriched media was spun down
at 1600RPM for 6 minutes at 32° Celsius to pellet any cells and debris. Both lentiviral and
retroviral infections were performed by adding 1mL virus-enriched media to pelleted cells and
mixing with 8µg polybrene per mL. The cells were centrifuged for 3-4 hours at 2000RPM at 32°
Celsius. After infection, cells were plated in a fresh 12-well plate in complete culture medium.
Generation of Murine Leukemia Cell Lines
Female C57BL/6J mice bearing wildtype Myd88+/+, Myd88-loxP (Myd88fl/fl), and Myd88
knockout (Myd88-/-) were obtained from the laboratory of Katherine Knight, Ph.D., who
originally acquired them from Jackson Labs. These mice were sacrificed by carbon dioxide
asphyxiation, followed by cervical dislocation, as indicated by our laboratory animal protocol.
Within 30 minutes of sacrifice, the long bones of the mouse hind limb, the tibia and femur, were
isolated and flushed with media using a 27 gauge syringe. A 70µM filter was applied to filter the
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bone marrow. Red blood cells were lysed and the remaining cell culture was selected for CD117positive hematopoietic progenitors.
EasySep mouse CD117 positive selection kit (Stemcell Technologies) was applied to select
CD117-positive cells from whole bone marrow culture. CD117 selection was individually
applied to such cultures obtained from mice bearing wildtype Myd88+/+, Myd88-loxP (Myd88fl/fl),
and Myd88 knockout (Myd88-/-) to isolate CD117+ cells bearing the same genotype. CD117+
cells were transformed by infection with retrovirus containing vectors bearing human cDNA
MLL-AF9, MLL-ENL, or AML-ETO. Retroviral infection was performed by centrifuging cells
with aliquoted virus for three hours at 2000 rotations per minute (RPM) at 22° Celsius. MLLAF9 and MLL-ENL are expressed on the MSCV expression vector, which also has a neomycin
resistance gene. Thus, they were selected on methylcellulose in the presence of 1.25mg/mL
G418. AML-ETO is expressed on the Migr1-GFP vector, and cells infected with AML-ETO
were purified by fluorescent-activated cell sorting (FACS). Once a purified population of
leukemia cells was established, these cells are referred to as pre-leukemia cells (PLCs). To
generate leukemia cells from these newly transformed cells, one million (106) PLCs were
transplanted per female C57BL/6J mouse after lethal 9.0 Gray irradiation using the RS-2000
Biological Research Irradiator (Rad Source). In addition to leukemia cells, 2x105 bone marrow
cells from a syngeneic donor Transplantation was performed several hours after irradiation, to
allow mice time to rest. Upon leukemia development, the circulating leukemia cells (LCs) were
collected from the spleen or bone marrow and purified under culture conditions.
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Derivation of Myd88Δ/Δ MLL-AF9 Leukemia Cells from Myd88fl/fl MLL-AF9 Leukemia
Cells
To determine the effect of Myd88 deletion on established leukemia cell lines, MLL-AF9 murine
leukemia cells bearing a LoxP-flanked Myd88 gene (Myd88fl/fl) were established. Deletion of the
Myd88 gene was achieved using two approaches. First, retroviral infection of Myd88fl/fl with Cre
on a Migr1-mCherry vector was performed by centrifugation (2,000RPM for 3 hours at 22°
Celsius) with 8µg polybrene per mL. Cre-expressing cells were identified by detection of
mCherry by flow cytometry and selectively sorted. Polymerase chain reaction (PCR) using
primers obtained from Jackson LaboratoryTM and a designed primer to confirm Myd88 deletion.
Alternatively, Myd88 deletion was achieved by first expressing a fusion protein of a modified
estrogen receptor (ERT2) and Cre (CreERT2). The fusion protein is excluded from the nucleus
in conditions without ERT2 stimulation, so Cre can only delete Myd88 in conditions of ERT2
stimulation. 4-hydroxytamoxifen (4OHT) is widely used to induce CreERT2 activation, and
10nM of 4OHT treatment for 16 hours was used to efficiently induce Myd88 deletion, which was
confirmed by PCR as described earlier.
Secondary Transplantation of MLL-AF9 Leukemia Cells
For secondary transplant of leukemia cells, female C57BL/6J mice were obtained from Jackson
LaboratoryTM. These mice were subjected to single sublethal irradiation doses of 4.5 or 5.0 Gray
or a lethal irradiation dose of 9.0 Gray, as indicated in each experiment. If mice were lethally
irradiated, then 2x105 bone marrow cells per mouse from syngeneic donor mice were
transplanted as well. Following irradiation, mice were allowed to rest for no less than three
hours. Murine MLL-AF9 cells were transplanted by tail vein injection. As indicated in each
experiment, 10,000 to 20,000 murine MLL-AF9 leukemia cells were transplanted per mouse.
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Following transplant, mouse water bottles were supplemented with 0.1mg/mL enrofloxacin
(Baytril) to prevent opportunistic bacterial infections following bone marrow irradiation.
Enrofloxacin stock solution was made at a concentration of 10mg/mL in autoclaved ddH2O and
diluted 1:100 when added to mouse water bottles. After day 14 following transplant,
enrofloxacin treatment was stopped. Beginning at 20 days after transplant, mice were monitored
every two days for leukemia development and daily once leukemia development is observed in
any single mouse. Upon leukemia development, as observed by mice with immobilized hind
limbs, overt anemia, and/or greatly reduced mobility and strength, mice were sacrificed by CO2
asphyxiation, followed by cervical dislocation. Following sacrifice, total body mass, liver mass,
and spleen mass were measured to assess leukemia status. If necessary to confirm leukemia
status, peripheral blood was collected by cardiac puncture and assessed by peripheral blood
smear and Hemavet analysis. Further, bone marrow cells were aspirated and filtered before
cytospin and Wright-Giemsa staining. If the transplanted leukemia cells expressed fluorescent
markers, the degree of these expression of these markers was assessed by flow cytometry. Lastly,
tissues from spleen, liver, lung, and kidney were fixed in zinc formalin for hematoxylin and
eosin staining by the Loyola Pathology Department.
IRAK Inhibitor Drug Treatment in vivo
Leukemia cells were transplanted as described for a secondary transplant. Mice were sublethally
irradiated at 4.5 Gray and transplanted with 10,000 cells by tail vein injection. Mouse drinking
water was supplemented with 0.1mg/mL enrofloxacin to prevent mortality from opportunistic
infections that would arise due to bone marrow ablation due to irradiation. Mice were divided
into 4 groups of 10. Drug vehicle was composed of a 10:90 ratio of DMSO:H2O to facilitate drug
solvency. The four treatment groups were treated as follows: (1) vehicle control; (2) 4mg/kg
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IRAK1/4 inhibitor (Sigma I5409); (3) 20mg/kg Compound 26 IRAK4 inhibitor (Calbiochem
531237); (4) combination treatment with both inhibitor doses. Mice were treated by i.p. injection
at 10, 12, 14, 16, and 18 days after transplantation. Following treatment, leukemia was allowed
to develop. Mice were sacrificed, and leukemia was verified by bone marrow cytospin,
peripheral blood smear, peripheral blood Hemavet analysis, spleen mass, liver mass, total body
mass, and staining of bone marrow and peripheral blood mononuclear cells with anti-Gr1 and
anti-CD11b fluorescently labelled antibodies.
Genotyping and Other Polymerase Chain Reaction Applications
DNA was harvested from pelleted cells after overnight 55° Celsius incubation with lysis buffer
(10mM Tris, 100mM NaCl, 10mM EDTA, 0.5% SDS) and 0.4µg/mL Proteinase K, followed by
isopropanol precipitation. Precipitated DNA was washed with 4° Celsius 70% ethanol and
resuspended in 30-100µL H2O. Polymerase chain reaction was performed using the GoTaq®
PCR kit as instructed (Promega Corporation, Catalog number M3001). Primers, listed 5’ to 3’
below were used to differentiate between wildtype, LoxP-flanked, and deleted Myd88 genotypes.
Refer to Figure 4 for the position of these primers on the gene. PCR was applied to genomic
DNA isolated by isopropanol precipitation with all three primers present. Mice and leukemia
cells with wildtype Myd88+/+ genotypes are expected to yield a 266 base pair product. Myd88fl/fl
genotypes are expected to yield a 353 base pair product, and Myd88-/-or Myd88Δ/Δ genotypes
produce a 550 base pair length product if knockout is present. Additionally, if only Forward
primer 1 and the reverse, are used, then the reaction yields an 852 base pair length product, so
the use of this PCR primer confirms the presence or absence of exon 3 deletion.
Forward Primer 1: TCC GAG AAG CCT TTA CAG GTG
Forward Primer 2: GTT GTG TGT GTC CGA CCG T
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(oIMR9481 from Jackson Laboratory)
Reverse Primer: GTC AGA AAC AAC CAC CAC CAT GC
(oIMR9482 from Jackson Laboratory)
Immunoblotting
Lysates were prepared by first counting cells from plated suspension culture or experimental
conditions using 0.4% Trypan blue (LONZA) on the TC10 automated cell counter (Bio-Rad).
Each count was performed twice, on thoroughly mixed cell culture, and averaged. One million
(106) cells were centrifuged at 1,600RPM and 4° Celsius for 6 minutes and washed twice in
phosphate buffered saline (PBS). Cell pellets and lysates were kept on ice through the process.
After washing, supernatant was removed by aspiration and the pellet was lysed in 300µL 1x lysis
buffer (Cell Signaling Technologies). Lysis buffer was supplemented with phosphatase and
protease inhibitors (PhosSTOP and cOmplete Tablets EASYpack, both from Roche). Following
addition of lysis buffer, lysates were frozen in the -80° Celsius freezer for at least 30 minutes.
Lysates were then thawed and sonicated. Sonicated lysates was centrifuged for 10 minutes at
14,000RPM at 4° Celsius. Supernatant was removed and the loading dye, with sodium dodecyl
sulfate (SDS) and β-mercaptoethanol (BME) was added before boiling samples for 10 minutes at
100° Celsius. Samples were electrophoresed on 10% acrylamide Tris-HCl. PageRuler Plus
prestained protein ladder was used to approximate molecular weights (Thermo Scientific
#26619). Samples were transferred to nitrocellulose using the Transblot-Turbo Transfer system
and the Ready-to-assemble transfer kit as indicated (Bio-Rad). Ponceau stain was applied to
verify successful transfer and cut the blots. Tris-buffered saline with Tween 20 (TBS-T) was
added to wash the Ponceau stain from the blot. Either 5% milk in TBS-T or 4% bovine serum
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Antibody Target

Species

Clonality

Isotype

Company

Β-ACTIN

Monoclonal

Mouse
IgG
Mouse
IgG
Rabbit

MLKL (D2I6N)

Human,
Mouse
Human,
Mouse
Human,
Mouse
Mouse,
Human
Human

Mlkl (D6W1K)

Mouse

Monoclonal

P38 MAPK

Human,
Mouse
Human,
Mouse
Human

Monoclonal

Human,
Mouse

Monoclonal

Santa Cruz
Biotechnology
Sigma-Aldrich
®
Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®

Mouse

Monoclonal

Ser358-p-MLKL Human

Monoclonal

RIP1

Human

Polyclonal

Rip3 (D4G2A)

Mouse

Monoclonal

RIP3 (E1Z1D)

Human

Monoclonal

TBK1/NAK
(D1B4)
Thr180/Tyr182p-p38
Thr183/Tyr185p-SAPK/JNK
(81E11)
TICAM-1

Human,
Mouse
Human,
Mouse
Human,
Mouse

Monoclonal

Human,
Mouse

Purified
Polyclonal

GAPDH
IRAK4
MYD88 (D80F5)

SAPK/JNK
Ser166-p-RIP1
Ser172-pTBK1/NAK
(D52C2)
Ser345-p-Mlkl

Monoclonal
Polyclonal
Monoclonal
Monoclonal

Monoclonal
Monoclonal

Monoclonal
Monoclonal

Table 1. Antibodies Used for Immunoblotting.

Rabbit
IgG
Rabbit
IgG
Rabbit
IgG
Rabbit
IgG
Rabbit
IgG
Rabbit
IgG
Rabbit
IgG
Rabbit
IgG
Rabbit
IgG
Rabbit

Catalog
Number
C-2: sc8432
G8795
4363S
4283S
14993S
37705S
9212S
9252S
44590S
5483S
37333S

Rabbit
IgG
Rabbit
IgG
Rabbit
IgG
Rabbit
IgG
Rabbit
IgG

Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®
Cell Signaling
Technology ®

Mouse

Biolegend ®

657102
1H4B01

91689S
4926S
95702S
13526S
3504S
9211
4668S
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albumin (BSA) in TBS-T was used to block the nitrocellulose blot while gently rocking it for 1
hour. Primary antibodies were added at 1:1,000 dilution in fresh blocking buffer and left
overnight at 4° Celsius. Three 5-minute washes were applied while rocking the blot following
primary antibody probe. Secondary antibody was applied at 1:1,250 dilution. All antibodies,
unless otherwise specified, were obtained from Cell Signaling Technologies. GAPDH antibody,
obtained from Sigma Aldrich, was used as a loading control and was diluted 1:5,000 and
corresponding secondary was also diluted 1:5,000. Horseradish peroxidase (HRP) linked
secondary rabbit or mouse antibodies allowed the visualization of protein bands by
chemiluminescence using the WesternBrightTM Quantum detection kit (Advansta).
Colony Formation Assay
Colony forming ability of cells under various genetic and pharmacological conditions was
assayed by a colony forming unit assay. Cells were mixed and counted twice. Average live cell
number was averaged and used to calculate the volume for 30,000 cells. 30,000 cells were mixed
by vortexing in 3mL of culture medium. 3,000 cells, or 300µL by volume, was then pipetted into
3mL of mouse (M3434) or human (H4100) methylcellulose (STEMCELL Technologies).
Methylcellulose and cells were vortexed for 20-30 seconds. Methylcellulose-cell mixture was
plated in three 30mm plates, with 1mL and 1,000 cells per plate. After plating, cells were
allowed to grow for 7-10 days and then counted and imaged.
AnnexinV Staining and Flow Cytometry Quantification
AnnexinV staining was performed to assay cell death following inducible gene deletion or drug
treatment. The BD Pharmingen APC AnnexinV Apoptosis Detection Kit was used as indicated.
Treated cells were washed twice in 1% FBS in 1% PBS. Following washes, cells were
resuspended in AnnexinV binding buffer (0.01 Hepes/NaOH, 0.14 M NaCl, 2.5mM CaCl2) and
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5µL APC-AnnexinV antibody was added. Cells were counterstained with 25µL 7aminoactinomycin D (7AAD) to exclude dead cells. 20,000 events or more were recorded for
each experiment. AnnexinV with propidium iodide (PI) or 7AAD counterstains were recorded on
BD LSRFORTESSATM or FACSCANTO IITM flow cytometers. Collected data was analyzed
using FlowJo V9.9.6. All flow cytometry experiments used these cytometers and FlowJo
analysis.
Cell Surface Staining and Determination of Median Fluorescent Intensity
Leukemia cells of interest were plated at 100,000 cells per mL and cultured overnight. Cultures
were counts by Trypan blue staining and 150,000 cells were centrifuged and washed twice in
wash buffer (1x PBS with 1% FBS). Fluorescent antibodies were diluted 1:20 and added to
~100µL wash buffer before mixing cells and antibody. If compensation controls were needed,
they were stained at this time. Cells were left in the dark for 20 minutes before adding 3mL wash
buffer and centrifuging to rinse any excess antibody. Cells stained with antibody were then
resuspended in 150-300µL wash buffer prior to flow cytometry analysis.
Cell Cycle Analysis
Cells with >90% viability as measured by Trypan Blue counting were plated at 100,000 cells per
mL and cultured overnight in complete medium. Cells were then pelleted and washed in 1x PBS.
Fixation and permeabilization was performed by dropwise addition of 5mL 70% ethanol chilled
at -20° Celsius. Fixed samples were kept overnight at -20° Celsius. On the day of analysis, fixed
cell samples were washed in 1x PBS twice, treated with 100µg/mL RNase A for 15 minutes at
37° Celsius, and stained with 50µg/mL propidium iodide or 25µg/mL 7-aminoactinomycin D
(7AAD). During data collection, singlets were gated based on the height and width ratio of the
relevant fluorescent channel on linear scale, and no fewer than 25,000 events were collected.
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Edu Incorporation Assay
Click-iTTM Edu Pacific BlueTM Flow Cytometry Assay Kit (Catalog number: C10418) was
purchased from ThermoFisher and used as indicated. Two days before the experiment, cells were
plated at 50,000 cells per mL. The viability of these cells was tested the day before the
experiment and cells were replated at 100,000 cells per mL if the viability was greater than 90%.
Edu incorporation was tested by adding 10µM Edu directly to culture conditions, without
replating, as instructed. The cells were incubated with Edu for 30 minutes before pelleting and
washing cells with 1% BSA in 1x PBS. Cells were then fixed and permeabilized and the reaction
was catalyzed per the manufacturer’s protocol. Edu assays were performed independently of cell
cycle analyses.
Details Regarding shRNA Sequences and Vectors
Over the course of this study, shRNA was purchased from Origene, Genecopia, and SigmaAldrich. Their respective sequences, vectors, and selection markers are detailed in Table 2.
These shRNA were expressed on lentiviral vectors by centrifugation and sorting as previously
described.
Real-Time Quantitative PCR
Real-time quantitative PCR (RT-PCR) was performed to assay relative transcript levels across
cell lines and treatment conditions of various targets. Cells (typically more than 106) were
pelleted and fixed in 750µL TRI Reagent (Sigma T9424), with 20µL 5N acetic acid. Organic
elements were removed by addition 100µL 1-Bromo-3-Chloropropane (Sigma B9673), mixing,
4° Celsius 12500RPM centrifugation, and careful removal of the aqueous layer. RNA was when
precipitated in isopropanol and washed in 70% ethanol with DEPC-treated water. RNA pellets
were dried and resuspended in DEPC water at 65° Celsius. To make cDNA, 2µg of RNA was
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first treated with DNase I (1UI/µL) for 30 minutes at 37° Celsius. DNase I was inactivated by
adding 25mM EDTA and heating the reaction to 65° Celsius for 10 minutes. Complementary
DNA (cDNA) was generated using the High Capacity Reverse Transcription Kit (Applied
Biosystems; Catalog: 4368814). The thermocycler conditions were as follows: 25° Celsius for 10
minutes, 37° Celsius for 120 minutes, and 85° Celsius for 8 seconds. The reaction was then
diluted six-fold and 4µL of the diluted RT reaction was used for the PCR reaction. RT-PCR
primers were obtained from IDT or Applied Biosystems and resuspended to a 20x concentration.
PCR reactions were performed in x2 Taqman Fast Advanced Master Mix (Applied Biosystems,
catalog: 4444557). Housekeeping β-actin transcript primers were labeled with HEX/VIC dye,
and experimental transcripts were amplified with FAM-labeled probes in duplex. Each assay was
performed in triplicate. Final qPCR reactions were as follows: 4µL cDNA product, 1µL
housekeeping gene primer, 1µL target gene primer, 4µL water, and 10µL Fast Advanced Master
Mix (Applied Biosystems, catalog: 4444557). RT-PCR reactions were performed on a
Quantstudio 6 Flex machine (Applied Biosciences). Cycling conditions were: 2 minutes at 50°
Celsius, 20 seconds at 95° Celsius, and 40 cycles of 1 second at 95° Celsius for and 20 seconds
at 60° Celsius. Data were analyzed using ΔΔCt to determine relative transcript levels.

shRNA
Target
IRAK1
IRAK1
IRAK1
IRAK1
IRAK1
Irak1
Irak1
Irak1

Irak1

Species Lab Vendor Catalog Number
Name
Sequence (5’-3’)
Human A
Sigma- 1. TRCN0000000543
Aldrich 2. CCGGCCCTCCTACCTGCTTACAATTCTCG
AGAATTGTAAGCAGGTAGGAGGGTTTTT
Human B
Sigma- 1. TRCN0000121238
Aldrich 2. CCGGCATCGCCATGCAGATCTACAACTCG
AGTTGTAGATCTGCATGGCGATGTTTTTG
Human C
Sigma- 1. TRCN0000000544
Aldrich 2. CCGGGCCCGAAGAAAGTGATGAATTCTCG
AGAATTCATCACTTTCTTCGGGCTTTTT
Human D
Sigma- 1. TRCN0000121138
Aldrich 2. CCGGGCCACCGCAGATTATCATCAACTCG
AGTTGATGATAATCTGCGGTGGCTTTTTG
Human E
Sigma- 1. TRCN0000121239
Aldrich 2. CCGGGAACACGGTGTATGCTGTGAACTCG
AGTTCACAGCATACACCGTGTTCTTTTTG
Mouse A
Sigma- 1. TRCN0000011877
Aldrich 2. CCGGCCTCAACGACTGGACATTCTTCTCGA
GAAGAATGTCCAGTCGTTGAGGTTTTT
Mouse B
Sigma- 1. TRCN0000055088
Aldrich 2. CCGGCAAGCAGAGTACCTAAGGAATCTCG
AGATTCCTTAGGTACTCTGCTTGTTTTTG
Mouse C
Sigma- 1. TRCN0000055089
Aldrich 2. CCGGGACACCGATACCTTCAGCTTTCTCGA
GAAAGCTGAAGGTATCGGTGTCTTTTTG
Mouse

D

Vector
(Selection)
pLKO.1
(Puromycin)

Knockdown
Yes

pLKO.1
(Puromycin)

Yes

pLKO.1
(Puromycin)

No

pLKO.1
(Puromycin)

No

pLKO.1
(Puromycin)

No

pLKO.1
(Puromycin)

Yes

pLKO.1
(Puromycin)

Yes

pLKO.1
(Puromycin)

No

Sigma- 1. TRCN0000271170
pLKO.1
Aldrich 2. CCGGTACCGAGCAGTCATGAGAAATCTCG (Puromycin)
AGATTTCTCATGACTGCTCGGTATTTTTG

Yes
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Irak1

Mouse

E

Tbk1

Mouse

A

Tbk1

Mouse

B

Tbk1

Mouse

C

Tbk1

Mouse

D

Tbk1

Mouse

E

TICAM
1
TICAM
1
TICAM
1
TICAM
1
Ticam1

Human A
Human B
Human C
Human D
Mouse

A

Ticam1 Mouse

B

Ticam1 Mouse

C

Sigma- 1. TRCN0000284313
Aldrich 2. CCGGTGGTGAAACAGAGCTTCTTAACTCG
AGTTAAGAAGCTCTGTTTCACCATTTTTG
Sigma- 1. TRCN0000353117
Aldrich 2. CCGGACATGACGGCGCATAAGATTTCTCG
AGAAATCTTATGCGCCGTCATGTTTTTTG
Sigma- 1. TRCN0000345144
Aldrich 2. CCGGCAGAACGCAGACTAGCTTATACTCG
AGTATAAGCTAGTCTGCGTTCTGTTTTTG
Sigma- 1. TRCN0000323444
Aldrich 2. CCGGCCAGAATCAGAATTTCTCATTCTCG
AGAATGAGAAATTCTGATTCTGGTTTTTG
Sigma- 1. TRCN0000345204
Aldrich 2. CCGGGGAACAGAACCGCGGTTTAACCTCG
AGGTTAAACCGCGGTTCTGTTCCTTTTTG
Sigma- 1. TRCN0000027015
Aldrich 2. CCGGCCAGAATCAGAATTTCTCATTCTCG
AGAATGAGAAATTCTGATTCTGGTTTTT
Origene 1. TL308823A
2. TCATCTACTCCTTGTTCAGCTCACCTGAC
Origene 1. TL308823B
2. CAGGACGCCATAGACCACTCAGCTTTCAT
Origene 1. TL308823C
2. CCTCATTATCCACCACGCACAGATGGTAC
Origene 1. TL308823D
2. CGCCACTCCAACTTTCTGTAGAAGATACC
Origene 1. TL505757A
2. CTCAGGTTCCTGTAGGAGATGATTCTCTG
Origene 1. TL505757B
2. CTGGAGTCCTTGAAGATGAACACAGTAGC
Origene 1. TL505757C
2. TGATGACAAGACTGAGTGTTCGGAGAACC

pLKO.1
(Puromycin)

No

pLKO.1
(Puromycin)

No

pLKO.1
(Puromycin)

Yes

pLKO.1
(Puromycin)

Yes

pLKO.1
(Puromycin)

No

pLKO.1
(Puromycin)

Yes

pGFP-CshLenti (GFP)
pGFP-CshLenti (GFP)
pGFP-CshLenti (GFP)
pGFP-CshLenti (GFP)
pGFP-CshLenti (GFP)
pGFP-CshLenti (GFP)
pGFP-CshLenti (GFP)

Yes
No
No
No
Yes
Yes
Yes
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Ticam1 Mouse

D

Origene 1. TL505757D
2. AGCTGCACTGTCTCCAAGATGCCATCGAT

pGFP-CYes
shLenti (GFP)

Table 2: Details for shRNA Sequences and Vectors. This table details the shRNA vectors, sequences, respective targets, annotation,
vector and mammalian selection marker of all shRNA applied in this dissertation. The “Lab Name” corresponds to the annotation used
for each shRNA throughout all experiments described here. Lastly, the catalog number and respective vendors are noted.
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CHAPTER THREE
RESULTS
TLR Signaling Components, including MYD88 and Downstream IRAK1 are Upregulated
and Associated with Poor Patient Survival in the TCGA Database
Previously, microarray analysis was applied to 580 adult primary patient AML samples by
with Jianjun Chen, Ph.D., at the University of Cincinnati (Figure 4) to determine whether TLRs
and downstream mediators are expressed in acute myeloid leukemia (AML) subtypes. The
microarray showed that TLR1, TLR2, TLR4, and TLR5 are overexpressed in M4 and M5
leukemia. Additionally, both MYD88 and TICAM-1 are overexpressed in M4 and M5 leukemia.
To determine whether TLRs and associated signaling pathways are overexpressed in other
publicly available datasets, relative transcript levels were assayed using the OncomineTM
Platform.188 These findings were confirmed in the published Wouters Leukemia dataset using
OncomineTM (Figure 5A).189 The Balgobind dataset showed an enrichment of TLR expression in
MLL-mutated AML compared to AML in which MLL is not mutated (Figure 5B).190 However,
despite established findings of increased inflammatory signaling with advancing age, surveying
Oncomine yielded no correlation between TLR signaling components with any age at diagnosis
in the leukemic clone (Figure 5C).
To determine whether signaling mediators in this pathway are associated with leukemia
progression and outcomes, I surveyed IRAK1, IRAK1 binding protein 1 (IRAK1-BP1), and
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PELLINO-1 using the BloodspotTM TCGA dataset browser.191 Consistent with the hypothesis
that MYD88-dependent signaling promotes non-acute promyelocytic leukemia (APL)
pathogenesis, overexpression of key mediators, IRAK1 and PELLINO-1 (Figure 6A and 6C),
required for MYD88-dependent signaling correlates with worse survival by Log-Rank statistical
analysis. In contrast, overexpression of a negative regulator of IRAK1 signaling, IRAK1-BP1,
correlates with more favorable survival outcomes (Figure 6B). Lastly the engagement of the IKK
complex by IRAK1 also correlates with poor survival (Figure 6D). To determine whether
expression of MYD88-independent signaling factors correlate with survival, TBK1, TRAF3
activation, and TICAM-1 were surveyed using the BloodspotTM TCGA browser.191 High
expression of TBK1 and TRAF3 correlates with poor survival when divided along median
expression (Figure 7A and 7B). Expression of TICAM-1 does not correlate with better or worse
survival across the whole TCGA dataset. When the TCGA dataset is narrowed to the samples
with the highest 10% or 25% of TICAM-1 expression, it correlates with favorable survival when
compared against the bottom 10% or 25% of samples (Figure 7C and 7D). Lastly TICAM-1 is
amplified in a small subset of AML samples. Within the TCGA dataset, TICAM-1 is amplified
in 1% of samples, and within the recently published TARGET dataset, it is amplified in 3% of
samples, representing the second most frequently amplified gene in the TARGET AML dataset
(Figure 8A and 8B). Importantly, when TICAM-1 expression was assayed, gain or amplification
of TICAM-1 resulted in a 0.5-1.0 log increase in expression (Figure 8C). When TICAM-1 was
surveyed in other available datasets, including acute lymphoblastic leukemia, chronic
lymphoblastic leukemia, myelodysplasia, and chronic myeloid leukemia, no such copy number
amplification was observed.
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Figure 5. Toll-like Receptor Pathways are Upregulated in Myelomonocytic and Monocytic
AML Subtypes and MLL-Rearranged AML. (A) Published Wouters leukemia dataset
(GSE14468) reveals upregulation of TLR signaling in myelomonocytic (M4) and monocytic (M5)
subtypes. P-values represent fold change of gene expression in M5 group to dataset average. (B)
Published Balgobind leukemia dataset (GSE17855) shows specific enrichment of TLR signaling
in MLL1-rearranged genes.
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Figure 6. TCGA Dataset Shows Survival Correlation with IRAK1 and IRAK1-Associated
Genes in AML. Transcript expression of IRAK1 and IRAK1-related genes across all AML
samples in the TCGA dataset. Asterisks in the heading indicate a Log-rank analysis pvalue<0.05. (A) Survival of TCGA AML patients is prolonged for patients with below-median
expression of IRAK1 (blue, dashed), and shortened for patients with above-median expression of
IRAK1 (red, solid). (B) High expression of IRAK1BP1, a negative regulator of IRAK1, is
associated with favorable survival. (C and D) Pellino-1 expression and gene signature
corresponding to IKK complex activity correlate with poor survival in TCGA AML samples.
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Figure 7. TCGA Survival Analysis Correlates with TICAM-1 Dependent Signaling
Components. (A) TBK1 expression correlates with poor survival when compared between the
upper and lower expression medians. (B) Gene signatures in the high-expressing median
corresponding to TRAF3-IRF3 activation correspond with poor survival compared to those in the
low expression median. (C and D) High TICAM-1 expression (black) correlates with poor survival
compared to low expression (red). The survival of the highest 10% or 25% TICAM-1 expression
was compared against the respective lowest 10% or 25% within the TCGA dataset.
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Figure 8. TICAM-1 is Recurrently Amplified in Separate AML Datasets. (A) Frequency of
TICAM-1 amplification or mutation by selected study as indicated. (B) Composite frequency of
TICAM-1 amplification, mutation, or deletion in leukemia types across the same study sample.
(C) TCGA TICAM-1 expression sorted by copy number amplification. Data was obtained and
visualized using cBioPortalTM.
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Toll-like Receptors are Expressed in Human and Murine Cell Lines
Next, to determine whether TLR1, TLR2, TLR4, and TLR5 are expressed in leukemia model
systems, we applied cell surface staining, using fluorescent antibodies. Consistent with
transcriptional data, TLR1, TLR2, and TLR4 were detected and expressed at the cell surface for
every cell line tested (Figure 9A, 9B, 9C). TLR5 is only expressed in the Mono-Mac-6 (MM6),
THP1, NB4, and HL60 cells (Figure 9A). The TLR expression of murine MLL-AF9 cells
mirrored that of several human cell lines in that TLR1, TLR2, and TLR4 were detected, but not
TLR5 (Figure 9C). Therefore, TLR expression is conserved in M4/M5 human cell lines and
murine MLL-AF9 leukemia cells.
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Figure 9. Cell Surface TLRs are Expressed on Human Cells and Transformed Murine
Models. (A) Compared to unstained controls, TLR1, TLR2, and TLR4 are expressed on human
HL60, MM6, Molm13, NB4, and THP1 cell lines. TLR5 is expressed on all cell lines except
Molm13 and NB4. (B) Human ML2 cell line expresses TLR1, TLR2, and TLR4, but not TLR5.
(C) Murine MLL-AF9 leukemia cells express TLR1, TLR2, and TLR4, but not TLR5.
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Germline Myd88 is Not Required for Transformation and Colony-Forming Efficiency when
Transformed with Fusion Proteins Reflecting MLL-Rearrangement or Core-Binding
Factor Mutations
Having shown that human and murine leukemia cell models are sensitive to IRAK inhibition,
I hypothesized that leukemia cells might find a way to evade such IRAK inhibition via a novel
resistance mechanism. To study the effect of complete loss of MYD88-dependent signaling in a
murine model, I devised two genetic approaches. First, Myd88-null (Myd88-/-) pre-leukemia cells
were derived from Myd88 knockout mice in parallel with leukemia cell derivation from Myd88wildtype (Myd88+/+) control mice (Figure 10A and 10B). Four different fusion proteins were
expressed by retroviral expression to first generate pre-leukemia cells (PLCs), which were
transplanted into mice and later harvested as leukemia cells (LCs) upon leukemia onset.
Interestingly, neither MLL-AF9 Myd88-/- PLCs nor Myd88-/- LCs showed a statistical difference
in the colony forming ability when compared to Myd88+/+ cells. MLL-ENL, CBFβ-MYH11, and
RUNX1-ETO PLCs were also derived and their clonogenic potential was measured by CFU
assays. Like MLL-AF9 PLCs, MLL-ENL cells showed no loss of colony forming ability when
derived from Myd88-/- mice and compared to Myd88+/+ leukemia cells. Interestingly, both
RUNX1-ETO and CBFβ-MYH11 PLCs demonstrated an increased colony number with Myd88-/PLCs, compared to Myd88+/+ PLCs (Figure 10C). Further study of Myd88-/- and Myd88+/+
leukemia cells, following primary transplant of PLCs into mice, indicates that germline Myd88null leukemia cells form colonies as efficiently as Myd88-expressing leukemia cells (Figure
10D). However, the remaining TLR signaling mediators are dysregulated in Myd88-/- PLCs, as
Ticam-1 protein levels are dramatically induced in the Myd88-null PLC background (Figure
10E). Based on this data, I concluded that loss of Myd88-dependent signaling prior to
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introduction of the leukemia MLL-fusion gene fails to limit leukemia cell function, as measured
by CFU assays. However, it also fails to accurately represent the effect of IRAK inhibition on
leukemia cells, since these Myd88-/- MLL-AF9 leukemia cells may be quite different from
Myd88+/+ MLL-AF9 cells.
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Figure 10. Myd88 is Not Required for AML Transformation and Exerts Fusion ProteinSpecific Effects. (A) Experimental scheme. (B) Genotyping of mice prior to retroviral fusion
protein infection. (C) Colony forming efficiency of transformed Myd88-/- pre-leukemia cells
relative to Myd88+/+ controls. Relative CFU efficiency was compared using a Student‘s t-test,
where n.s. indicates p>0.05, * indicates p<0.05 and **** indicates p<0.0001. (D) Colony forming
efficiency of leukemia cells (E) Immunoblot of MLL-rearranged and RUNX1-ETO
transformations confirming Myd88 deletion and assaying Ticam-1 levels.

67
Cre-LoxP Inducible Myd88 Deletion Models Disruption of Irak1/4 Signaling in MLL-AF9
Cells and Results in a Competitive Disadvantage
To accurately model the effect of chronic IRAK inhibition and lost MYD88-dependent
signaling by way of Myd88 deletion, I applied the Cre-Lox system. The Cre-Lox system utilizes
recombinant genetic engineering to place conserved LoxP sequences such that they flank key
genes or exons in noncoding regions. In the presence of flanking LoxP sites, expression of the
bacterial Cre recombinase results in deletion of the DNA interval in between the two LoxP sites.
Mice with such LoxP sites flanking exon 3 of Myd88 (Myd88fl/fl, Figure 11A) were generously
provided to us for experimentation by Katherine Knight, Ph.D. and Dominick Kennedy, Ph.D.
These mice bear the genotype described by and commercially available from the Jaxson
Laboratory. Using these mice, Myd88fl/fl MLL-AF9 leukemia cells were derived by retroviral
MLL-AF9 expression and transplantation into a primary host most as previously described
(Figure 11B). Introduction of Cre-recombinase by retroviral expression was shown to efficiently
and reliably delete Myd88, yielding Myd88Δ/Δ cells (Figure 11C and 11D). To determine whether
short-term Myd88 deletion alters the MLL-AF9 phenotype, Migr1-GFP empty vector controls
(EV) and Migr1-GFP-Cre vectors were expressed by retrovirus in Myd88+/+ controls and
Myd88fl/fl MLL-AF9 leukemia cells. Based on whether the infected fraction of GFP+ Cre+
Myd88Δ/Δ population remained level or declined relative to levels measured at 2 days postinfection (DPI), I could infer whether Myd88 deletion is dispensable or required for MLL-AF9
leukemia pathogenesis. Compared to control infections, the GFP+ Cre+ Myd88Δ/Δ population in
infected Myd88fl/fl MLL-AF9 cells, demonstrated a decline, indicating that Myd88 expression
and signaling are required for MLL-AF9 leukemia cell survival and a competitive growth
advantage. Because prior experiments by Li et al.182 have shown that joint inhibition of IL-1β
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and TNFα signaling suppresses leukemia cell stemness features, I hypothesized that TNFα
treatment might rescue the lost GFP+ Cre+ Myd88Δ/Δ population, and also performed the
experiment in the presence of TNFα (Figure 11E). TNFα treatment partially, but not completely
rescues the GFP+ Cre+ Myd88Δ/Δ population. The elevated GFP+ fraction in TNFα-treated
infections is lost over time and is comparable to untreated Myd88-/- MLL-AF9 leukemia cells by
8 days after infection. In conclusion, Myd88 deletion, and consequent loss of Myd88-dependent
signaling, suppresses murine MLL-AF9 leukemia cell growth. Myd88 deletion also exerts a
dominant effect over TNFα signaling such that TNFα treatment fails to rescue this phenotype.
Thus, I sought to further interrogate downstream Myd88-dependent signaling and characterize
the phenotype of Myd88-null leukemia cells.
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Figure 11. Inducible Myd88 Deletion Results in Competitive Disadvantage in in vitro Culture.
(A) Scheme for specific deletion of Myd88 exon 3, including primer location and base pair length
fl/fl
of murine intron and exon sequences. (B) Scheme for derivation of Myd88 leukemia cells. (C)
PCR genotyping verification of efficient Myd88 deletion after retroviral Cre recombinase
expression and sorting. (D) Immunoblot of designated cells to confirm loss of Myd88 protein
+/+
levels. (E) Cre recombinase or empty vector Migr1 were expressed in Myd88
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Myd88 Deletion Fails to Reduce Myd88-Dependent Signaling to Jnk and NF-κB
Additionally, the Cre+ Myd88Δ/Δ leukemia cells were used to determine whether any
significant loss of downstream signaling pathways occurred in the Cre+ Myd88Δ/Δ cell lines.
Downstream Myd88 signaling is characterized by IRAK4 auto-phosphorylation in the activation
domain induced by oligomerization with Myd88 assembled at the TLR or IL-1R undergoing
stimulation. First, 30 minute IL-1β stimulation was used to demonstrate that Cre+ Myd88Δ/Δ cells
were unable to induce IRAK4 phosphorylation (Figure 12A). Despite this, downstream Jnk and
NF-κB signaling were unchanged after 30 minute stimulation at 20ng/mL or 50ng/mL (Figure
12B). Despite our initial hypothesis that MYD88-dependent signaling primarily acts through
established, canonical Jnk and NF-κB signaling pathways, immunoblotting data obtained from
mouse indicate that the pro-leukemic effect of MYD88 signaling occurs through a pathway
independent of both NF-κB and Jnk.
Despite this, treatment of murine Cre+ Myd88Δ/Δ and Myd88+/+ murine leukemia cells with high
doses of TLR ligands elicit downstream activation of NF-κB and Jnk, in an Myd88-dependent
manner (Figure 12C and 12D). However, Jnk activation is dependent on Myd88 expression
while NF-κB is activated in the presence or absence of Myd88 when Ticam-1 independent
signaling is induced. Consistent with a lack of TLR5 detected by cell surface staining (Figure
7C), bacterial flagellin failed to induce any downstream signaling. In the course of these studies,
Tbk1 was found to be induced in a Tlr2-Myd88 dependent manner (Figure 12E). Tlr2-Myd88TICAM-1-Tbk1 induction was later published in the literature using a peritoneal macrophage
model.78 These findings led me to hypothesize that chronic IL-1β treatment promotes leukemia
cell growth. However, when co-cultured with recombinant murine IL-1β, murine MLL-AF9
transformed cells demonstrate no change in cell growth (Figure 13A). Further, co-culture with

LPS, results in Cre+ Myd88Δ/Δ leukemia cell number suppression, relative to untreated cells

71

(Figure 13B). In conclusion, while TLR signaling may induce downstream NF-κB and Jnk
activity, Myd88 is not required to maintain its expression. As in previous studies on IL-1β and
TNFα, I hypothesized that the primary mechanism of pathogenesis via MYD88-dependent
signaling was by activation of downstream NF-κB transcription factors and JNK kinases, and
AP-1 transcription factors by extension. While high doses of LPS and PAM3CSK4 were
sufficient to induce NF-κB activation by phosphorylation and JNK phosphorylation in the
presence of Myd88, IL-1β stimulation failed to induce a likewise activation of these downstream
signaling pathways.
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Figure 12. Downstream TLR Ligand and IL-1β Signaling is Lost in Myd88-/- MLL-AF9 Cells.
(A) Immunoblot of IRAK4 phosphorylation after 30 minute 20ng/mL IL-1b treatment in Myd88+/+
and Myd88-/- MLL-AF9 cells. (B) Downstream Jnk and NF-kB phosphorylation after IL-1b
treatment at 20ng/mL or 50ng/mL for 30 minutes in Myd88+/+ and Myd88-/- MLL-AF9 cells. (C)
Immunoblot of NF-kB phosphorylation in Myd88+/+ and Myd88-/- MLL-AF9 cells after treatment
with LPS, PAM3CSK4, or bacterial flagellin. (D) Immunoblot of Jnk phosphorylation in Myd88+/+
and Myd88-/- MLL-AF9 cells after treatment with LPS, PAM3CSK4, or bacterial flagellin. (E)
Immunoblot of phosphorylated Tbk1, Tbk1, and Gadph following timed treatment of Myd88+/+
and Myd88-/- MLL-AF9 cells with 1ug/mL LPS or 1ug/mL PAM3CSK4 (PAM).
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Figure 13. Chronic Stimulation with IL-1β has no Effect on Cell Growth, and LPS
Specifically Suppresses Myd88-/-Cre+ MLL-AF9 Cell Growth. (A) Growth curve with and
without 20ng/mL IL-1b treatment in suspension culture. (B) Growth curve with and without
designated doses of LPS in suspension culture. P-values are derived from Student’s t-test
comparison to untreated controls. N.S. indicates p>0.05, * indicates p<0.05, ** indicates p<0.01,
and *** indicates p<0.001.
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Cre Toxicity Limits Colony Forming Potential
To determine whether intact genomic Myd88 and Myd88-dependent signaling are required for
colony forming ability, I likewise expressed Migr1-mCherry-Cre in Myd88fl/fl MLL-AF9 cells
and control Myd88+/+ MLL-AF9 cells. Within 48 hours of infection, mCherry+ cells were sorted
by FACS and plated in M3434 methycellulose (StemCell) at 1000 cells per mL. Cre-expression
demonstrated a clear toxicity, reducing the colonies of both the Myd88fl/fl MLL-AF9 cells and
control Myd88+/+ MLL-AF9 cells tenfold relative to controls expressing Migr1-EV (Figure
14A). The negative effect of Cre expression on colony formation remains when Cre-infect cells
were kept in suspension culture and plated three weeks after infection (Figure 14B)
To address this issue, I used a variant of Cre recombinase with a fusion to a modified estrogen
receptor, hereafter referred to as CreERT2. CreERT2 is sequestered in the cytoplasm unless ER
ligands are introduced to in vitro culture or in vivo animal models, which allows for transport to
the nucleus and activation of Cre. Using this approach, I hoped to reduce or eliminate any toxic
side effects of Cre expression and more closely study the effect of Myd88 deletion on leukemia
cell function. To induce genomic Myd88 deletion, I began by treating Myd88+/+ controls and
Myd88fl/fl MLL-AF9 leukemia cells expressing either empty vector or CreERT2 with 0.5µM 4hydroxytamoxifen (4OHT) in methylcellulose culture to induce nuclear translocation of the
CreERT2 fusion. The 0.5µM 4OHT dose yielded likewise Cre-mediated toxicity (Figure 15A).
Even 40nM doses of 4OHT result in CreERT2-mediated toxicity in both methylcellulose and
liquid culture (Figure 15B and 15C). Therefore, I dosed the 4OHT to the nanomolar range and
found doses as low as 2.5nM 4OHT were sufficient to induce Myd88 deletion (Figure 15D).
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Figure 14. Cre Expression Induces Non-Specific Toxicity. (A) Colony forming efficiency of
Myd88+/+ and Myd88fl/fl MLL-AF9 cells with recent Cre expression. Cre recombinase was
retrovirally expressed on two Myd88+/+ MLL-AF9 cell lines and the Myd88fl/fl MLL-AF9 cells. 48
hours after retroviral expression, GFP+-Cre expressing cells were sorted and plated on
methylcellulose. (B) Colony forming efficiency of sorted Cre-expressing and empty vectorexpressing cells that were maintained in culture for three weeks and then plated on
methylcellulose. P-values reflect Student’s t-test and indicate * = p<0.05; ** = p<0.01; *** =
p<0.001; and **** = p<0.0001.
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Figure 15. CreERT2 Induction Results in Highly Efficient Recombination and Toxicity at
High Tamoxifen Doses. (A) CFU efficiency with induction of CreERT2 at 500nM 4OHT in
methylcellulose. (B) Pretreatment of LCs with EtOH or 40nM 4OHT for 24 hours followed by
CFU assay. (C) 40nM 4OHT treatment and subsequent AnnexinV/7AAD assay with EtOH vehicle
control treatment, EV-Migr1, CreERT2-Migr1, Myd88+/+ and Myd88fl/fl. (D) PCR assay of
recombination efficiency from 1nM to 40nM.
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CreERT2-Mediated Myd88 Deletion Limits MLL-AF9 Leukemia Cell Proliferation and
Colony Forming Ability
Thus, 10nM 4OHT was selected as a treatment dose. Myd88+/+ controls and Myd88fl/fl MLLAF9 leukemia cells expressing Migr1-EV or Migr1-CreERT2 were thus treated with 10nM
4OHT to selectively induce Myd88 deletion. Cells were treated in suspension culture in complete
media for 16 hours before washing away the 4OHT and allowing 48-hour recovery in suspension
culture (Figure 16A). Using this approach, Myd88 is efficiently deleted (Figure 16B). Within the
recovery period, a slight reduction in cell number and viability was observed in cells undergoing
Myd88 deletion, but not in control groups (Figure 16C). Following the recovery period, cells
were counted and plated in methylcellulose at 1,000 cells per mL. Compared to vehicle-treated
controls, the Myd88Δ/Δ leukemia cells formed colonies at 50% lower efficiency (Figure 16G). To
explain the phenotypes of growth disadvantages and reduced colony forming ability, several
hypotheses were proposed. First, the deletion of Myd88 and loss of downstream signaling led to
cell death. Second, partial differentiation accounted for the loss of proliferation in vitro.
To test the hypothesis that Myd88 expression is required for survival and viability, leukemia
cells were assayed for cell death by AnnexinV-APC and 7AAD staining. As with the CFU assay,
CreERT2+ Myd88fl/fl leukemia cells and controls were treated for 16 hours with 4OHT or ethanol
vehicle, washed, and cultured for an additional 48 hours before staining. Surprisingly, cell
viability remained comparable to vehicle control treatments (Figure 16D). In conclusion, Myd88
expression is not required for MLL-AF9 cell viability, even shortly after Myd88 deletion.
However, Myd88 deletion suppresses growth rate as determined by cell cycle analysis and
growth curves (Figure 16E and 16F). In vitro treatment of Myd88+/+ and Myd88-/-CreERT2+ MLLAF9 cells with daunorubicin reveals an approximately 8-fold reduction in the LC50 of Myd88-/-

Creert2+
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Mll-AF9 cells compared to Myd88 expressing cells (Figure 23H)/ Therefore, Myd88 is

required for colony-forming ability, proliferation, and resistance to daunorubicin-induced cell
death in MLL-AF9 cells.
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Figure 16. CreERT2-Mediated Myd88 Deletion Reduces Colony Forming Efficiency and
Proliferation.
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Figure 16. CreERT2-Mediated Myd88 Deletion Reduces Colony Forming Efficiency and
Proliferation. (A) Scheme for CreERT2 induction. (B) PCR verification of Myd88 deletion. (C)
Cell counts and viability after 4OHT treatment. (D) AnnexinV/7AAD assay 48 hours after 4OHT
treatment. CreERT2-activation in an Myd88fl/fl background is indicated by a red box. (E) Growth
curve assay. (F) Cell cycle analysis after staining with 7AAD (G) Colony forming efficiency assay
following 10nM 4OHT treatment. (H) MTS assay on Myd88+/+ and Myd88-/-CreERT2+ MLL-AF9
cells treated with increasing doses of daunorubicin. P-values reflect Student’s t-test and indicate *
= p<0.05; ** = p<0.01; *** = p<0.001; and **** = p<0.0001.
Myd88 is Not Required for Jnk1/2, Erk1/2, Stat3α, or
p38 Downstream Signaling Activation
To test whether this reduced proliferation and colony-forming phenotype occurs as a result of
reduced downstream signaling, previous immunoblotting experiments were repeated on CreERT2+
Myd88Δ/Δ leukemia cells. Of note, lysates for these experiments were collected 72 hours after
4OHT treatment. As described previously, phosphorylation of Irak4 is reduced (Figure 17A), but
the phosphorylation of Jnk1/2 Erl1/2, p38α and Stat3α are unchanged (Figure 17B and 17C).
Therefore, even in the event of recent Myd88 deletion, these downstream signaling pathways are
unchanged. Two lanes with lysates from Myd88-deleted cells are represented. The first (left) lane
is from cells with recent (72 hours) Myd88 deletion, and the second (right) lane is from cells in
which Myd88 deletion was induced 2 weeks prior to lysate collection. Therefore, Myd88 and
Myd88-dependent signaling are not required to maintain the activation of these pathways in MLLAF9 cells.
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Figure 17. Myd88 and Myd88-Dependent Signaling are Not Required for JNK, p38, or ERK
Activation in MLL-AF9 Cells.
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Figure 17. Myd88 and Myd88-Dependent Signaling are Not Required for JNK, p38, or ERK
Activation in MLL-AF9 Cells. Myd88-expressing leukemia cells and those with inducible Myd88
deletion were assayed for downstream activity. The Myd88-deletion cell line on the right are cells
that have Myd88 deletion induced for 2 weeks, and the lane to its left are lysates of cells with
Myd88 deletion induced 72 hours earlier. (A) Immunoblot of Myd88, p-Irak4, Irak4, and Gapdh
for MLL-AF9 cells with and without Myd88 expression. (B) Immunoblot of Stat3a/b, p-p38, p38,
and Gapdh. (C) Immunoblot of p-Jnk, Jnk, p-Erk, Erk, and Gapdh.
Myd88 is Required to Maintain MLL-AF9 Leukemia Cell Surface Markers and Prevent
Partial Differentiation
To test the hypothesis that Myd88 is required for maintenance of murine MLL-AF9 in a stemlike state, first, Wright-Giemsa staining was used to assess the morphologic changes in
CreERT2+ Myd88Δ/Δ leukemia cells (Figure 18A) CD117 and CD11b were used as markers for
leukemia cell stemness and differentiation, respectively. When stained for CD11b, CreERT2+
Myd88Δ/Δ leukemia cells show a 2.5-fold gain over Myd88fl/fl cells (Figure 18B). Myd88Δ/Δ
leukemia cells demonstrated a partial loss of the leukemia cell stemness marker CD117 relative
to Myd88fl/fl controls (Figure 18C). Together, these findings indicate that Myd88Δ/Δ leukemia cells
are partially differentiated. To determine whether this partial differentiation phenotype is specific
to inducible Myd88 deletion or shared among MLL-AF9 Myd88-null cells, several previously
described Myd88-/- leukemia cell lines and Cre+ Myd88Δ/Δ leukemia cells were stained for CD117
and CD11b and compared to Myd88+/+ controls (Figure 18D). The mean fluorescence intensity
(MFI) of CD117 showed a similar 25-50% loss in all cell lines, and the MFI of CD11b showed a
2-2.5 fold increase compared to Myd88+/+ controls. This same ratio of 2.5 fold increase in
CD11b and partial reduction of CD117 occurs in cells bearing germline Myd88 deletion as well
(Figure 18E). Myd88 is therefore required for maintenance of MLL-AF9 cells in an
undifferentiated state, regardless of whether Myd88 deletion occurs before or after introduction
of the MLL-AF9 fusion protein.
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Figure 18. Myd88 Deletion Results in Partial Differentiation of MLL-AF9 Cells. (A) WrightGiemsa microscopy images of Myd88+/+ and Myd88-/- MLL-AF9 cells. (B) CD11b median
fluorescent intensity (MFI) in isogenic Myd88fl/fl, Myd88-/- bulk culture, and clonal Myd88-/- MLL-
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AF9 populations with CreERT2-mediated Myd88 deletion. (C) CD117 MFI in isogenic Myd88fl/fl,
Myd88-/- bulk culture, and clonal Myd88-/- MLL-AF9 populations with CreERT2-mediated Myd88
deletion. (D) CD117 and CD11b overlay plot for Myd88-/- MLL-AF9 cells expressing Cre. (E)
MFI for CD117 and CD11b for MLL-AF9 cells with germline Myd88-/- genotype, with PCR
genotyping. MFIs represent three independent experiments and were compared using a Student’s
t-test and indicate * = p<0.05; ** = p<0.01; *** = p<0.001; and **** = p<0.0001.
Transplantation of Myd88Δ/Δ Leukemia Cells Yields Prolonged Leukemia Latency
Compared to Myd88-Expressing Leukemia Cells
To determine whether observed partial differentiation has an effect on in vivo
leukemogenesis, CreERT2+ Myd88Δ/Δ MLL-AF9 leukemia cells were transplanted into irradiated
mice and monitored for leukemia development. Leukemia development was confirmed by bone
marrow microscopy, peripheral blood smears, and hepatomegaly and splenomegaly caused by
infiltrating leukemia cells. Compared to those transplanted with Myd88+/+ MLL-AF9 controls,
mice transplanted with CreERT2+ Myd88Δ/Δ MLL-AF9 leukemia cells develop leukemia at a
median of 40 days after transplantation, 14 days after controls develop leukemia, at a median of
26 days (Figure 19). These data also correspond to the treatment of transplanted MLL-AF9
leukemia cells with high doses of IRAK1/4 inhibitors previously described in vivo. Therefore,
the deletion of Myd88 in the MLL-AF9 background delays leukemogenesis in an in vivo
transplantation model. Further, intact Myd88 is required for MLL-AF9-transformed cells to
cause leukemia at a comparable time to Myd88-expressing cells.
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Figure 19. Myd88-/- MLL-AF9 Leukemia Cell Transplantation Results in Delayed
Leukemogenesis in vivo. Survival of C57BL/6J mice transplanted with Myd88+/+ or Myd88-/-Cre+
MLL-AF9 leukemia cells (n=5 each). Statistical comparison reflects results of Log-rank and
Mantel-Cox comparisons, with * indicating p<0.05.
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Myd88 Deletion or IRAK1/4 Inhibitor Sensitizes MLL-AF9 Cells to ATRA
Because Myd88 is required for the maintenance of the MLL-AF9 leukemia cell surface
markers associated with stem cell-like features (CD117) and the suppression of those associated
with differentiation (CD11b), I hypothesized that Myd88-/- MLL-AF9 leukemia cells might be
sensitive to ATRA-induced differentiation. When treated in suspension culture, a clear
morphologic differentiation is induced in Myd88-/- MLL-AF9 cells compared to Myd88+/+ MLLAF9 cells (Figure 20A), despite ATRA suppressing cell growth to a similar degree in suspension
culture (Figure 20B). When Myd88-/- and Myd88+/+ MLL-AF9 cells were plated in
methylcellulose following 5 days of treatment with 500nM ATRA, colony forming ability is
suppressed (Figure 20C). Treatment with ATRA for 5 days induces CD11b, specifically in
Myd88-/- MLL-AF9 cells (Figure 20D). However, CD117 levels are unchanged. In vivo,
treatment with ATRA prolongs leukemia development in mice transplanted with Myd88-/- MLLAF9 cells, but not in those transplanted with Myd88+/+ MLL-AF9 cells (Figure 20E). These data
support the conclusion that Myd88 deletion partially sensitizes the MLL-AF9 cell to ATRAinduced differentiation. To determine if IRAK1/4 inhibitor can sensitize wildtype cells to
ATRA-induced differentiation, methylcellulose was treated with DMSO, 5µM IRAK1/4
inhibitor, 100nM ATRA, or both. The treatment of Myd88+/+ MLL-AF9 cells with both
IRAK1/4 inhibitor and 100nM ATRA, both not either individually suppressed colony forming
ability (Figure 20F). In conclusion, IRAK1/4 inhibitor treatment, while suppressing cell growth,
prevents cell surface marker alterations associated with ATRA-induced differentiation in MLLAF9 cells.
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Figure 20. ATRA Treatment Augments Myd88-/- MLL-AF9 Cell Partial Differentiation and
Delays Leukemia Development in vivo. (A) Wright-Giemsa staining of Myd88+/+ and Myd88-/MLL-AF9 cells treated with ATRA or DMSO vehicle. (B) Growth curve of Myd88+/+ and Myd88/MLL-AF9 cells treated with ATRA or DMSO. (C) CD117 and CD11b histogram with ATRA
treatment. (D) RT-PCR of Hoxa9 with in vitro ATRA treatment. (E) Treatment of Myd88+/+ and
Myd88-/- MLL-AF9 cells with ATRA in vivo delays leukemia development for Myd88-/-, but not
Myd88+/+ MLL-AF9 cells. (F) Co-treatment of MLL-AF9 cells with 5µM IRAK1/4 inhibitor,
100nM ATRA, or both. Data represent three independent experiments and were compared using a
Student’s t-test or ANOVA with Tukey’s HSD test, with n.s. indicating p>0.05, * indicating
p<0.05, ** indicating p<0.01, *** indicating p<0.001, and **** indicating p<0.0001.
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Inhibition or Knockdown of IRAK1 in MLL-AF9 Leakemia Cells Results in Phenotype
Distinct from the Myd88 Knockout Phenotype
The correlation between in vivo studies of IRAK1/4 inhibitors and CreERT2+ Myd88Δ/Δ MLLAF9 leukemia cells led to the hypothesis that Myd88-dependent signaling, as mediated by
IRAK4 and IRAK1 is required to prevent the observed partial differentiation phenotype. This
hypothesis is further validated by lost IRAK4 phosphorylation. To test this hypothesis, IRAK1/4
inhibitor (Sigma) was applied to wildtype MLL-AF9 cells in vitro, over five (Figure 21A-D) and
seven days (Figure 21E-F), sufficient time periods to acquire partial differentiation. Surprisingly,
CD11b and CD117 cell surface markers remained unchanged relative to DMSO-treated controls
(Figure 21C-D). Because the inhibitors act on IRAK1 and IRAK4, this finding suggests that
Myd88-mediated partial differentiation occurs independently of IRAK signaling. Interestingly,
treatment over seven days with IRAK1/4 inhibitor induces accumulation of CD117, and loss of
CD11b, indicating that treated leukemia cells gain cell surface markers associated with cell
stemness and lose markers associated with differentiation. Co-treatment with ATRA abolishes
this effect and the cell surface markers resemble those of cells treated with DMSO controls
(Figure 21E-F).
To test this, IRAK1 was selected as a knockdown target because of its position downstream
of Irak4. Knockdown to Irak1 was applied by lentiviral shRNA infection and selection (SigmaAldrich) and validated by quantitative real-time PCR (qRT-PCR) and immunoblotting (Figure
22A-B, 22G-H). Despite efficient knockdown (Irak1KD MLL-AF9), these cells failed to
recapitulate the partial differentiation findings of Myd88Δ/Δ MLL-AF9 leukemia cell lines (Figure
22C-D). Furthermore, Irak1KD MLL-AF9 cells demonstrated no meaningful change in colonyforming efficiency or consistent change in proliferation (Figure 22E-F). Thus, the Myd88-
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deletion-dependent partial differentiation occurs independently of Irak signaling, as evidenced by
robust and consistent evidence from pharmacologic inhibition and shRNA genetic knockdown.
Comparable to Myd88+/+ cells, IrakKD in a CreERT2+ Myd88Δ/Δ MLL-AF9 background elicits no
phenotype change (Figure 22I-L). Based on these shRNA data, the Myd88 deletion partial
differentiation phenotype occurs in an Irak1-independent manner.
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Figure 21. IRAK1/4 Inhibitor Treatment Alone or Combined with ATRA Treatment Fails
to Induce Similar Partial Differentiation Phenotype. (A) Growth curve of IRAK1/4 inhibitor
treatment over five days. (B) Viability of five-day IRAK1/4-inhibitor treatment. (C) CD117 MFI
of MLL-AF9 cells after 5 days of IRAK1/4 inhibitor treatment. (D) CD11b MFI of MLL-AF9
cells after 5 days of IRAK1/4 inhibitor treatment. (E) CD117 MFI of MLL-AF9 cells after sevenday treatment with IRAK1/4 inhibitor, ATRA, or both. (F) CD11b MFI of MLL-AF9 cells after
seven-day treatment with IRAK1/4 inhibitor, ATRA, or both. Data represent three independent
experiments and were compared using a Student’s t-test or ANOVA with Tukey’s HSD test, with
n.s. indicating p>0.05, * indicating p<0.05, ** indicating p<0.01, *** indicating p<0.001, and
**** indicating p<0.0001.
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Figure 22. Irak1 is Not Required for MLL-AF9 Leukemia Undifferentiated State,
Proliferation, Colony Formation, or Sensitivity to IRAK1/4 Inhibitor in Myd88+/+ or Myd88-

93
Background. (A) RT-PCR validation of Irak1 knockdown (Irak1KD) in Myd88+/+ MLL-AF9
cells. (B) Immunoblot validation of Irak1 knockdown in Myd88+/+ MLL-AF9 cells. (C)
Representative plots of Irak1KD Myd88+/+ MLL-AF9 cells. (D) CD117 and CD11b MFI of Irak1KD
Myd88+/+ MLL-AF9 cells. (E) Colony forming efficiency of Irak1KD Myd88+/+ MLL-AF9 cells
relative to scrambled controls. (G) Growth curve of Irak1KD Myd88+/+ MLL-AF9 cells relative to
scrambled controls. (G) RT-PCR validation of Irak1KD in Myd88-/-CreERT2 MLL-AF9 cells. (H)
Irak1 immunoblot of Irak1KD Myd88-/-CreERT2 MLL-AF9 cells. (I) Representative plots of Irak1KD
Myd88-/-CreERT2 MLL-AF9 cells. (J) CD117 and CD11b MFI of Irak1KD Myd88-/-CreERT2 MLL-AF9
cells. Data represent three independent experiments and were compared using a Student’s t-test,
with n.s. indicating p>0.05, * indicating p<0.05, ** indicating p<0.01, *** indicating p<0.001,
and **** indicating p<0.0001.
/-

TLR Signaling is Active in Human AML Cell Lines, which Respond to IRAK1/4 Inhibitor
Treatment
To demonstrate that TLR signaling is activated, human cells were assayed by immunoblotting
for active phosphorylated downstream kinases. Phosphorylated IRAK4, IRAK1, and TBK1 were
observed in the majority of human cell lines, indicating that, even in vitro, basal TLR stimulation
is present in these cells (Figure 23A). Having observed overexpression in several primary patient
datasets, expression of key MYD88-dependent TLR signaling molecules, and the activation of
said MYD88-dependent TLR mediators, I hypothesized that MYD88-dependent signaling is
required for leukemia cell pathogenesis. To test this idea, I first treated human cell lines with an
IRAK1/4 inhibitor (I5409 Sigma, Figure 23B). A subset of human cells lines treated with
IRAK1/4 inhibitor demonstrated a dose-dependent reduction in cell number over several days of
treatment when assayed by growth curves. Unlike MV4:11, MM6, and THP-1, which showed
both early and late dose-dependent reduction in cell number, Molm13 and RS4:11 showed only
late dose-dependent responses, and HL60 showed a minimal response. Published data by Liang
et al. indicates that this selective sensitivity is due to the presence or absence of MLLrearrangements, whose phenotypes are augmented by degradation of MLL1 downstream of
MYD88-dependent signaling.181 Likewise, murine leukemia cell lines transformed with human
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MLL-AF9 (MA9 LCs), demonstrated a dose-dependent sensitivity to IRAK1/4 inhibitors in vitro
(Figure 23C).
Since IRAK1/4 inhibitors suppress leukemia cell growth in in vitro models, I hypothesized
that inhibition of IRAKs might limit the colony-forming capacity as measured by
methylcellulose colony forming unit assays (CFU). Plating cells on methylcellulose serves as an
in vitro assay to approximate leukemogenic potency by measuring the efficiency of colony
forming ability, out of the total number of cells plated. In the setting of leukemia cells, the CFU
assay measures the ability of individual cells or a small cohort of cells to generate and propagate
colonies in semi-solid medium. This quantification approximates non-adherent cell growth,
proliferation, and the degree of leukemia cell differentiation or stemness. Despite other reports
that IRAK1/4 inhibitors suppress colony-forming ability, IRAK1/4 inhibition of murine MLLAF9 cells while plated in methylcellulose failed to elicit a loss of CFUs in wildtype, Myd88-/-,
and Tnfr1/2-/- MLL-AF9 backgrounds (Figure 23D). Interestingly, IRAK1/4 inhibitor is also
effective in suppressing cell proliferation in Myd88-/- MLL-AF9 leukemia cells, in addition to
Myd88+/+ MLL-AF9 cells (Figure 23E). These findings, with those of IRAK1/4 inhibitors on
wildtype Myd88+/+ MLL-AF9 cells showed no change in CD117 and CD11b levels, suggest that
IRAK1/4 inhibitors suppress the growth of the bulk leukemia cell population, but leave colonyforming cells and leukemia stem cells intact. Lastly, the IRAK1/4 inhibitor, when applied as a
single agent, does not induce a partial differentiation phenotype in the murine MLL-AF9 model
as measured by any of the applied assays. Additionally, the sensitivity of Myd88-/- MLL-AF9 to
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IRAK1/4 inhibitors suggests that IRAK1/4 inhibitors have off-target effects or that Irak4 or Irak1
are activated in a Myd88-/- MLL-AF9 background.
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Figure 23. Human Cell Line Subsets Express Downstream TLR Signaling Components and
are Sensitive to IRAK1/4 Inhibitors. (A) Immunoblot of human AML cell lines and RS4:11 Bcell acute lymphoblastic leukemia cell line demonstrate varying degrees of TLR mediator
expression and activity. (B) Inhibitors of downstream IRAK1/4 kinase (IRAKi) result in a dosedependent reduction in cell number compared to DMSO-treated controls. (C) Treatment of murine
MLL-AF9 cells with IRAKi results in dose-dependent reduction of cell number. (D) Irak1/4
inhibitor treatment of both Myd88+/+ and Myd88-/- MLL-AF9 leukemia cells on methylcellulose
and resulting colony forming efficiency. Data represent three independent experiments with error
bars as standard deviations and were compared using a Student’s t-test, with n.s. indicating p>0.05,
* indicating p<0.05, ** indicating p<0.01, *** indicating p<0.001, and **** indicating p<0.0001.
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IRAK1/4 Inhibitor Treatment Delays Leukemia Development in vivo
To follow up with the IRAK1/4 inhibitor in vitro study, IRAK1/4 (Sigma I5409) and IRAK4
(Calbiochem 531237) inhibitors were applied in vivo. I performed the following experiment in
collaboration with Kevin Liang, Andrew Volk, Ph.D., and Ali Shilatifard, Ph.D after they
independently determined that MYD88-dependent signaling was required for AML pathogenesis
using human leukemia cell line models.181 To determine whether a murine model is sensitive to
likewise loss of MYD88-dependent signaling, inhibitors of downstream IRAKs were applied in
an in vivo syngeneic transplant study. Mice were divided into treatment groups of vehicle
control, 4mg/kg IRAK1/4 (Sigma), 20mg/kg Compound 26 IRAK4 inhibitor (Calbiochem
531237), and combination treatment with both inhibitors. Ten mice per treatment group were
sublethally irradiated (4.5Gy) and transplanted with 5,000 wildtype MLL-AF9 leukemia cells
each. 4mg/kg IRAK1/4 (Sigma) and/or 20mg/kg Compound 26 IRAK4 inhibitor (Calbiochem)
were administered by five i.p. injections at days 10, 12, 14, 16, and 18 after transplantation.
Vehicle control and combination treatments were applied concurrently. When treated with
IRAK1/4 inhibitor (Sigma) survival was prolonged by a median of 2.5 days, as determined by
Log-rank Mantel-Cox statistical testing (Figure 24A). However, the alternative IRAK4 inhibitor
(Calbiochem) treatment group failed to yield an effect, and treated mice showed no survival
advantage (Figure 24B). To expand upon this in vivo study, we hypothesized that the dose was
not sufficient to effectively inhibit IRAK1/4 in vivo, and repeated this experiment after
increasing the dose five-fold and delaying treatment initiation. This second in vivo
transplantation experiment was performed in collaboration with Ali Shilatifard, Ph.D. at
Northwestern University by Andrew Volk, Ph.D. using murine MLL-AF9 leukemia cells that I
derived and used in previous transplant studies. Treatments of 8mg/kg IRAK1/4 inhibitor and
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75mg/kg IRAK4 inhibitor leukemia development significantly delayed leukemia development
when mice were treated early, starting at day 10 post-transplantation (Figure 24C), or late, during
‘blast phase’ with treatments beginning at day 19 post-transplantation (Figure 24D).181
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Figure 24. IRAK1/4 Inhibitor Treatment Delays Leukemia Development in vivo. All mice
were sublethally irradiated (4.5Gy) and transplanted with 5x103 MLL-AF9 leukemia cells.
Treatment for panel A, B, and C reflects i.p. drug administration every 48 hours from day 10 to
day 18. P-values reflect Log-rank Mantel-Cox survival analysis. (A) Survival of mice (n=10)
treated with 4mg/kg IRAK1/4 inhibitor (p=0.0203). (B) Survival of mice (n=10) treated with
20mg/kg IRAK1/4 inhibitor treatment (p=0.7614). (C) Survival of mice (n=9-10) with 75mg/kg
IRAK4 inhibitor (p=0.0028) or 8mg/kg IRAK1/4 inhibitor (p<0.0001). (D) Survival of mice
treated with 75mg/kg IRAK4 inhibitor (p=0.0006) or 8mg/kg IRAK1/4 inhibitor (p<0.0001)
beginning on day 19. Panels C and D are representative of in vivo transplantation study and
IRAK1/4 inhibitor treatment at higher doses performed by Andrew Volk using MLL-AF9
leukemia cells that I derived. They were previously published in Cell by Liang et al. and are used
here with permission.
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Microarray Expression Data and TCGA Survival Correlations Implicate TICAM-1
Expression with AML Pathogenesis
The previously described primary patient microarray showed an overexpression of TICAM1/TRIF in the acute monocytic leukemia (AMoL, M4/M5) subset. Overexpression of TLR4 but
not TLR3, receptors known to induce TICAM-1/TRIF-dependent signaling, was also detected.
Upon survey of the TCGA dataset, 2% of AML cases were shown to have amplification of
TICAM-1/TRIF, with few other know mutations, indicating it is relatively conserved (Figure 7).
Likewise, a clear survival correlation is found between low transcript levels of TICAM1/TRIF in
AML. Furthermore, TICAM-1/TRIF transcripts are elevated in patients with AML relapse
(Figure 6).
The study of TICAM-1/TRIF in AML was first prompted by the observation that TICAM1/TRIF protein level is elevated in Myd88-null PLCs with retroviral overexpression of MLLAF9, MLL-ENL, or AML1/RUNX1-ETO immunoblots (Figure11). This observation lead to the
hypothesis that the induction of TICAM-1-TRIF functionally compensates for Myd88 deletion,
and, by extension, IRAK1/4 inhibtion. This hypothesis was later tested by Ticam-1/Trif shRNA
knockdown in Myd88-/- MLL-AF9 cells. Despite efficient knockdown with all shRNAs (Figure
25A-B), the CFUs for all groups remain comparable (Figure 25C), and cell surface markers
remain unchanged (Figure 25D) so Ticam-1/Trif does not act to compensate for Myd88 signaling
in MLL-AF9 leukemia.
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Figure 25. Ticam-1 Knockdown Fails to Augment Myd88-/-Cre+ MLL-AF9 Partial
Differentiation Phenotype. (A) RT-PCR validation of Ticam-1 knockdown (Ticam-1KD) in
Myd88-/-Cre+ MLL-AF9 cells compared to scrambled controls. (B) Knockdown efficiency of
Ticam-1KD Myd88-/-Cre+ MLL-AF9 cells as measured by immunoblot. (C) Colony forming unit
assay of Ticam-1KD Myd88-/-Cre+ MLL-AF9 cells relative to scrambled controls. (D) Histogram
comparison of scrambled control expressing to Ticam-1KD Myd88-/-Cre+ MLL-AF9 cells CFUs.
Data assayed in triplicate and were compared using a Student’s t-test, with n.s. indicating p>0.05,
* indicating p<0.05, ** indicating p<0.01, *** indicating p<0.001, and **** indicating p<0.0001.
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Ticam-1 is Required for Efficient MLL-AF9 Leukemia Cell Proliferation and ColonyForming Ability
However, despite this, the primary patient and TCGA data suggest an independent role for the
TLR adaptor TICAM-1/TRIF in AML. To further explore whether Ticam-1/Trif contributes to
AML pathogenesis in a murine model, lentiviral Ticam-1/Trif shRNA was expressed in wildtype
MLL-AF9 leukemia cells and confirmed by qRT-PCR and immunoblotting (Figure 26A-B).
Confirmed Ticam-1/Trif knockdown led to reduction in CFUs (Figure 26C). Ticam1KD MLLAF9 cells demonstrate a profound growth deficiency, which is made clear by growth curves
(Figure 26D), Edu incorporation (26E), and cell cycle analysis (26F).
To determine whether partial differentiation is responsible for reduced proliferation and CFUs
in Ticam1KD MLL-AF9 cells, Wright-Giemsa staining and cell surface markers were studied.
Wright-Giemsa staining showed a morphological change in the leukemia cells indicative of
partial differentiation (Figure 27E). Upon cell surface staining, the Ticam1KD MLL-AF9 cells
showed a 70-80% reduction in CD117 MFI (Figure 27A-B) and all knockdowns except for one
showed a likewise increase in CD11b MFI (Figure 27C-D), relative to MLL-AF9 cells
expressing scrambled control vectors. Interestingly, the most efficient knockdown, shTicam-1 A,
shows no change in CD11b, so Ticam-1 may not be required to prevent CD11b accumulation.
These phenotypes indicate that Ticam-1 is required for MLL-AF9 CD117 and CD11b cell
surface marker maintenance, proliferation, and colony forming ability.
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Figure 26. Ticam-1 Knockdown Suppresses Colony Forming Efficiency and Proliferation in
MLL-AF9 Cells. (A) RT-PCR validation of Ticam-1 knockdown (Ticam-1KD) in Myd88+/+
MLL-AF9 cells compared to scrambled controls. (B) Ticam-1 immunoblot of Ticam-1KD
Myd88+/+ MLL-AF9 cells. (C) Colony forming efficiency in Ticam-1KD Myd88+/+ MLL-AF9
cells. (D) Absolute and relative growth curve of Ticam-1KD Myd88+/+ MLL-AF9 cells. (E) Edu
uptake after 30 minutes for Ticam-1KD Myd88+/+ MLL-AF9 cells. (F) Propidium iodide cell
cycle analysis of Ticam-1KD Myd88+/+ MLL-AF9 cells. Data represent three or more independent
experiments, performed in triplicate, and were compared using a Student’s t-test, with n.s.
indicating p>0.05, * indicating p<0.05, ** indicating p<0.01, *** indicating p<0.001, and ****
indicating p<0.0001.

104

Figure 27. Ticam-1 Knockdown Yields a Partial Differentiation Phenotype. (A) CD117 MFI
of Ticam-1KD Myd88+/+ MLL-AF9 cells. (B) Histogram of CD117 distribution for each Ticam-1KD
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MLL-AF9 cell line. (C) CD11b of Ticam-1KD Myd88+/+ MLL-AF9 cells. (D) Histogram of CD11b
distribution for each Ticam-1KD MLL-AF9 cell line. (D) Wright-Giemsa stained SCR CTLexpressing and Ticam-1KD Myd88+/+ MLL-AF9 cells taken with 100x lens. Data represent three
independent experiments, performed in triplicate, and were compared using a Student’s t-test, with
n.s. indicating p>0.05, * indicating p<0.05, ** indicating p<0.01, *** indicating p<0.001, and
**** indicating p<0.0001.
Tbk1 Knockdown Does Not Result in the Ticam-1 Knockdown Phenotype
To determine how Ticam-1 knockdown leads to a partial differentiation and suppressed
proliferation phenotype, the downstream signaling pathways of Ticam-1 were interrogated. TLR
signaling downstream of Ticam-1 includes activation of Tbk1 and IKKε, leading to their
phosphorylation of IRFs to induce an interferon response. Both Myd88+/+ and Myd88Δ/Δ MLLAF9 leukemia cells show a robust sensitivity to the Tbk1 inhibitor BX795 (Invivogen, tlrl-bx7)
in methylcellulose (Figure 28A). To determine whether this effect is specific to Tbk1 and
whether the Ticam-1/Trif knockdown phenotype is due to a loss of Tbk1 activation, shRNA
knockdown was applied. Genetic knockdown of Tbk1 was confirmed by qRT-PCR and
immunoblotting (Figure 28B). To determine whether Tbk1 signaling contributes to the
Ticam1/Trif phenotype, cell lines were assayed for CD117 and CD11b surface markers, growth
curves, and cell cycle alteration. Surprisingly, no changes occurred in these assays relative to
scrambled control MLL-AF9 cell lines (Figure 28C). Tbk1KD MLL-AF9 cells were assayed by
cell cycle analysis and colony forming assay, but knockdown of Tbk1 yields no changes in these
phenotypes (Figure 28D and 28E). Therefore, Tbk1 is not required for the phenotype observed
with Ticam-1/Trif knockdown. Additionally, the BX795 inhibitor is likely inhibiting other
targets in addition to Tbk1 to suppress colony forming ability.
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Figure 28. Tbk1 Knockdown Does Not Result in a Phenotype Comparable to Ticam-1
Knockdown. (A) Treatment of MLL-AF9 cells with Myd88+/+ and Myd88-/- backgrounds with
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BX795 TBK1 inhibitor. (B) RT-PCR and immunoblot validation of Tbk1 knockdown (Tbk1KD) in
MLL-AF9 cells. (C) Colony forming efficiency of Tbk1KD MLL-AF9 cells. (D) Cell cycle analysis
of Tbk1KD MLL-AF9 cells. (D) CD117 histogram comparison of Tbk1KD MLL-AF9 cells to those
expressing scrambled controls. (E) CD11b histogram comparison of Tbk1KD MLL-AF9 cells to
those expressing scrambled controls. Data represent three independent experiments and were
compared using a Student’s t-test, with n.s. indicating p>0.05, * indicating p<0.05, ** indicating
p<0.01, *** indicating p<0.001, and **** indicating p<0.0001.
TICAM-1 Maintains RIPK1 and RIPK3 to Protect Leukemia Cell Function
Alternative downstream signaling pathways for Ticam-1/Trif were explored. Ticam-1/Trif is
known to have a RHIM domain by which it interacts with the necroptotic signaling pathway
components RIPK1 and RIPK3. Previous studies by our lab have implicated by RIPK1 and
RIPK3 in the pathogenesis of MLL-AF9 leukemia using human and murine samples and
knockout cell lines. Like Ticam-1 knockdown cells, Ripk1 and Ripk3 knockout cells
demonstrate a phenotype of partial differentiation.187 To test whether Ticam-1 phenotype is
related to the Ripk1/3 knockout phenotype, murine MLL-AF9 cells with Ticam1/Trif knockdown
were probed for phosphorylated and total Ripk3 (Figure 29A), as well as phosphorylated and
total Mlkl itself (Figure 28B). In Ticam-1KD cell lines, the knockdown of Ticam-1 is
accompanied by a loss of total Ripk3, which leads to a loss of p-Mlkl. Less efficient Ticam-1
knockdown (shB) does not elicit this effect. Thus, the Ticam-1 protein is required to protect the
protein stability of RIPK3 and enable pro-leukemic necroptotic signaling. Upon transplantation
into mice, Ticam-1 knockdown delays leukemogenesis in a Myd88+/+ MLL-AF9 background
(Figure 30A, 30B). Despite this finding, leukemia development was delayed overall, and it could
not be established that Ticam-1 knockdown in addition to Myd88 deletion further delays
leukemogenesis in vivo (Figure 30C).
To determine whether this phenotype is reproducible in human cell lines, shRNA against
TICAM-1 was expressed in all available human leukemia cell lines, including HL60, ML-2,
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MM6. Molm13, MV4:11, RS4:11 (B-cell leukemia), THP1, and U937. Despite this, the only cell
line in which durable knockdown at protein and transcript level was confirmed was the ML-2
cell line (Figure 31A and 31B). ML-2 is a human cell line derived from an acute
myelomonocytic leukemia patient with t(6;11)(q27;q23) translocation, resulting in MLL-AF6
fusion protein, a near-tetraploid karyotype, and deletion of the wildtype MLL1 allele.192 When
this cell line was likewise assayed for Tbk1 phosphorylation, a partial, but not complete,
reduction of signal was observed (Figure 31C). When ML-2 cells bearing TICAM-1 knockdown
were assayed for RIPK1, RIPK3, and MLKL, a loss of total protein was observed for both
RIPK1 and RIPK3 (Figure 31D). Interestingly, RIPK3 transcript was induced 30-fold compared
to scrambled controls and inefficient knockdowns (Figure 31E). Consistent with this, the
reduction in TICAM-1, RIPK1, and RIPK3, resulted in a loss of p-MLKL (Figure 31F). When
assayed for colony-forming ability, these cells demonstrated a 4-fold reduction in CFU ability
relative to scrambled controls (Figure 31G). Thus, when TICAM-1 knockdown is achieved in
human ML-2 cells, it leads to destabilization of RIPK1 and RIPK3 protein level and disrupts
their pro-leukemic signaling described in Xin et al.187
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Figure 29. Ticam-1 Knockdown Efficiency Correlates with Ripk3 Protein Level and Mlkl
Activity in Murine MLL-AF9 Cells. (A) Immunoblot of phosphorylated Ripk3 and total Ripk3
in Ticam-1KD Myd88+/+ MLL-AF9 cells. (B) Immunoblot of phosphorylated Mlkl and total Mlkl
in Ticam-1KD Myd88+/+ MLL-AF9 cells. (C) RT-PCR of Ripk3 in murine MLL-AF9 cell lines.
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Figure 30. Ticam-1 is Required for Leukemogenesis in vivo in the Murine MLL-AF9 Model
System. Transplantation study of mice transplanted with 10,000 MLL-AF9 cells expressing
scrambled control or one of two shTicam-1 constructs, annotated as shA (A) and shD (B) vectors
(n=8 for each group). (C) Survival of mice transplanted with Myd88-/- MLL-AF9 cells expressing
either scrambled control or shTicam-1 C. Difference between groups is determined using Logrank Mantel-Cox statistical analysis, with n.s. indicating p>0.05, * indicating p<0.05, and **
indicating p<0.01.
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Figure 31. TICAM-1 Knockdown in Human ML-2 Cell Lines Suppresses Colony-Forming
Ability and Destabilizes RIPK1 and RIPK3 Protein Level. (A) RT-PCR validation of TICAM1KD in ML-2 cell line. (B) Immunoblot of TICAM-1 in ML2 cell line. (C) TBK1 immunoblot of
ML-2 TICAM-1 knockdown and scrambled control expressing cell lines. (D) RIPK1 and RIPK3
immunoblot of TICAM-1KD ML-2 cells. (E) RIPK3 transcript in scrambled control and TICAM1KD ML-2 cells as measured by RT-PCR. (F) MLKL immunoblot in TICAM-1KD ML-2 cells and
scrambled control. (G) Colony forming assay of scrambled control and TICAM-1KD ML-2 cells.

CHAPTER FOUR
DISCUSSION
This dissertation sought to determine whether MYD88-dependent and TICAM-1-mediated
signaling have a role in the context of AML model systems. I hypothesized that MYD88dependent signaling and TICAM-1-dependent TLR signaling promote leukemia cell proliferation
and loss of cell surface markers associated with stemness. Accordingly, I predicted that their
inhibition or genetic ablation would result in increased cell death, reduced proliferation, and
partial differentiation. In this study, signaling components of TLR signaling were found to be
expressed in human and murine leukemia model cell lines and associated with poor patient
survival. Disruption of TLR signaling by genetic knockdown or deletion of MYD88 or TICAM1 reduced leukemia cell function in several assays. Both MYD88-dependent and TICAM-1mediated signaling support the undifferentiated leukemia stem cell phenotype through
independent mechanisms. The respective deletion and knockdown of MYD88 and TICAM-1
reduced cell stemness markers, colony forming units, proliferation, leukemogenesis in vivo,
while increasing differentiation markers (Figure 32). These results indicate a novel function of
both TLR adaptors in MLL-AF9 leukemia to protect the undifferentiated status of leukemia cells
and their leukemogenic capacity.
In M4/M5 AML subtypes, overexpression of cell surface TLRs and adaptors MYD88 and
TICAM-1 were shown in a large patient cohort and published datasets. Further, several TLR
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Figure 32. Toll-like Receptor Signaling in AML – Conclusions.
mediators for both MYD88 and TICAM-1-dependent signaling, including IRAK1 and TBK1, are
correlated with adverse outcomes in the TCGA dataset. This led to the hypothesis that TLR
signaling is activated in a subset of leukemia cells, with prognostic and therapeutic implications.
In both human and mouse cell lines, TLRs and their downstream signaling components are
expressed, functionally responsive to known TLR stimuli, and phosphorylated, indicating
constitutive activity. Both MYD88-dependent and MYD88-independent signaling pathways
were shown to have baseline activity. With this preliminary data, the hypothesis that TLR
signaling supports the leukemia cell phenotype was proposed. To test this hypothesis, both
pharmacological and genetic approaches targeting critical adaptor proteins MYD88 and TICAM1 were employed.
Much of the study on TLR signaling in AML has been performed in MLL-rearranged models
or those driven by genes activated by MLL fusions.181, 182, 185 The first approach I employed
transformed Myd88+/+ or Myd88-/- CD117+ progenitor cells. Surprisingly, following
transformation, colony forming efficiency is unchanged for both MLL-AF9 and MLL-ENL
constructs. When colony forming potential was tested in transformed Myd88+/+ or Myd88-/-
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MLL-AF9 leukemia cells, following primary transplantation, colony forming ability again
remained unchanged. Therefore, Myd88 and Myd88-dependent signaling are not required for
MLL-rearranged transformation and leukemogenesis in murine models.
Like other studies, these experiments primarily explored the contribution of TLR signaling to
leukemia pathogenesis, using models that primarily reflect the AML myelomonocytic and
monocytic subtypes in which TLR and adaptor protein expression is enhanced. However, the
role of TLR signaling in AMLs in which TLR expression is relatively reduced, such as RUNX1ETO and CBFβ-MYH11 fusions, remains unexamined. The microarray performed by Jianjun
Chen, Ph.D. revealed that, in these leukemia subtypes, cell surface TLRs, adaptor proteins
MYD88 and TICAM-1, and downstream mediators were downregulated, relative to average
expression in the leukemia sample cohort. Interestingly, when murine progenitor cells were
transformed with RUNX1-ETO expression vectors, the Myd88-/- genotype enhances CFU
efficiency. These findings suggest that the inhibition or genetic deletion of TLR signaling may
result in more potent forms of these AML subtypes. Therefore, MYD88-dependent TLR
signaling exerts an anti-leukemic effect in these cells, but is required in other leukemia subtypes.
Further study is merited to determine why RUNX1-ETO and CBFβ-MYH11 colony forming
efficiency is enhanced in an Myd88-/- background. Perhaps a reduction of MYD88-dependent
signaling protects RUNX1-ETO and CBFβ-MYH11 leukemic colony-forming and stem cells.
Conversely, TLR stimulation in leukemia cells bearing these fusion proteins may act to attenuate
these leukemia cells through an unstudied mechanism, either in a cell autonomous manner or via
cytokine signals secreted in response to the TLR stimulation. However, since much of the
supporting literature examined the role of TLR signaling in MLL-rearranged models, this study
was planned around that leukemia cell subtype.
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Rather than starting with a Myd88-/- background MLL-AF9 leukemia cell, the MLL-AF9
model was used to generate a leukemia cell line with Cre/LoxP-mediated inducible Myd88
deletion. Using this approach, the deletion of Myd88 could be used to mimic complete inhibition
of Myd88-dependent signaling in an established leukemia cell line. With the MLL-AF9 model,
CreERT2-mediated inducible deletion of Myd88 was applied to test this hypothesis and carefully
controlled to avoid Cre-mediated and CreERT2-mediated off-target toxicity. Of note, the low
threshold for CreERT2-mediated toxicity and cell death underlies the need to carefully control
the application of the Cre/LoxP system in model systems for leukemia and other malignancies.
In this study, the expression of Cre and over-activation of CreERT2 in MLL-AF9 leukemia cells
resulted in cell death, reduction in proliferative capacity, and impaired colony forming capacity.
These findings reflect the hazards of permanently overexpressing targeted recombinases and
nucleases, including CRISPR Cas9, in cell lines for experimentation and were consistent with
published literature on Cre recombinase.193, 194 Cre is also known to act on cryptic LoxP sites
found in mammalian genomes and suppresses proliferation in several model systems.194, 195
Activation of Cre or CreERT2, with no other treatment, causes regression of murine lymphomas
in vivo.196 Despite the efficiency of targeted deletion of LoxP flanked genes or sgRNA-targeted
genome sequences, the expression of genomic recombinases and nucleases must be carefully
controlled to account for these off-target effects. Previous studies on Cre recombinase have
demonstrated a range of expression in which Cre recombinase is effective, yet exerts no
detectable toxicities.197 Application of CreERT2 or self-deleting Cre recombinase has been
shown to avert genomic toxicity caused by Cre in mammalian systems.198 These studies illustrate
the need for appropriate LoxP-free controls, even in experiments in which Cre recombinase is
expressed under the control of an endogenous promoter.
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Inducible Myd88 deletion and subsequent loss of downstream signaling yields a partial
differentiation phenotype, as measured by colony forming ability, cell surface markers for both
leukemia cell stemness (CD117) and macrophage differentiation (CD11b), proliferation, and in
vivo transplantation. Interestingly, despite the numerous studies linking MYD88-dependent TLR
signaling to downstream TAK1-dependent NF-kB, JNK/AP-1, and p38 pathways, both germline
and inducible Myd88-/- leukemia cells show no change in these pathways. The unchanged
activation of NF-kB may be due to dysregulation of other inflammatory mediators, such as
TNFa, that converge on NF-kB activation in leukemia cells. With the autocrine production of
and stimulation by these factors, leukemia cells may be able to maintain NF-kB activity even
with genetic deletion of upstream TLR mediators.
These findings are consistent with those of Liang et al., who, using shRNA screen and RNAsequencing showed that a MYD88-IRAK4-UBE20 signaling axis in MLL-rearranged leukemia
is required for UBE20-mediated ubiquitination of the MLL1/KMT2A C-terminal domain. This
results in the degradation of MLL1/KMT2A and allowed the mutated fusion protein to dominate
epigenetic loci. In their human cell line model, they noted that knockdown of any upstream
TLR/IL-1R mediator failed to alter transcripts of NF-kB-regulated genes as measured by RNA
sequencing.181 While the study by Liang et al. links IL1R/TLR-MYD88-IRAK4 signaling to the
stability of the MLL1 to tip the epigenetic balance toward MLL-fusion proteins, and used IRAK
and UBE20 inhibitors to suppress leukemogenesis in vitro and in vivo to great effect, several
discrepancies persist between our studies. First, Cre-mediated Myd88 deletion, in our system,
delayed MLL-AF9 leukemogenesis by two weeks, whereas application of the IRAK1/4 inhibitor
delays median leukemia much greater that two weeks, beyond the course of the experiment. The
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knockdown of Irak1 in murine MLL-AF9 cells failed to elicit a comparable phenotype and failed
to suppress growth or colony forming ability consistently. These findings lead to the concern that
IRAK1/4 inhibitors exert unknown off-target effects because the inhibitors yield a stronger
phenotype than either genetic model.
Recent studies examining S100A8 and S100A9-mediated TLR4 stimulation link the
observed partial differentiation phenotype to JNK signaling, but not NF-kB signaling.185 Of note,
S100A8 and S100A9, both TLR4 ligands, elicits ligand-specific effects, with S100A8 blocking
the differentiation induced by S100A9. The study described in the dissertation applied genetic
deletion and knockdown of TLR adaptors to determine their net contribution to the leukemia cell
phenotype. The findings presented here indicate that basal stimulation of TLR pathways protect
MLL-AF9 leukemia cells in an undifferentiated state. However, downstream signaling of p38,
JNK, and NF-kB in Myd88-/- MLL-AF9 leukemia cells remain unchanged. These observations
merit further study into the precise role of mediators of downstream MYD88-dependent
signaling, TAK1 and TRAF6, in AML and related disorders. Numerous studies have shown that
TRAF6 is specifically dysregulated in MDS, but the impact of this dysregulation on TAK1
activity and that of TAK1-induced pathways also is unclear. If activation of terminal downstream
signaling is conserved and activated in malignancy and MDS, then the precise pathogenic
mechanism remains undetermined.
These findings are also in contrast to those of lymphoma models bearing L265P mutations.123
Both the initial characterization of the MYD88 L265P mutation enriched in subsets of
lymphomas describe its mechanism as one of spontaneous MYD88 oligomerization and
constitutive activation of IRAK and BTK downstream kinases. This results primarily in a
molecular signature characterized by upregulation of NF-kB-regulated genes. NF-kB is also
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known to be downstream of activated MYD88-dependent signaling in preclinical models for
acute T-cell lymphoblastic leukemia.199 The decoupling of MYD88-dependent TLR activity at
baseline from NF-kB activity may be specific to myeloid malignancy. The persistence of NF-kB
activity in leukemia cells may also be due to the presence of other cytokines and oncogenic,
active signaling that maintain NF-kB activation. Also, it may be partially explained by
differential effects of TAK1 in myeloid cells compared to other tissues. While TAK1 is required
for the phosphorylation of IKKa, p38, ERK, and JNK, in TLR signaling, it is known to have
suppressive effects on inflammation as well. In unstimulated conditions, TAK1 suppresses
inflammasome activation in myeloid cells by suppressing NLRP3 inflammasome activation and
reducing basal NF-kB activity to limit downstream TNFa transcription.46 The inflammatory
modulatory effect of TAK1 extends to hepatic tissues, since hepatocyte-specific TAK1 deletion
results in an inflammatory state progressing to fibrosis and hepatocellular carcinoma.200 This
progression is limited by TLR4 or MYD88 deletion. While this study demonstrates the
immunomodulatory effect of TAK1, it also shows that TLR4- and MYD88-dependent signaling
have pro-inflammatory and pro-tumorigenic effects in the absence of TAK1, which might
indicate additional TLR-dependent downstream pathways. With respect to the malignant
myeloid cell population, the specific role of TAK1 for NF-kB induction and other downstream
signaling, as well as TLR-dependent, TAK1-independent pro-inflammatory pathways must be
determined. Interestingly, myeloid-specific Tak1 deletion results in spontaneous
myelomonocytic leukemia development, though the status of downstream NF-kB and other
signaling pathways is unclear.201
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In all MLL-AF9 cells tested bearing Myd88 deletion, the cell surface markers and
morphologic staining indicate a partial differentiation phenotype. Therefore, Myd88 is required
to maintain the MLL-AF9 leukemia cells in an undifferentiated state. Interestingly, similar cell
stemness and differentiation marker levels were observed, relative to Myd88-expressing controls,
in all Myd88-null cells, whether deletion is germline, Cre-mediated, or CreERT2-mediated. To
determine whether downstream activity of IRAK1 and IRAK4 were required to protect the
undifferentiated leukemia cell, wildtype leukemia cells were treated with IRAK1/4 inhibitor for
five or seven days and assayed for cell surface markers. IRAK1/4 inhibitor treatment suppressed
cell growth in suspension culture, but failed to induce partial differentiation cell surface
phenotype. The inhibitor also failed to suppress leukemia cell colony-forming efficiency,
contrasting with other studies.181 Further, IRAK1/4 inhibitor is equally effective in Myd88+/+ and
Myd88-/- MLL-AF9 backgrounds, even when the Myd88-/- MLL-AF9 cells were later found to
lack detectable Irak1 protein. These results were particularly surprising, since published data
indicated that IRAK1/4 inhibitor selectively suppresses murine and human IRAK with
comparable treatment doses. These findings suggest one of two conclusions, either Irak signaling
is required and active in Myd88-/- MLL-AF9 leukemia cells, even in the absence of Myd88, or
off-target effects are partially responsible for effects of IRAK1/4 inhibitors.
Unlike in Myd88-/- MLL-AF9 cells, efficient IRAK1 knockdown failed to induce partial
differentiation in MLL-AF9 leukemia cells, indicating that IRAK1 and IRAK4 are not required
for induction of partial differentiation in MLL-AF9 leukemia cells. These findings suggest either
a specific role for MYD88, perhaps independent of its functions in TLR signaling, or that
MYD88 is capable of inducing unknown downstream signaling to mediate this antidifferentiation phenotype independently of IRAK signaling. Recently, several novel attributes of
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MYD88 have been described. The MYD88 accessory adaptor MAL is known to interact directly
with TRAF6, and this interaction is required for TLR-induced NF-kB induction.202 If IRAK1/4
are not required for TRAF6-NF-kB induction in leukemia cells, then that might explain the
observed phenotype. Proteomic and RNA sequencing approaches would be best equipped to
determine the MYD88 interactome and transcriptional consequences of MYD88 deletion or
mutation.
The role of TICAM-1 and TICAM-1-dependent signaling in AML and leukemia cell lines and
models, outside of this study, remains unexamined. TICAM-1 is established as an inducer of
IRFs and transcription of type I interferon, which has antileukemic effects.187, 203 To determine
the contribution of MYD88-independent signaling, mediated by TICAM-1, shRNA knockdown
against TICAM-1 was applied in murine models and human cell lines. The knockdown of Ticam1 in wildtype MLL-AF9 leukemia cells elicited a phenotype marked by loss of colony forming
efficiency. Ticam-1 knockdown also resulted in reduction in proliferation, as measured by
growth curves, Edu uptake, and cell cycle analysis. Morphological analysis and cell surface
staining revealed that this reduction in proliferative capacity of Ticam-1KD MLL-AF9 cells is due
to a partial differentiation phenotype independent from that of the Myd88 deletion model. To
determine precisely how Ticam-1 contributes to the maintenance of the undifferentiated
leukemia cell phenotype, known downstream signaling pathways were surveyed.
TICAM-1 is known to induce IRFs in a TRAF3-TBK1-IKKe-dependent manner. MLL-AF9
leukemia cells responded robustly to TBK1-targeted inhibitor BX-795. To determine the precise
relationship of TBK1 to this phenotype, a Tbk1-specific shRNA was applied in the MLL-AF9
mouse model. Knockdown of Tbk1 failed to elicit a partial differentiation response or a reduction
in proliferation. Tbk1 knockdown also failed to reduce CFU efficiency observed with Ticam1
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knockdown. Therefore, the Ticam-1-dependent partial differentiation phenotype is not mediated
by Tbk1.
Ticam-1 is known to interact with Ripk1 and Ripk3 to induce necroptotic cell death in
immune cells with TLR3 stimulation. Ripk3 protein level is reduced in Ticam1KD MLL-AF9
cells despite modest reduction in Ripk3. Therefore, Ticam-1 is required for Ripk3 protein
stability. The reduction of Ripk3 protein level yields a reduction in phosphorylated Mlkl,
indicating a reduction in necroptotic signaling. TICAM-1 knockdown in the ML2 cell line
resulted in a comparable phenotype with a reduction in proliferation and colony forming
efficiency. Further, TICAM-1 knockdown resulted in a likewise reduction in RIPK1 and RIPK3
protein level, again resulting in a loss of phosphorylated MLKL. Necroptotic signaling has
previously been shown to be required for leukemia cells in both murine and human models.187
The ability of TICAM-1 to stabilize critical necroptotic kinases RIPK1 and RIPK3 is a novel
relationship between these signaling pathways.
Although relatively unexamined, systemic TICAM-1 stimulation or administration of
downstream interferons is known to have anti-leukemic effects as described in previous sections.
Study of downstream TICAM-1 signaling found that the pro-leukemic effect of TICAM-1 occurs
independently of TBK1, the downstream TLR mediator involved in IRF activation. Further study
showed, in both human and murine leukemia cell models, that TICAM-1 protects RIP kinases
from degradation, permitting their pro-leukemic activation of MLKL and NF-kB as previously
described. Whether TICAM-1 is able to interact with RIP kinases and prevent their degradation
when TICAM-1 specific TLR stimulation is induced remains to be determined. Perhaps, in
addition to inducing transcription of an interferon response, recruitment of TICAM-1 to the
stimulated receptor sequesters TICAM-1, allowing RIPK1/RIPK3 degradation in leukemia cells.
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This phenomenon might also account for the neutral or negative phenotypic responses to TLR3
and TLR4 stimulation reported here and elsewhere. Alternatively, TNFα signaling is known to
be induced in AML, and RIPK1 and TRAF E3 ligases are known to function in the TNFα
receptor complex. Perhaps TICAM-1 plays an as of yet undetermined role in this receptor
complex. The precise mechanism of TICAM-1 in these complexes, however, remains to be
determined.
However, the findings of TICAM-1 knockdown in the ML-2 cell line must be further
discussed. ML-2 is a human AML cell line with a distinct genetic background. It has a neartetraploid karyotype, with duplications of several chromosomes, including chromosome 11. It
has two copies of the MLL-AF6 fusion protein, and no functional MLL1 gene. Therefore,
because TICAM-1 knockdown is able to induce such a robust phenotype in the ML-2 genetic
background, TICAM-1 is acting independently of MLL1 and may require MLL-rearrangement.
However, whether the presence of functional MLL1 masks the effects of TICAM-1 knockdown
remains undetermined. Though TICAM-1-targeting shRNA expression vectors were expressed in
several human cells lines, the knockdown was verified at protein and transcript levels was only
achieved in the ML-2 cell line. To determine whether TICAM-1 knockdown elicits a similar
phenotype in other human cell lines, future study will expand TICAM-1 knockdown to human
cell lines, with attention given to establishing TICAM-1 knockdown in genetic backgrounds with
and without MLL-rearrangements.
Likewise, the murine MLL-AF9 model, while an efficient and useful preclinical model for
MLL-AF9 AML, is not without flaws. When AML arises in a patient due to a MLL
translocation, one allele of both MLL and its fusion partner are consumed in the generation the
genomic translocation and resulting in-frame fusion protein. The murine MLL-AF9 model
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system, while bearing a close resemblance to human AML with the same translocation, does not
exactly mimic human disease in a molecular and genetic sense. The introduction of human MLLAF9 to murine hematopoietic progenitor cells is achieved by retroviral infection and selection of
infected clones using neomycin resistance as a selection marker. First, in contrast to MLL-AF9
rearrangements treated in the clinic, the introduction of the MLL fusion protein in this manner
conserves two allelic copies of both MLL and AF9. The occurrence of a translocation, in
comparison, would leave only one functional allele of both MLL and AF9, while retaining their
respective N- and C-terminals in the fusion protein. Second, the introduction of MLL-AF9 by
retroviral infection yields two additional unfavorable possibilities. First, the genomic
incorporation of the retroviral vector may generate additional mutations and disrupt other
signaling pathways or gene expression regulatory pathways by integrating into the genome at an
essential site, resulting in a MLL-AF9 leukemia model bearing additional, undetected alterations.
Second, the use of retrovirus to introduce the human MLL-AF9 fusion protein introduces a risk
inherent to the technique that multiple retroviral sequences, and multiple MLL-AF9 expression
vectors, may integrate into the genome, resulting in an excessive overexpression of the fusion
protein.
Because each of these experimental flaws introduce the possibility that the data that we have
collected and presented in this study do not accurately model the pathogenesis of AML in
patients, additional studies must be undertaken to clarify the roles of MYD88 and TICAM-1 in
human systems and primary patient samples. First, whether TICAM-1-dependent signaling is
required in other human cell lines, in addition to ML-2 must be investigated. This approach will
be undertaken using either shRNA knockdown or CRISPR/Cas9 genomic deletion. Alternative
shRNA sequences will be obtained, as the human shRNA obtained from Origene was only
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effective in the ML-2 cell line and failed to knockdown TICAM-1 in any other cell line.
Accordingly, whether TICAM-1 knockdown correlates with RIPK1 and RIPK3 protein level
reduction in other human cell lines, and whether this phenotype correlates with specific human
cell line genotypes, will be determined. If such a correlation is reproducible, RIPK1 and RIPK3
will be re-expressed to determine if TICAM-1-mediated protein-level stabilization is the
mechanism by which RIPK1 and RIPK3 protein level is maintained, as I would hypothesize
based on data presented here. Further, the precise interaction between TICAM-1 and RIP
proteins will be explored to determine how TICAM-1 maintains RIP protein levels, whether it is
through a transcriptional effect, direct interaction, or some other mechanism. Lastly, the
mechanism of RIPK1 and RIPK3 degradation will be determined using inhibitors directed
against proteasome, A20, autophagy, and other degradation processes.
If the reduction of RIPK1 and RIPK3 protein level is shown to be unrelated to the TICAM-1mediated phenotype, then targeted disruption of the highly redundant TRAF network will be
explored, first by overexpressing TICAM-1 with specific mutations in domains required for
TRAF2, TRAF3, and TRAF6 interactions. If interaction with TRAFs is also not required for
leukemia cell colony-forming ability, proliferation, and findings, then whole exome RNAsequencing will be applied to identify specific transcriptional alterations between both human
and murine cell lines with TICAM-1 knockdown and their respective scrambled controls.
With respect to MYD88, future studies include generating both MYD88 and IRAK1
knockdown in several human cell lines to determine whether the phenotypes reflecting the
requirement for MYD88 to prevent partial differentiation and maintain colony-forming ability
and proliferation, but no change with IRAK1 knockdown or inhibition, are reproducible in
human cell lines. If, as expected, MYD88, but not IRAK1, is required for leukemia cell
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proliferation, colony-forming ability, and maintenance of cell surface markers, then wholeexome RNA sequencing will be applied to identify novel IRAK1-independent factors
downstream of MYD88 that mediate the pro-leukemic effects of MYD88.
In conclusion, TLR signaling adaptors MYD88 and TICAM-1 are required for MLL-AF9
pathogenesis in myelomonocytic and monocytic (M4/M5) AML subtypes. IRAK1/4 and TBK1,
downstream of MYD88 and TICAM-1 respectively, are both efficiently targeted by specific
inhibitors, but those inhibitors and their specific knockdown fail to elicit a phenotype comparable
to MYD88 or TICAM-1 knockdown. These findings indicate that alternative functions or
complex partners for MYD88 and TICAM-1 facilitate pro-leukemic effects. Despite the
phenotypic observations that led to this conclusion, the exact downstream mechanisms of the
phenotypes derived by MYD88 and TICAM-1 deletion or knockdown remain the subject of
several key questions that will hopefully be clarified by future studies.

REFERENCE LIST
1.

Estrov, Z. et al. Phenylarsine oxide blocks interleukin-1beta-induced activation of the
nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of
acute myelogenous leukemia cells. Blood 94, 2844-53 (1999).

2.

Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-20
(2010).

3.

Hayashi, F., Means, T.K. & Luster, A.D. Toll-like receptors stimulate human neutrophil
function. Blood 102, 2660-9 (2003).

4.

Yanez, A., Goodridge, H.S., Gozalbo, D. & Gil, M.L. TLRs control hematopoiesis during
infection. Eur J Immunol 43, 2526-33 (2013).

5.

Wei, Y. et al. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia 27,
1832-40 (2013).

6.

Rhyasen, G.W. & Starczynowski, D.T. IRAK signalling in cancer. Br J Cancer 112, 232-7
(2015).

7.

Kawasaki, T. & Kawai, T. Toll-like receptor signaling pathways. Front Immunol 5, 461
(2014).

8.

Skevaki, C., Pararas, M., Kostelidou, K., Tsakris, A. & Routsias, J.G. Single nucleotide
polymorphisms of Toll-like receptors and susceptibility to infectious diseases. Clin Exp
Immunol (2015).

9.

Takeuchi, O., Hoshino, K. & Akira, S. Cutting edge: TLR2-deficient and MyD88-deficient
mice are highly susceptible to Staphylococcus aureus infection. J Immunol 165, 5392-6
(2000).

10.

Zhang, S.Y. et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science
317, 1522-7 (2007).

11.

Anderson, K.V., Bokla, L. & Nusslein-Volhard, C. Establishment of dorsal-ventral polarity
in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 42,
791-8 (1985).

127

128
12.

Medzhitov, R., Preston-Hurlburt, P. & Janeway, C.A., Jr. A human homologue of the
Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-7
(1997).

13.

Wang, J., Zhang, Z., Liu, J., Zhao, J. & Yin, D. Ectodomain Architecture Affects Sequence
and Functional Evolution of Vertebrate Toll-like Receptors. Sci Rep 6, 26705 (2016).

14. Whitham, S. et al. The product of the tobacco mosaic virus resistance gene N: similarity to
toll and the interleukin-1 receptor. Cell 78, 1101-15 (1994).
15.

Gay, N.J., Packman, L.C., Weldon, M.A. & Barna, J.C. A leucine-rich repeat peptide
derived from the Drosophila Toll receptor forms extended filaments with a beta-sheet
structure. FEBS Lett 291, 87-91 (1991).

16.

Narayanan, K.B. & Park, H.H. Toll/interleukin-1 receptor (TIR) domain-mediated cellular
signaling pathways. Apoptosis 20, 196-209 (2015).

17.

Hultmark, D. Macrophage differentiation marker MyD88 is a member of the Toll/IL-1
receptor family. Biochem Biophys Res Commun 199, 144-6 (1994).

18.

Wesche, H., Henzel, W.J., Shillinglaw, W., Li, S. & Cao, Z. MyD88: an adapter that
recruits IRAK to the IL-1 receptor complex. Immunity 7, 837-47 (1997).

19.

Medzhitov, R. et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family
signaling pathways. Mol Cell 2, 253-8 (1998). 20. Hoshino, K. et al. Cutting edge: Tolllike receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide:
evidence for TLR4 as the Lps gene product. J Immunol 162, 3749-52 (1999). 21.
Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice:
mutations in Tlr4 gene. Science 282, 2085-8 (1998).

21.

Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice:
mutations in Tlr4 gene. Science 282, 2085-8 (1998).

22.

Poltorak, A. et al. Genetic and physical mapping of the Lps locus: identification of the toll4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 24, 340-55
(1998).

23.

Jin, M.S. et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a
tri-acylated lipopeptide. Cell 130, 1071-82 (2007).

24.

Qi, H. et al. Toll-like receptor 1(TLR1) Gene SNP rs5743618 is associated with increased
risk for tuberculosis in Han Chinese children. Tuberculosis (Edinb) (2014).

25.

Takeuchi, O. et al. Cutting Edge: Role of Toll-Like Receptor 1 in Mediating Immune
Response to Microbial Lipoproteins. The Journal of Immunology 169, 10-14 (2002).
128

129
26.

Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like
receptor 5. Nature 410, 1099-103 (2001).

27.

Yoon, S.I. et al. Structural basis of TLR5-flagellin recognition and signaling. Science 335,
859-64 (2012).

28.

Liu, L. et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA.
Science 320, 379-81 (2008).

29.

Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. Recognition of doublestranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413, 732-8
(2001).

30.

Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7
and 8. Science 303, 1526-9 (2004).

31.

Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-5 (2000).

32.

Ahmad-Nejad, P. et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like
receptors at distinct cellular compartments. Eur J Immunol 32, 1958-68 (2002).

33.

Kim, Y.M., Brinkmann, M.M., Paquet, M.E. & Ploegh, H.L. UNC93B1 delivers
nucleotide-sensing toll-like receptors to endolysosomes. Nature 452, 234-8 (2008).

34.

Oosting, M. et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor.
Proc Natl Acad Sci U S A 111, E4478-84 (2014).

35.

Tanji, H., Ohto, U., Shibata, T., Miyake, K. & Shimizu, T. Structural reorganization of the
Toll-like receptor 8 dimer induced by agonistic ligands. Science 339, 1426-9 (2013).

36.

Latz, E. et al. Ligand-induced conformational changes allosterically activate Toll-like
receptor 9. Nat Immunol 8, 772-9 (2007).

37.

Lee, S.M., Hutchinson, M. & Saint, D.A. The role of Toll-like receptor 4 (TLR4) in cardiac
ischaemic-reperfusion injury, cardioprotection and preconditioning. Clin Exp Pharmacol
Physiol 43, 864-71 (2016).

38.

Yu, M. et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26, 1749 (2006).

39.

Kasimsetty, S.G. & McKay, D.B. Ischemia as a factor affecting innate immune responses
in kidney transplantation. Curr Opin Nephrol Hypertens 25, 3-11 (2016).

130
40.

Luong, M. et al. Stimulation of TLR4 by recombinant HSP70 requires structural integrity
of the HSP70 protein itself. J Inflamm (Lond) 9, 11 (2012).

41.

Wheeler, D.S. et al. Extracellular Hsp72, an endogenous DAMP, is released by virally
infected airway epithelial cells and activates neutrophils via Toll-like receptor (TLR)-4.
Respir Res 10, 31 (2009).

42.

Mathur, S., Walley, K.R., Wang, Y., Indrambarya, T. & Boyd, J.H. Extracellular heat
shock protein 70 induces cardiomyocyte inflammation and contractile dysfunction via
TLR2. Circ J 75, 2445-52 (2011).

43.

Huang, H. et al. Hepatocyte-specific high-mobility group box 1 deletion worsens the injury
in liver ischemia/reperfusion: a role for intracellular high-mobility group box 1 in
cellular protection. Hepatology 59, 1984-1997 (2014).

44.

Tsung, A., Tohme, S. & Billiar, T.R. High-mobility group box-1 in sterile inflammation. J
Intern Med 276, 425-43 (2014).

45.

Kattah, M.G., Malynn, B.A. & Ma, A. Ubiquitin-Modifying Enzymes and Regulation of
the Inflammasome. J Mol Biol 429, 3471-3485 (2017).

46.

Malireddi, R.K.S. et al. TAK1 restricts spontaneous NLRP3 activation and cell death to
control myeloid proliferation. J Exp Med 215, 1023-1034 (2018).

47.

Sheedy, F.J. & O'Neill, L.A. The Troll in Toll: Mal and Tram as bridges for TLR2 and
TLR4 signaling. J Leukoc Biol 82, 196-203 (2007).

48.

Suzuki, N. et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in
mice lacking IRAK-4. Nature 416, 750-6 (2002).

49.

Li, S., Strelow, A., Fontana, E.J. & Wesche, H. IRAK-4: a novel member of the IRAK
family with the properties of an IRAK-kinase. Proc Natl Acad Sci U S A 99, 5567-72
(2002).

50.

Ferrao, R. et al. IRAK4 dimerization and trans-autophosphorylation are induced by
Myddosome assembly. Mol Cell 55, 891-903 (2014).

51.

Lin, S.C., Lo, Y.C. & Wu, H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in
TLR/IL-1R signalling. Nature 465, 885-90 (2010).

52.

Strickson, S. et al. Roles of the TRAF6 and Pellino E3 ligases in MyD88 and RANKL
signaling. Proc Natl Acad Sci U S A 114, E3481-E3489 (2017).

53.

Wang, C. et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 34651 (2001).

131
54.

Hirata, Y., Takahashi, M., Morishita, T., Noguchi, T. & Matsuzawa, A. Post-Translational
Modifications of the TAK1-TAB Complex. Int J Mol Sci 18 (2017).

55.

Kawai, T. et al. Lipopolysaccharide stimulates the MyD88-independent pathway and
results in activation of IFN-regulatory factor 3 and the expression of a subset of
lipopolysaccharide-inducible genes. J Immunol 167, 5887-94 (2001).

56.

Kaisho, T. et al. Endotoxin can induce MyD88-deficient dendritic cells to support T(h)2
cell differentiation. Int Immunol 14, 695-700 (2002).

57.

Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor
signaling pathway. Science 301, 640-3 (2003).

58.

Yamamoto, M. et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter
that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J
Immunol 169, 6668-72 (2002).

59.

Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T. & Seya, T. TICAM-1, an adaptor
molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat
Immunol 4, 161-7 (2003).

60.

Fitzgerald, K.A. et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll
adapters TRAM and TRIF. J Exp Med 198, 1043-55 (2003).

61.

Matsumoto, M. et al. Subcellular localization of Toll-like receptor 3 in human dendritic
cells. J Immunol 171, 3154-62 (2003).

62.

Oshiumi, H. et al. TIR-containing adapter molecule (TICAM)-2, a bridging adapter
recruiting to toll-like receptor 4 TICAM-1 that induces interferon-beta. J Biol Chem 278,
49751-62 (2003).

63.

Enokizono, Y. et al. Structures and interface mapping of the TIR domain-containing
adaptor molecules involved in interferon signaling. Proc Natl Acad Sci U S A 110,
19908-13 (2013).

64.

Ohnishi, H. et al. TRAM is involved in IL-18 signaling and functions as a sorting adaptor
for MyD88. PLoS One 7, e38423 (2012).

65.

Li, X.Q. et al. MiR-27a ameliorates inflammatory damage to the blood-spinal cord barrier
after spinal cord ischemia: reperfusion injury in rats by downregulating TICAM-2 of the
TLR4 signaling pathway. J Neuroinflammation 12, 25 (2015).

66.

Funami, K., Matsumoto, M., Obuse, C. & Seya, T. 14-3-3-zeta participates in TLR3mediated TICAM-1 signal-platform formation. Mol Immunol 73, 60-8 (2016).

132
67.

Ma, X. et al. Molecular basis of Tank-binding kinase 1 activation by
transautophosphorylation. Proc Natl Acad Sci U S A 109, 9378-83 (2012).

68.

Sasai, M. et al. Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor
participates in activation of the Toll-like receptor 3/4 pathway. Mol Immunol 47, 128391 (2010).

69.

Smith, H. et al. The role of TBK1 and IKKepsilon in the expression and activation of
Pellino 1. Biochem J 434, 537-48 (2011).

70.

Kaiser, W.J. et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J
Biol Chem 288, 31268-79 (2013).

71.

Kaczmarek, A., Vandenabeele, P. & Krysko, D.V. Necroptosis: the release of damageassociated molecular patterns and its physiological relevance. Immunity 38, 209-23
(2013).

72.

Meylan, E. et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B
activation. Nat Immunol 5, 503-7 (2004).

73.

Najjar, M. et al. RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation
by Toll-like Receptor 4. Immunity 45, 46-59 (2016).

74.

Dunne, A. et al. IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and
degradation of MyD88 adaptor-like (Mal). J Biol Chem 285, 18276-82 (2010).

75.

Kubo-Murai, M. et al. IRAK-4-dependent degradation of IRAK-1 is a negative feedback
signal for TLR-mediated NF-kappaB activation. J Biochem 143, 295-302 (2008).

76.

Zilberman-Rudenko, J. et al. Recruitment of A20 by the C-terminal domain of NEMO
suppresses NF-kappaB activation and autoinflammatory disease. Proc Natl Acad Sci U S
A 113, 1612-7 (2016).

77.

Das, T., Chen, Z., Hendriks, R.W. & Kool, M. A20/Tumor Necrosis Factor alpha-Induced
Protein 3 in Immune Cells Controls Development of Autoinflammation and
Autoimmunity: Lessons from Mouse Models. Front Immunol 9, 104 (2018).

78.

Nilsen, N.J. et al. A role for the adaptor proteins TRAM and TRIF in toll-like receptor 2
signaling. J Biol Chem 290, 3209-22 (2015).

79.

Wang, Y.C. et al. Toll-like receptor 2/4 heterodimer mediates inflammatory injury in
intracerebral hemorrhage. Ann Neurol 75, 876-89 (2014).

133
80.

Huang, B., Park, D.W. & Baek, S.H. TRIF is a regulator of TLR2-induced foam cell
formation. Mol Med Rep 14, 3329-35 (2016).

81.

Arai, F. & Suda, T. Regulation of hematopoietic stem cells in the osteoblastic niche. Adv
Exp Med Biol 602, 61-7 (2007).

82.

Arai, F. & Suda, T. Maintenance of quiescent hematopoietic stem cells in the osteoblastic
niche. Ann N Y Acad Sci 1106, 41-53 (2007).

83.

Asada, N. & Katayama, Y. Regulation of hematopoiesis in endosteal microenvironments.
Int J Hematol 99, 679-84 (2014).

84.

Bigas, A., D'Altri, T. & Espinosa, L. The Notch pathway in hematopoietic stem cells. Curr
Top Microbiol Immunol 360, 1-18 (2012).

85.

Duncan, A.W. et al. Integration of Notch and Wnt signaling in hematopoietic stem cell
maintenance. Nat Immunol 6, 314-22 (2005).

86.

He, Q. et al. Inflammatory signaling regulates hematopoietic stem and progenitor cell
emergence in vertebrates. Blood 125, 1098-106 (2015).
Sawamiphak, S., Kontarakis, Z. & Stainier, D.Y. Interferon gamma signaling positively
regulates hematopoietic stem cell emergence. Dev Cell 31, 640-53 (2014).

87.
88.

Li, Y. et al. Inflammatory signaling regulates embryonic hematopoietic stem and
progenitor cell production. Genes Dev 28, 2597-612 (2014).

89.

Orelio, C., Haak, E., Peeters, M. & Dzierzak, E. Interleukin-1-mediated hematopoietic cell
regulation in the aorta-gonad-mesonephros region of the mouse embryo. Blood 112,
4895-904 (2008).

90.

Robin, C. et al. An unexpected role for IL-3 in the embryonic development of
hematopoietic stem cells. Dev Cell 11, 171-80 (2006).

91.

Espin-Palazon, R. et al. Proinflammatory signaling regulates hematopoietic stem cell
emergence. Cell 159, 1070-85 (2014).

92.

Qiu, P., Pan, P.C. & Govind, S. A role for the Drosophila Toll/Cactus pathway in larval
hematopoiesis. Development 125, 1909-20 (1998).

93.

Balmer, M.L. et al. Microbiota-derived compounds drive steady-state granulopoiesis via
MyD88/TICAM signaling. J Immunol 193, 5273-83 (2014).

94.

Manz, M.G. & Boettcher, S. Emergency granulopoiesis. Nat Rev Immunol 14, 302-14
(2014).

134
95.

De Luca, K. et al. The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human
hematopoietic stem cells to a myeloid cell fate. Leukemia 23, 2063-74 (2009).

96.

Nagai, Y. et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate
immune system replenishment. Immunity 24, 801-12 (2006).

97.

Sioud, M., Floisand, Y., Forfang, L. & Lund-Johansen, F. Signaling through toll-like
receptor 7/8 induces the differentiation of human bone marrow CD34+ progenitor cells
along the myeloid lineage. J Mol Biol 364, 945-54 (2006).

98.

Herman, A.C. et al. Systemic TLR2 agonist exposure regulates hematopoietic stem cells
via cell-autonomous and cell-non-autonomous mechanisms. Blood Cancer J 6, e437
(2016).

99.

Megias, J. et al. Direct Toll-like receptor-mediated stimulation of hematopoietic stem and
progenitor cells occurs in vivo and promotes differentiation toward macrophages. Stem
Cells 30, 1486-95 (2012).

100. Zhao, J.L. et al. Conversion of danger signals into cytokine signals by hematopoietic stem
and progenitor cells for regulation of stress-induced hematopoiesis. Cell Stem Cell 14,
445-59 (2014).
101. Boettcher, S. et al. Endothelial cells translate pathogen signals into G-CSF-driven
emergency granulopoiesis. Blood 124, 1393-403 (2014).
102. Baldridge, M.T., King, K.Y., Boles, N.C., Weksberg, D.C. & Goodell, M.A. Quiescent
haematopoietic stem cells are activated by IFN-gamma in response to chronic infection.
Nature 465, 793-7 (2010).
103. Yanez, A. et al. Signalling through TLR2/MyD88 induces differentiation of murine bone
marrow stem and progenitor cells to functional phagocytes in response to Candida
albicans. Cell Microbiol 12, 114-28 (2010).
104. Yanez, A., Murciano, C., O'Connor, J.E., Gozalbo, D. & Gil, M.L. Candida albicans
triggers proliferation and differentiation of hematopoietic stem and progenitor cells by a
MyD88-dependent signaling. Microbes Infect 11, 531-5 (2009).
105. Welner, R.S. et al. Lymphoid precursors are directed to produce dendritic cells as a result
of TLR9 ligation during herpes infection. Blood 112, 3753-61 (2008).
106. Buechler, M.B., Teal, T.H., Elkon, K.B. & Hamerman, J.A. Cutting edge: Type I IFN
drives emergency myelopoiesis and peripheral myeloid expansion during chronic TLR7
signaling. J Immunol 190, 886-91 (2013).

135
107. Esplin, B.L. et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J
Immunol 186, 5367-75 (2011).
108. Schuettpelz, L.G. et al. G-CSF regulates hematopoietic stem cell activity, in part, through
activation of Toll-like receptor signaling. Leukemia 28, 1851-60 (2014).
109. Abdelmagid, S.M., Barbe, M.F. & Safadi, F.F. Role of inflammation in the aging bones.
Life Sci 123, 25-34 (2015).
110. Herault, A. et al. Myeloid progenitor cluster formation drives emergency and leukaemic
myelopoiesis. Nature 544, 53-58 (2017).
111. Rakoff-Nahoum, S. & Medzhitov, R. Regulation of spontaneous intestinal tumorigenesis
through the adaptor protein MyD88. Science 317, 124-7 (2007).
112. Klimosch, S.N. et al. Functional TLR5 genetic variants affect human colorectal cancer
survival. Cancer Res 73, 7232-42 (2013).
113. Royse, K.E. et al. Expression of pattern recognition receptor genes and mortality in patients
with colorectal adenocarcinoma. Int J Mol Epidemiol Genet 8, 8-18 (2017).
114. Zhao, X.L. et al. High-mobility group box 1 released by autophagic cancer-associated
fibroblasts maintains the stemness of luminal breast cancer cells. J Pathol 243, 376-389
(2017).
115. Semlali, A. et al. Toll-like receptor 4 as a predictor of clinical outcomes of estrogen
receptor-negative breast cancer in Saudi women. Onco Targets Ther 10, 1207-1216
(2017).
116. Cheng, B.Y. et al. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma. Cancer Res 78, 23322342 (2018).
117. Zhan, Z. et al. Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of
lung cancer cells through the promotion of TRAF6 ubiquitination. Autophagy 10, 25768 (2014).
118. Rong, Y. et al. TRAF6 is over-expressed in pancreatic cancer and promotes the
tumorigenicity of pancreatic cancer cells. Med Oncol 31, 260 (2014).
119. Zhang, D. et al. Constitutive IRAK4 Activation Underlies Poor Prognosis and
Chemoresistance in Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 23, 1748-1759
(2017).

136
120. Alvarado, A.G. et al. Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression
of Self-Renewal through Reduced TLR4 Expression. Cell Stem Cell 20, 450-461 e4
(2017).
121. Gupta, P., Ghosh, S., Nagarajan, A., Mehta, V.S. & Sen, E. beta-defensin-3 negatively
regulates TLR4-HMGB1 axis mediated HLA-G expression in IL-1beta treated glioma
cells. Cell Signal 25, 682-9 (2013).
122. Treon, S.P. et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia.
N Engl J Med 367, 826-33 (2012).
123. Ngo, V.N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470,
115-9 (2011).
124. Xu, L. et al. Detection of MYD88 L265P in peripheral blood of patients with
Waldenstrom's Macroglobulinemia and IgM monoclonal gammopathy of undetermined
significance. Leukemia 28, 1698-704 (2014).
125. Landgren, O. & Staudt, L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med
367, 2255-6; author reply 2256-7 (2012).
126. Jimenez, C. et al. MYD88 L265P is a marker highly characteristic of, but not restricted to,
Waldenstrom's macroglobulinemia. Leukemia 27, 1722-8 (2013).
127. Lee, J.H., Jeong, H., Choi, J.W., Oh, H. & Kim, Y.S. Clinicopathologic significance of
MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. Sci Rep 7,
1785 (2017).
128. Pham-Ledard, A. et al. High frequency and clinical prognostic value of MYD88 L265P
mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol
150, 1173-9 (2014).
129. Takano, S. et al. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central
Nervous System Lymphoma: Multi-Institutional Analysis. World Neurosurg 112, e69e73 (2018).
130. Scott, J.S. et al. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88(L265P)
Diffuse Large B-Cell Lymphoma. J Med Chem 60, 10071-10091 (2017).
131. .
132. Yang, G. et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic
cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood
122, 1222-32 (2013).

137
133. Akinleye, A., Chen, Y., Mukhi, N., Song, Y. & Liu, D. Ibrutinib and novel BTK inhibitors
in clinical development. J Hematol Oncol 6, 59 (2013).
134. Karube, K. et al. Integrating genomic alterations in diffuse large B-cell lymphoma
identifies new relevant pathways and potential therapeutic targets. Leukemia 32, 675684 (2018).
135. Lynch, R.C. & Advani, R.H. Dramatic Response with Single-Agent Ibrutinib in Multiply
Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation. Case Rep Oncol
10, 813-818 (2017).
136. Cogle, C.R. Incidence and Burden of the Myelodysplastic Syndromes. Curr Hematol Malig
Rep 10, 272-81 (2015).
137. Ma, X., Does, M., Raza, A. & Mayne, S.T. Myelodysplastic syndromes: incidence and
survival in the United States. Cancer 109, 1536-42 (2007).
138. Zeidan, A.M. et al. Comparison of clinical outcomes and prognostic utility of risk
stratification tools in patients with therapy-related vs de novo myelodysplastic
syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 31,
1391-1397 (2017).
139. Wei, Y. et al. Global H3K4me3 genome mapping reveals alterations of innate immunity
signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+
cells. Leukemia 27, 2177-86 (2013).
140. Dimicoli, S. et al. Overexpression of the toll-like receptor (TLR) signaling adaptor
MYD88, but lack of genetic mutation, in myelodysplastic syndromes. PLoS One 8,
e71120 (2013).
141. Rhyasen, G.W. et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic
syndrome. Cancer Cell 24, 90-104 (2013).
142. Maratheftis, C.I., Andreakos, E., Moutsopoulos, H.M. & Voulgarelis, M. Toll-like
receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased
apoptosis in myelodysplastic syndromes. Clin Cancer Res 13, 1154-60 (2007).
143. Schneider, R.K. et al. Rps14 haploinsufficiency causes a block in erythroid differentiation
mediated by S100A8 and S100A9. Nat Med 22, 288-97 (2016).
144. Zambetti, N.A. et al. Mesenchymal Inflammation Drives Genotoxic Stress in
Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia. Cell
Stem Cell 19, 613-627 (2016).

138
145. Kuninaka, N. et al. Expression of Toll-like receptor 9 in bone marrow cells of
myelodysplastic syndromes is down-regulated during transformation to overt leukemia.
Exp Mol Pathol 88, 293-8 (2010).
146. Starczynowski, D.T. et al. Identification of miR-145 and miR-146a as mediators of the 5qsyndrome phenotype. Nat Med 16, 49-58 (2010).
147. Fang, J. et al. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune
signaling with myelodysplasia. Nat Immunol 18, 236-245 (2017).
148. Zhang, X., Lv, D., Zhang, Y., Liu, Q. & Li, Z. Clonal evolution of acute myeloid leukemia
highlighted by latest genome sequencing studies. Oncotarget 7, 58586-58594 (2016).
149. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by wholegenome sequencing. Nature 481, 506-10 (2012).
150. Siegel, R.L., Miller, K.D. & Jemal, A. Cancer statistics, 2018. CA Cancer J Clin 68, 7-30
(2018).
151. Schnegg-Kaufmann, A. et al. Improvement of relative survival in elderly patients with
acute myeloid leukaemia emerging from population-based cancer registries in
Switzerland between 2001 and 2013. Cancer Epidemiol 52, 55-62 (2018).
152. Fircanis, S., Merriam, P., Khan, N. & Castillo, J.J. The relation between cigarette smoking
and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological
studies. Am J Hematol 89, E125-32 (2014).
153. Zhou, J. et al. Bone marrow mononuclear cells up-regulate toll-like receptor expression and
produce inflammatory mediators in response to cigarette smoke extract. PLoS One 6,
e21173 (2011).
154. Tong, H. et al. A Meta-Analysis of the Relationship between Cigarette Smoking and
Incidence of Myelodysplastic Syndromes. PLoS One 8, e67537 (2013).
155. Du, Y., Fryzek, J., Sekeres, M.A. & Taioli, E. Smoking and alcohol intake as risk factors
for myelodysplastic syndromes (MDS). Leuk Res 34, 1-5 (2010).
156. Bueso-Ramos, C.E., Kanagal-Shamanna, R., Routbort, M.J. & Hanson, C.A. TherapyRelated Myeloid Neoplasms. Am J Clin Pathol 144, 207-18 (2015).
157. Kern, W. et al. Risk-adapted therapy of AML: the AMLCG experience. Ann Hematol 83
Suppl 1, S49-51 (2004).
158. Zwaan, M.C., Reinhardt, D., Hitzler, J. & Vyas, P. Acute leukemias in children with Down
syndrome. Pediatr Clin North Am 55, 53-70, x (2008).

139
159. de Rooij, J.D., Zwaan, C.M. & van den Heuvel-Eibrink, M. Pediatric AML: From Biology
to Clinical Management. J Clin Med 4, 127-49 (2015).
160. Link, D.C. et al. Identification of a novel TP53 cancer susceptibility mutation through
whole-genome sequencing of a patient with therapy-related AML. JAMA 305, 1568-76
(2011).
161. Savage, S.A. & Dufour, C. Classical inherited bone marrow failure syndromes with high
risk for myelodysplastic syndrome and acute myelogenous leukemia. Semin Hematol 54,
105-114 (2017).
162. Harris, J.W., Koscick, R., Lazarus, H.M., Eshleman, J.R. & Medof, M.E. Leukemia arising
out of paroxysmal nocturnal hemoglobinuria. Leuk Lymphoma 32, 401-26 (1999).
163. Shimamura, A. Aplastic anemia and clonal evolution: germ line and somatic genetics.
Hematology Am Soc Hematol Educ Program 2016, 74-82 (2016).
164. Saultz, J.N. & Garzon, R. Acute Myeloid Leukemia: A Concise Review. J Clin Med 5
(2016).
165. Dombret, H. et al. International phase 3 study of azacitidine vs conventional care regimens
in older patients with newly diagnosed AML with >30% blasts. Blood 126, 291-9
(2015).
166. Rowe, J.M. et al. Adult patients with acute myeloid leukemia who achieve complete
remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980
patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.
Cancer 116, 5012-21 (2010).
167. Bennett, J.M. et al. Proposals for the classification of the acute leukaemias. FrenchAmerican-British (FAB) co-operative group. Br J Haematol 33, 451-8 (1976).
168. Lo-Coco, F. et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N
Engl J Med 369, 111-21 (2013).
169. Ades, L. et al. Very long-term outcome of acute promyelocytic leukemia after treatment
with all-trans retinoic acid and chemotherapy: the European APL Group experience.
Blood 115, 1690-6 (2010).
170. Vardiman, J.W. et al. The 2008 revision of the World Health Organization (WHO)
classification of myeloid neoplasms and acute leukemia: rationale and important
changes. Blood 114, 937-51 (2009).

140
171. Shih, L.Y. et al. Characterization of fusion partner genes in 114 patients with de novo acute
myeloid leukemia and MLL rearrangement. Leukemia 20, 218-23 (2006).
172. Mohan, M., Lin, C., Guest, E. & Shilatifard, A. Licensed to elongate: a molecular
mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 10, 721-8 (2010).
173. Lin, C. et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared
subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 37,
429-37 (2010).
174. Faber, J. et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias.
Blood 113, 2375-85 (2009).
175. Guo, H. et al. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged
leukemia. Int J Cancer 141, 324-335 (2017).
176. Corral, J. et al. An Mll-AF9 fusion gene made by homologous recombination causes acute
leukemia in chimeric mice: a method to create fusion oncogenes. Cell 85, 853-61
(1996).
177. Ignatz-Hoover, J.J. et al. The role of TLR8 signaling in acute myeloid leukemia
differentiation. Leukemia 29, 918-926 (2015).
178. Villamon, E. et al. Imiquimod inhibits growth and induces differentiation of myeloid
leukemia cell lines. Cancer Cell Int 18, 15 (2018).
179. Nourizadeh, M. et al. In vitro induction of potent tumor-specific cytotoxic T lymphocytes
using TLR agonist-activated AML-DC. Target Oncol 9, 225-37 (2014).
180. Weigel, B.J. et al. Prolonged subcutaneous administration of 852A, a novel systemic tolllike receptor 7 agonist, to activate innate immune responses in patients with advanced
hematologic malignancies. Am J Hematol 87, 953-6 (2012).
181. Liang, K. et al. Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged
Leukemia. Cell 168, 59-72 e13 (2017).
182. Li, J. et al. Sensitizing leukemia stem cells to NF-kappaB inhibitor treatment in vivo by
inactivation of both TNF and IL-1 signaling. Oncotarget 8, 8420-8435 (2017).
183. Volk, A. et al. Co-inhibition of NF-kappaB and JNK is synergistic in TNF-expressing
human AML. J Exp Med 211, 1093-108 (2014).
184. Carter, A., Silvian-Draxler, I. & Tatarsky, I. Effect of interleukin-1, tumor necrosis factoralpha, and interferon-alpha on the blast cells of acute myeloblastic leukemia. Am J
Hematol 40, 245-51 (1992).

141
185. Laouedj, M. et al. S100A9 induces differentiation of acute myeloid leukemia cells through
TLR4. Blood 129, 1980-1990 (2017).
186. Bosman, M.C. et al. The TAK1-NF-kappaB axis as therapeutic target for AML. Blood 124,
3130-40 (2014).
187. Xin, J. et al. Sensitizing acute myeloid leukemia cells to induced differentiation by
inhibiting the RIP1/RIP3 pathway. Leukemia 31, 1154-1165 (2017).
188. Rhodes, D.R. et al. ONCOMINE: a cancer microarray database and integrated data-mining
platform. Neoplasia 6, 1-6 (2004).
189. Wouters, B.J. et al. Double CEBPA mutations, but not single CEBPA mutations, define a
subgroup of acute myeloid leukemia with a distinctive gene expression profile that is
uniquely associated with a favorable outcome. Blood 113, 3088-91 (2009).
190. Balgobind, B.V. et al. Evaluation of gene expression signatures predictive of cytogenetic
and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 96, 221-30
(2011).
191. Bagger, F.O. et al. BloodSpot: a database of gene expression profiles and transcriptional
programs for healthy and malignant haematopoiesis. Nucleic Acids Res 44, D917-24
(2016).
192. Tanabe, S. et al. Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent
breakpoint in AF6 in three patients and in the ML-2 cell line. Genes Chromosomes
Cancer 15, 206-16 (1996).
193. Schmidt-Supprian, M. & Rajewsky, K. Vagaries of conditional gene targeting. Nat
Immunol 8, 665-8 (2007).
194. Loonstra, A. et al. Growth inhibition and DNA damage induced by Cre recombinase in
mammalian cells. Proc Natl Acad Sci U S A 98, 9209-14 (2001).
195. Thyagarajan, B., Guimaraes, M.J., Groth, A.C. & Calos, M.P. Mammalian genomes
contain active recombinase recognition sites. Gene 244, 47-54 (2000).
196. Li, Y., Choi, P.S., Casey, S.C. & Felsher, D.W. Activation of Cre recombinase alone can
induce complete tumor regression. PLoS One 9, e107589 (2014).
197. Baba, Y., Nakano, M., Yamada, Y., Saito, I. & Kanegae, Y. Practical range of effective
dose for Cre recombinase-expressing recombinant adenovirus without cell toxicity in
mammalian cells. Microbiol Immunol 49, 559-70 (2005).

142
198. Silver, D.P. & Livingston, D.M. Self-excising retroviral vectors encoding the Cre
recombinase overcome Cre-mediated cellular toxicity. Mol Cell 8, 233-43 (2001).
199. Li, Z. et al. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to
chemotherapies. J Clin Invest 125, 1081-97 (2015).
200. Song, I.J. et al. The contribution of toll-like receptor signaling to the development of liver
fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. Int J Cancer 142, 81-91
(2018).
201. Lamothe, B. et al. Deletion of TAK1 in the myeloid lineage results in the spontaneous
development of myelomonocytic leukemia in mice. PLoS One 7, e51228 (2012).
202. Verstak, B. et al. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for
TLR2- and TLR4-mediated NF-kappaB proinflammatory responses. J Biol Chem 284,
24192-203 (2009).
203. Benjamin, R. et al. Continuous delivery of human type I interferons (alpha/beta) has
significant activity against acute myeloid leukemia cells in vitro and in a xenograft
model. Blood 109, 1244-7 (2007).

VITA
The author, Joseph, was born in Winfield, IL on September 19, 1989 to John and Sandy
Cannova. He attended the University of Notre Dame in Indiana, where he pursued undergraduate
research projects on the Mycobacteria marinum secretion system in the lab of Patricia
Champion, Ph.D. Joe earned a Bachelor’s of Science, magna cum laude, in Biological Sciences
in May 2012. After graduation, Joe matriculated into the Loyola University Chicago Stritch
School of Medicine M.D./Ph.D. Program. After completing two years of medical school, he
began his graduate education in the Biochemistry and Molecular Biology Program under the
mentorship of Jiwang Zhang, M.D., Ph.D.
Joe’s dissertation work on the pro-leukemic effect of Toll-like receptor adaptor proteins
MYD88 and TICAM-1 was supported by an Arthur J. Schmitt Graduate Student Scholarship
through the Arthur J. Schmitt Foundation. After completion of his graduate studies, Joe will
return to the Stritch School of Medicine to complete his medical degree. After completing the
M.D./Ph.D. Program at Loyola University Chicago, Joe plans to enroll in a physician scientist
training program to further both his basic science and clinical training.

143

144

